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Endogenous and exogenous stresses (e.g. mutations, reduction and oxidation, extremes of pH 
or temperature) can cause the unfolding or misfolding of proteins. Failure to refold or 
degrade misfolded/unfolded proteins can result in their aggregation to form either structured 
fibrils or unstructured amorphous aggregates. These can accumulate and deposit within intra- 
or extracellular environments to cause pathologies by physically disrupting tissue function 
(deposits) or exerting cytotoxicity (soluble protein oligomers). To deal with this, a complex 
network of protein quality control mechanisms have evolved to maintain proteins at their 
correct levels and in their native structures. As a consequence of aging, however, protein 
quality control systems lose efficacy and the ability of the body to defend itself against a 
variety of serious protein deposition diseases is decreased. Intracellularly, chaperones and 
proteases cooperatively maintain protein homeostasis (proteostasis) by ensuring correct 
protein folding, maintaining protein solubility, and degrading non-native or aggregated 
proteins. Relatively little is known, however, about the extracellular counterpart(s) of these 
processes even though many protein misfolding diseases have pathologies associated with 
extracellular protein aggregation and deposition. Recently discovered extracellular 
chaperones (such as alpha-2 macroglobulin and clusterin) are believed to function similarly to 
small heat shock proteins, by binding to and solubilising non-native proteins and protein 
oligomers, and facilitating their clearance by receptor-mediated endocytosis. The tissue 
plasminogen activation system also appears to play a role in extracellular proteostasis via its 
ability to activate plasminogen to plasmin in response to fibrillar protein aggregates, and the 
ability of plasmin to subsequently degrade these species. 
 
This thesis reports that the chaperone activity of alpha-2 macroglobulin can be enhanced in 
response to a variety of conditions related to diseases, such as reductive/oxidative stress, and 
increased protease secretion. The ability of alpha-2 macroglobulin dimers and monomers 
formed by oxidation and reduction, respectively, and protease activated alpha-2 
macroglobulin to inhibit protein aggregation was found to be more potent than that of the 
native alpha-2 macroglobulin tetramer. In addition, the level of chaperone activity of alpha-2 
macroglobulin correlated with the level of surface-exposed hydrophobicity, with alpha-2 
macroglobulin dimers/monomers and alpha-2 macroglobulin complexed with proteases 
having significantly higher surface-exposed hydrophobicity than native alpha-2 
macroglobulin. Pre-formed alpha-2 macroglobulin:protease complexes were able to partially 
xvi 
 
degrade some aggregating chaperone client proteins, however, these complexes are rapidly 
cleared in vivo and thus the limited degradation of client proteins is unlikely to be 
physiologically relevant. However, protease activation of alpha-2 macroglobulin following its 
binding to misfolded proteins would assist in clearance of the complexes by cell-surface 
receptors. 
 
Further findings presented in this thesis suggest the existence of a novel system in which 
proteases and circulating extracellular chaperones act synergistically as key agents in 
extracellular proteostasis, together mediating the progressive degradation and safe clearance 
of large insoluble protein deposits. Tissue plasminogen activator and plasminogen were 
shown to co-localise on the surface of amorphously aggregated proteins via their binding to 
lysine residues, enhancing the formation of plasmin. It was also shown that when bound to 
insoluble protein aggregates, tissue plasminogen activator was partially shielded from 
inhibition by plasminogen activator inhibitor type-2 and active plm was shielded from 
inhibition by alpha-2 antiplasmin. The action of plasmin on amorphous protein aggregates 
was shown to release smaller soluble fragments of protein. The plasmin-generated protein 
fragments were bound and internalised (via different mechanisms) to both endothelial and 
microglial cells, and were subsequently trafficked to lysosomes in both cell types. When 
incubated with cells, protein fragments generated from different types of protein aggregates 
all elicited the formation of reactive oxygen species and ensuing cytotoxicity. Extracellular 
chaperones were able to bind to these toxic protein fragments, significantly ameliorating their 
negative effects on cells. These results indicate that extracellular proteases and chaperones 
may act together in extracellular proteostasis to inhibit the development of age-related protein 
deposition diseases. The results reported in this thesis are a promising first step towards 
understanding how extracellular proteostasis is maintained. Continued advances in this field 
may lead to confirmation of the operation of these processes in vivo and, ultimately, to the 
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CHAPTER 1 : INTRODUCTION 
 
1.1 General introduction 
Proteostasis refers to all those processes that maintain homeostasis of the amounts and 
structural forms of proteins. In the extracellular context, this refers only to those processes 
operating outside cells (for example, maintenance of fold and solubility properties, inhibition 
of aggregation, clearance of aggregates). In order to preserve normal physiological functions 
and general proteostasis in the human body, appropriate protein “quality control” 
mechanisms must operate in the extracellular space (Yerbury et al. 2005; Wyatt et al. 2013). 
It stands to reason that in human diseases in which extracellular protein 
aggregation/deposition is associated with pathology, the capacity of these mechanisms to 
compensate sufficiently is exceeded. For example, in autoimmune diseases, circulating 
immune complexes accumulate in the kidney, joints and elsewhere and give rise to 
inflammatory responses (Rosenberg et al. 2002). Furthermore, a large family of serious 
diseases named the “Protein Deposition Diseases”, which includes Alzheimer’s disease, 
corneal dystrophy, rheumatoid arthritis, amyotrophic lateral sclerosis, and type II diabetes, 
involve native proteins partially unfolding as a result of mutations, or in response to physical 
or chemical stresses (ionic and oxidative), to generate insoluble, pathological extracellular 
aggregates (Table 1.1) (Buchner 1996; Vidair 1996; Dobson 2001; Wang et al. 2002; Dobson 
2003; Truscott 2005; Swash 2013). Protein aggregates can themselves be toxic and large 
deposits can disrupt tissue and organ function (Walsh et al. 2002; Caughey 2003; Guo 2009).  
 
Proteins may unfold from their native structure and subsequently aggregate into either 
elongated fibres or large unstructured (amorphous) clumps of protein aggregate (Stranks et 
al. 2009). These can become localised in deposits that form either intracellularly and/or 
extracellularly. Intracellularly, a complex and well characterised network of protein quality 
control mechanisms have evolved to preserve proteostasis, involving a combination of two 
strategies: (i) ensuring correct protein folding and maintaining solubility (Buchner 1996; Fink 
1999), or (ii) degrading non-native or aggregated proteins. Both proteases and chaperones are 
key players in this context (Buchner 1996; Kaufman 2002). Corresponding extracellular 
mechanisms of proteostasis are much less well understood, even though many protein 
deposition diseases present with pathologies characterised by the extracellular deposition of 
protein aggregates (Table 1.1).  




Recently discovered extracellular chaperones are believed, like the “holdase” small heat 
shock proteins, to bind to and solubilise non-native proteins and protein oligomers (Kumita et 
al. 2007). The tissue plasminogen activation system also appears to play a role in 
extracellular proteostasis via its ability to activate plasminogen to plasmin in response to non-
native fibrillar aggregates, and the ability of plasmin to subsequently degrade these species 
(Radcliffe 1981; Radcliffe 1983; Machovich and Owen 1997; Tucker 2000; Samson et al. 
2009). This review will present a summary of what is currently known about protein 
misfolding and aggregation as well as associated protein-deposition pathologies and diseases, 
intra- and extracellular mechanisms of proteostasis and describes a recently proposed model 
of extracellular proteostasis involving synergy between proteolytic systems and extracellular 
chaperones may be a functionally critical mechanism in extracellular proteostasis (Wyatt et 
al. 2013). 
 
1.2 Protein folding and disease 
1.2.1 The protein folding theory 
The correct folding of a newly synthesised polypeptide chain into a precise and unique 
tertiary structure along with the shielding of exposed hydrophobic regions is essential for a 
protein to become functional and stable in the biological environment, as proteins that have 
failed to fold correctly are associated with a variety of pathological conditions (Dobson 2003; 
Stirling 2003). Small proteins (60-100 residues) are ideal for studying the structural 
transitions that occur during protein folding as they convert from an unfolded to a native state 
via a “two step model” and do not form long lived intermediates. However, larger proteins 
(>100 residues) fold via transition states and involve the formation of stable intermediates 
which have a unique secondary structure (Figure 1.1A) (Fink 1999; Dobson 2003; Stirling 
2003). The first step of folding begins as soon as the nascent polypeptide is emerging from 
the ribosome with the rapid formation of organised elements of secondary structure such as 
α-helices and β-sheets, establishing H-bonds between amino acids in the primary amino acid 
sequence. The protein then undergoes hydrophobic collapse; hydrophobic residues are largely 
segregated from the surrounding aqueous environment to form the hydrophobic core of an 
intermediate structure known as the “molten globule”. These intermediates are partially 
folded, and mostly un-organised with some hydrophobic regions still exposed to the milieu 
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and thus susceptible to protein aggregation. The final steps of protein folding are relatively 
slow, and species are long-lived involving re-arrangement of the inner core of the protein and 
expulsion of water allowing the protein to achieve its “native”, biologically functional state. 
During this stage most of the tertiary structure is established by formation of disulfide 
bridges, ion-pairs and cis/trans isomerisation of peptide bonds (Fink 1999; Fersht 2000; 
Minton 2000; Cheung 2002; Csermely 2003; Yang and Gruebele 2003). The most recent 
studies into protein folding suggest that it should be thought of as a free energy-dependent, 
conformationally dynamic folding landscape termed the “energy landscape” (Figure 1B) 
(Baldwin 1994; Dobson 2003; Krishna 2004). It can be envisaged as a downward path on a 
funnel-like free energy surface representing the decreasing number of conformations, as well 
as a decrease in entropy and free energy available as a protein moves towards its native 
structure. Folding involves a stochastic search of the conformations available to a polypeptide 
chain, and as the native states of proteins are more thermodynamically stable than the non-
native, the landscape will be biased towards the native state and “funnel” the proteins towards 
this conformation. The folding protein may pass through transition states and form 
intermediates, with the molten globule state being the most stable. Other proteins may not 
reach native conformation and remain trapped as misfolded intermediates, which may then 
form insoluble protein aggregates (Dobson 1999; Dinner et al. 2000; Dobson 2003; Stirling 
2003; Krishna 2004). Protein folding is not a straightforward process. Intracellular molecular 
chaperones are particularly important in the folding of proteins by recognising and forming 
complexes with folding proteins, thereby stabilising intermediates and shielding hydrophobic 
residues to allow correct folding to occur (Csermely 1997; Beissinger and Buchner 1998; 
Csermely 1999; Frydman 2001; Csermely 2003; Giffard et al. 2004).  
 
 




Figure 1.1 The mechanisms of protein folding. (A) The three major steps of protein folding in vitro 
Folding begins with the formation of α-helices and β-sheets followed by hydrophobic collapse 
forming the “molten globule” intermediate. During the last steps of folding the inner hydrophobic 
core is re-organised to yield the native protein. Modified from Csermely et al., 2003. (B) Multi-
dimensional funnel-shaped energy landscape. Folding occurs on a free energy surface representing the 
decreasing number of conformations available to a protein as the native state is approached. The 
trajectory of the landscape will be biased towards the native state and “funnel” the proteins towards 
this conformation. Modified from Krishna et al., 2004. 
 
1.2.2 Protein unfolding, misfolding and aggregation 
A typical human synthesises an average of 2.5 g protein/kg/day, required to sustain 
homeostasis (Norton 1981). Despite the importance of having correctly folded functional 
native proteins, approximately 30% of newly synthesised proteins in eukaryotes do not reach 
their native conformation, and even correctly folded native proteins have decreased stability 
when exposed to damaging and denaturing conditions (Schubert 2000; Chiti and Dobson 
2006; Tan 2009). Thus, the propensity of native proteins to misfold and potentially aggregate 
is an intrinsic property. Misfolding of proteins is greatly influenced by primary structure, 
specific mutations can accelerate the process greatly (Chiti et al. 2003; Greenbaum et al. 
2005). Additionally, environmental factors can put undue strain on a partially folded or native 
protein allowing them to lose their conformation more rapidly, including denaturing 
conditions such as extremes of pH and temperature, glycation, oxidative stress and 
The role of proteases and chaperones in extracellular proteostasis 
5 
 
mechanical sheer stress, which is of particular concern to extracellular proteins undergoing 
shear stresses as they are pumped around the body in blood (Davies and Delsignore 1987; 
Dobson 1999; Bouma et al. 2003; Yerbury et al. 2005).  
 
Protein aggregates are categorised into two main kinds based on their structures: (i) highly 
ordered, slow-forming ribbons of cross-beta structure termed amyloid fibrils, and (ii) 
disorganised, rapidly-forming three-dimensional “clot-like” clumps of amorphous aggregates. 
These will be discussed in the following section 1.2.3.  
 
1.2.3 Fibrillar and amorphous aggregation 
Amyloid fibrils are protein aggregates with a highly organised misfolded structure associated 
with a number of pathological conditions where normal soluble proteins polymerise to form 
insoluble fibrils (Sipe 1994). A wide range of proteins unrelated to amyloid diseases have 
been observed to form fibrils, suggesting that all polypeptide chains are able to form this 
structure (Chiti 1999; Dobson 2003). Amyloid fibrils are long unbranched twisted structures 
of four proto-filaments that twist around each other to form a hollow tube (Dobson 1999; 
Dobson 2003). They have a characteristic “cross-β” X-ray fibre diffraction pattern, indicating 
a core parallel β-sheet structure with inter-chain H-bonds parallel to the axis (Marsh 1955; 
Antzutkin 2000). These highly ordered H-bonds allow the fibrils to persist in the body, build 
up, and encourage further fibril formation (Dobson 2003). Alzheimer’s disease is an example 
of a protein deposition disease resulting from the formation of extracellular amyloid deposits 
consisting of an aggregated amyloid β peptide. The amyloid forming pathway follows a 
characteristic pattern consisting of a lag/nucleation phase, elongation/fibril growth phase, and 
a final plateau phase (Figure 1.2). During the lag phase the protein is partially unfolded and 
soluble prefibrillar oligomers or nuclei are formed. Next, the nuclei transform into 
protofibrils which grow and associate during the elongation phase to form mature amyloid 
fibrils. Congo Red and Thioflavin T are dyes, used to indicate the presence of mature 
amyloid fibrils, which bind to structural elements of the fibrils (β-sheets) and not to specific 
amino acid sequences.  




Figure 1.2 The amyloid forming pathway. During the lag (nucleation) phase soluble prefibrillar 
oligomers or nuclei are formed. The native protein is destabilised and partially unfolded resulting in a 
number of intermediately folded species, some of which will aggregate to form nuclei. The nuclei 
transform into protofibrils which during the elongation phase grow and laterally associate to form 
mature fibrils. Modified from Wilson et al., 2008 and Chiti and Dobson, 2006. 
 
Amorphous or disordered aggregation is a process that occurs often in nature. For example, it 
is associated with several age-related diseases such as cataract (Truscott 2005). Amorphous 
aggregates lack any defined structure and are thought to assemble through the misfolding and 
exposure of once-internal hydrophobic residues, followed by random associations with 
similar species into larger structures (Linding et al. 2004; Chiti and Dobson 2006). Unlike 
linear processes of aggregation, where monomeric species form linear chains (as seen in the 
formation of amyloid fibrils), amorphous aggregation can be thought of as a three-
dimensional process, where misfolded monomers can associate from any direction (Stranks et 
al. 2009). It is thought that due to this property, amorphous aggregation is a comparatively 
rapid process, in which as aggregates increase in size the surface area available for monomer 
association increases (Stranks et al. 2009). However, like amyloid fibrils, the formation of 
amorphous aggregates first requires a nucleation step where a critical mass of aggregated 
core proteins must be reached before transition back to a monomeric state is energetically 
unfavourable. While some amorphous and pseudo-fibrillar structures can contain some cross-
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beta structure (as seen in human albumin modified by glycation), the large size of the protein 
prevents them from acquiring the order and regular structure typical of real amyloid fibrils 
(Bouma et al. 2003; Hassan et al. 2011). The presence of partially unfolded, multidomain 
proteins does not allow the protein to form ordered amyloid fibrils as each single protein 
molecule can form a variety of contacts with other similarly unfolded molecules resulting in 
amorphous structures (Hassan et al. 2011). 
 
1.2.4 Diseases linked with protein aggregation, and the underlying mechanisms of 
pathology 
Protein aggregates are implicated in the pathology of numerous serious human diseases 
termed protein deposition diseases (PDDs), which include age related, systemic, and 
neurological disorders (Table 1.1) (Dobson 1999; Yerbury et al. 2007; Wyatt et al. 2009). 
These diseases all share a common aspect which is the appearance and formation of non-
native misfolded proteins which have then aggregated into insoluble proteinaceous deposits 
ranging in size from relatively innocuous deposits to comparatively large insoluble senile 
plaques (Taylor 2002; Chiti and Dobson 2006; Chakravarthy et al. 2010). During disease, the 
complex network of protein quality control mechanisms that have evolved to maintain 
proteins at their correct levels and in their native structures is overcome and is unable to cope 
and maintain proteostasis (Soti and Csermely 2003; Morimoto 2006). In addition to their 
direct toxic effects, aggregated proteins can also indirectly promote damaging pathologies 
through excessive inflammatory responses, the processing of neuroendocrine factors, and 
activation of tissue plasminogen activator (Casserly and Topol 2004; Kranenburg et al. 2005; 
Herczenik and Gebbink 2008). Common pathological aspects of PDDs include oxidative 
stress, hyperglycemia, inflammation and hyper tension, and can exacerabate the misfolding of 
proteins and aggregation (Davies and Delsignore 1987; Berlett and Stadtman 1997; Dobson 
1999; Bouma et al. 2003; Yerbury et al. 2005; Morimoto 2006). It is unclear whether these 
pathological aspects are the cause or the effect of the disease.  
 
Aside from diseases which present with extracellular protein deposits (Table 1.1), pathologies 
of several PDDs involve the prion-like spread of cytosolic misfolded proteins between 
neighbouring cells and the release of aggregates into the extracellular space (Munch et al. 
2011; Holmes and Diamond 2012; Hofmann et al. 2013). There are multiple hypotheses 
about which processes may be involved in the contiguous spread of toxic aggregate species. 
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In Alzheimer’s disease, Parkinson’s disease, and dementia (Parkinson’s disease-related), this 
can occur during apoptotic or autolytic cell death following the escape of aggregate from the 
lumen of lysosomes, or following their exocytosis independently of the endoplasmic 
reticulum and Golgi apparatus; this may also occur in ALS (Lee et al. 2005; Holmes and 
Diamond 2012; Gendreau and Hall 2013; Hofmann et al. 2013; Tsujimura et al. 2014). 
Conversely, the spread and propagation of protein aggregates derived from constitutively 
secreted extracellular proteins can be explained by “seeding-like” mechanistic behaviour 
where aggregate fragments can serve as templates and sites of nucleation for extracellular 
deposition, as well as intracellular deposition following their binding to cell-surface receptors 
and internalisation (Furukawa et al. 2013; Roberts et al. 2013). Improvement in the treatment 
of extracellular PDDs can only progress through better understanding of the underlying 
mechanisms of protein aggregate toxicity and how the complex networks of quality control 
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Table 1.1 Examples of peptides or proteins forming intracellular or extracellular non-amyloid deposits in human diseases 
Diseases associated with the deposits of the 
peptide or protein 
 




name of peptide 





Age-related macular degeneration 
 






Wyatt, A. (2009) 
Corneal dystrophy 
 






Truscott, R.J. (2005) 








Yong, J.L. et al. (2009) 










Neumann, M. et al. (2006) 
Kerman, A. et al. (2010) 











Wang, J. et al. (2003) 
Swash, M. (2013) 
Heavy chain deposition disease 
 









Aucouturier, R. et al. (1993) 









Perutz, M.F. and Windle, 
A.H. (2001) 









Joh, K. et al. (1990) 
Medullary cystic kidney disease - Familial 
juvenile hyperuricemic nephropathy - 
Glomerulocystic kidney disease  
Tamm-Horsfall urinary 





Rampoldi, L. et al. (2003) 
Bleyer, A.J. et al. (2005) 
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Multiple myeloma (Russell bodies) 
 






Matthews, J.B. (1983) 
Shultz, L.D. et al. (1987) 
Multiple myeloma (Russell bodies) 
 






Matthews, J.B. (1983) 












Singleton, A.B. et al. (2003) 









Danpure, C.J. et al. (1993) 
Rheumatoid arthritis 
 






Robinson, J.J. et al. (1993) 
++
Protein forms fibrillar non-amyloid deposits or tangles with semi-organised structure 
SS
Protein found as a mixture of amyloid and amorphously structured species 
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1.3 Maintenance of proteostasis 
1.3.1 The role of protein quality control 
It is necessary for the survival of organisms, that systems have evolved to deal with the 
massive task of maintaining protein homeostasis (proteostasis). It is imperative that the body 
efficiently isolate and rapidly clear any non-native unfolded protein or aggregates as quickly 
as they appear, as not to do so may be the cause of many PDDs mentioned in the previous 
section (Buchner 1996; Kaufman 2002). Molecular chaperones are conserved families of 
proteins that can prevent irreversible protein aggregation and keep proteins on the correct 
folding pathway by selectively binding to exposed hydrophobic regions on non-native 
proteins to form soluble complexes. The folding of most newly synthesised proteins will 
involve interaction with one or more molecular chaperones (Buchner 1996; Fink 1999; 
Dobson 2003). Chaperones act as catalysts, interacting with the substrate protein and 
increasing the efficiency of the folding process by reducing the chance for competing 
reactions. Chaperones can either assist in the folding/refolding of proteins in an active ATP-
dependent process, or work in a passive ATP-independent mode, for example the small heat 
shock proteins which simply hold non-native proteins in a stable and soluble form in 
preparation for future refolding or targeting for degradation by lysosomes or proteasomes 
(Fink 1999; Hartl and Hayer-Hartl 2002; Csermely 2003; Soti and Csermely 2003).  
 
1.3.2 The intracellular protein quality control system 
The endoplasmic reticulum (ER) is an important site for protein folding and secretion in 
eukaryotes and has thus evolved an efficient protein quality control system (Kaufman 2002). 
Intracellularly, a misfolded or aggregated protein is handled in one of three ways (Figure 
1.3). (i) The “unfolded protein response” may be stimulated, leading to the expression of 
molecular chaperones and translocation proteins that can refold proteins or direct them for 
proteolysis. (ii) Transportation to the lysosome via vesicle transport for degradation. (iii) 
Targeting of the protein for immediate ER-associated degradation (ERAD) via retro-
translocation to the ubiquitin-proteasome system in the cytosol. Proteins that reach the Golgi 
apparatus and remain misfolded are recognised as abnormal and may be sent back to the ER 
for ERAD, or undergo lysosomal/vacuolar degradation (Hong 1996; Shamu 1998; Brodsky 
and Mc Cracken 1999; Arvan et al. 2002; Kaufman 2002). 




Figure 1.3 Summary of the intracellular mechanisms of protein quality control. Non-native 
proteins may i) interact with molecular chaperones that either assist with refolding or direct them for 
proteolysis, ii) be transported to the lysosome via vesicle transport for degradation, or iii) be targeted 
for degradation via retro-translocation to the ubiquitin-proteasome system in the cytosol. When these 
quality control systems fail the non-native protein may accumulate in the endoplasmic reticulum or 
cytosol. Modified from Yerbury et al., 2005. 
 
The major classes of intracellular chaperones are the heat shock proteins (HSPs) and small 
heat shock proteins (sHSPs). Many of the small heat shock proteins are upregulated during 
stress conditions and prevent aggregation by binding to exposed hydrophobic regions of 
stressed proteins in an ATP-independent process, thereby protecting proteins from potential 
co-association with one another (Buchner 1996; Fink 1999; Hartl and Hayer-Hartl 2002). 
However, other heat shock proteins such as HSP70 use ATP to facilitate folding and 
refolding, competing against aggregation processes (Fink 1999). Molecular chaperones are 
the cornerstone of the protein quality control system, and when their capacity is exceeded or 
they can no longer perform their function, they can help to segregate toxic aggregated 
proteins by forming aggresomes or inclusion bodies in the cytosol (Kopito 2000; Barral 2004; 
Yerbury et al. 2005).  
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1.3.3 The extracellular protein quality control system 
Despite intracellular quality control, non-native proteins enter the extracellular space, yet 
under normal conditions aggregates do not accumulate and cause disease (Wyatt et al. 2013). 
Evidence suggesting the existence of an extracellular protein quality control system arose 
from research conducted in the 80’s, and 90’s. Margineanu and Ghetie (1981) found that in 
vivo non-native proteins were degraded more rapidly than native proteins (Margineanu and 
Ghetie 1981), and later Senior et al. (1991) showed that liposomes with exposed hydrophobic 
regions on their surface were cleared from circulation more rapidly than those with a 
hydrophilic outer layer (Senior et al. 1991). While these experiments suggested the existence 
of an extracellular proteostasis system, the components of such a system had long remained a 
mystery. Extracellular proteolysis of misfolded proteins was thought unlikely, as the 
proteasome is 300 times less abundant (<400 to 2400 ng/mL depending on ELISA technique) 
in plasma than inside cells and requires ATP (Zoeger et al. 2006; Sixt and Dahlmann 2008), 
which is 1000 times less abundant (31 – 51 nM) in the extracellular environment (Farias et al. 
2005). Intracellular chaperones could also be excluded as their concentrations in the 
extracellular environment are in the ng/mL range, and their chaperone capacity would be 
quickly overwhelmed in times of stress (Wilson et al. 2008). Current evidence suggests that 
extracellular chaperones (ECs) such as clusterin, alpha-2 macroglobulin and haptoglobin act 
as both sensors and disposal-mediators of misfolded proteins, termed “client proteins” in 
extracellular fluids. For specific information on individual ECs see section 1.3.3.1 and 
1.3.3.2. ECs function similarly to small heat shock proteins by (i) binding in an ATP-
independent manner to hydrophobic residues normally buried within the core of proteins but 
which have become exposed due to protein unfolding, and (ii) maintaining the solubility of 
extracellular misfolded proteins (preventing their aggregation) by forming complexes with 
them and directing them to cell surface receptors where they are internalised by receptor-
mediated endocytosis and proteolytically degraded in lysosomes (Yerbury et al. 2005; Wilson 
et al. 2008; Wyatt et al. 2009; Yerbury 2009) (Figure 1.4). The involvement of clusterin and 
alpha-2 macroglobulin (and proteases) in maintaining extracellular proteostasis will be the 
focus of this thesis.  
 




Figure 1.4 The proposed extracellular mechanisms of protein quality control. Extracellular 
chaperones bind to exposed hydrophobic regions on non-native proteins to form stable complexes. 
These chaperone-client complexes are internalised via receptor mediated endocytosis where they are 
directed by vesicles to the lysosome for degradation. This system is particularly important in the liver 
and macrophages. Modified from Yerbury et al., 2005. 
 
1.3.3.1 Clusterin 
Clusterin (CLU) is a conserved heterodimeric glycoprotein consisting of α- and β-chains 
connected by disulfide bonds. Its expression is upregulated in response to various cellular 
stresses and diseases and it is abundant in tissue fluids such as plasma, semen, milk, urine and 
cerebrospinal fluid. Many putative functions were proposed for CLU but most of these lacked 
experimental evidence to substantiate them (Kapron et al., 1997; Rosenburg and Silkensen, 
1995; Choi-Miura et al., 1992; Blaschuk et al., 1983; Fritz and Murphy, 1993). Humphreys et 
al. (1999) reported the ability of CLU to protect a variety of proteins from stress induced 
precipitation by binding to hydrophobic regions and forming soluble high molecular weight 
complexes, a chaperone-like action similar to that of the sHSPs (Humphreys et al. 1999; 
Poon et al. 2002). This work was extended and it was demonstrated that CLU works via an 
ATP-independent mechanism and does not refold proteins, but holds them in a stable state 
competent for subsequent refolding (Poon et al. 2000). CLU is found associated with 
Alzheimer’s plaques in the brain (Calero et al. 2000), thus an obvious extension of the 
characterisation of the chaperone action of CLU was to investigate its interaction with 
amyloid forming proteins. Yerbury et al. (2007) reported that at molar ratios of CLU to client 
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protein of 1:10 (eg. CLU:Aβ), CLU inhibits the formation of amyloid fibrils by a number of 
proteins by binding to pre-fibrillar intermediates, not mature fibrils (Yerbury et al. 2007). 
However, at higher CLU to client protein ratios of 1:500 (eg. CLU:Aβ), CLU increases the 
formation of amyloid structures (of several client proteins) and promotes aggregate toxicity. 
It has been proposed that prefibrillar species are toxic, which explains why at low 
concentrations CLU can promote the cytoxicity of amyloid aggregates. At low concentrations 
CLU may be unable to interact with all exposed regions of hydrophobicity, instead stabilising 
aggregating proteins into structures which are toxic (Yerbury et al. 2007; Wilson et al. 2008). 
CLU has been shown to facilitate the clearance of Aβ in brains of mice (Bell et al. 2007). 
Studies with CLU-knockout mice support the hypothesis that CLU performs an important 
physiological role as an extracellular chaperone. Aging mice deficient in CLU developed a 
progressive glomerulopathy characterised by the deposition of insoluble protein deposits of 
immunoglobulins in the mesangium of the kidney (Rosenberg et al. 2002). Another study 
involving double-knockout mice deficient in CLU and apolipoprotein E concluded that these 
two proteins work in conjunction to inhibit the deposition of fibrillar Aβ aggregates in a 




Alpha-2-macroglobulin (A2M) is given a dedicated chapter which explores the impact of 
different quaternary structures of A2M, and A2M:protease complexes on its ability to 
chaperone aggregating client proteins. For a more in depth review of A2M see Chapter 3, 
section 3.1. However in short, like CLU and haptoglobin, A2M is a secreted glycoprotein 
with disulfide linked subunits, abundant in human plasma; it can mediate ligand degradation 
via receptor-mediated endocytosis, and is known to be associated with amyloid deposits in 
Alzheimer’s disease (Jensen and Sottrup-Jensen 1986; Sottrup-Jensen 1989; Ashcom 1990; 
Fabrizi et al. 2001). A2M protects misfolded proteins from stress induced precipitation by 
forming stable complexes with them via hydrophobic reactions in an ATP-independent 
holdase mechanism, similar to that of the sHSPs (French et al. 2008). A2M is synthesised by 
microglia and is known to be associated with amyloid deposits in Alzheimer’s disease, 
forming stable complexes with prefibrillar amyloid-beta (Aβ) which can then be degraded via 
a lipoprotein receptor-related protein (LRP)-mediated pathway (Narita et al. 1997; Hughes et 
al. 1998; Yerbury et al. 2009). Thus A2M may also play a role in inhibiting the progression 
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of Alzheimer’s disease by minimising the concentration of amyloid monomers available for 
nucleation and suppressing the aggregation of Aβ. A2M is best known as a broad spectrum 
inhibitor of proteases that functions in haemostatic and inflammatory reactions (Harpel 1973; 
Imber 1981). As A2M is both chaperone and protease inhibitor (French et al. 2008), this 
would potentially allow for cooperation between chaperone and proteolytic mechanisms of 
protein quality control.  
 
 
1.4 The plasminogen activation system 
The extracellular fibrinolytic system termed the “plasminogen activation system” has been 
reported to play a role in extracellular proteostasis. Fibrillar protein aggregates are able to 
initiate the plasminogen activation system, which is then able to degrade the protein 
aggregates to facilitate their removal (Tucker et al. 2000; Kranenburg et al. 2002; Gebbink 
2011). 
 
1.4.1 Tissue-type plasminogen activator-mediated plm generation and fibrinolysis 
The plasminogen system consists of many proteolytic enzymes with functions ranging from 
tumour invasion and metastasis, tissue remodelling (Reuning 1998; Dano 2005), reproduction 
(Gilabert et al. 1995), to the inflammatory response (Clemmensen and Andersen 1982) and 
haemostasis (Mathias 2007). The functionality of the plasminogen activation system requires 
the involvement of several proteins. These include the main enzyme of this system plasmin 
(plm; a broad spectrum serine protease), plasminogen (plg; the zymogen form of plm), 
specific mammalian plg activators, urokinase (uPA) and tissue-type plg activator (tPA), as 
well as plg-activator inhibitors type-1 and -2 (PAI-1/PAI-2), and plasmin specific inhibitors 
alpha-2-antiplasmin (A2AP) and A2M (Figure 1.5) (Anonick et al. 1990; Andreasen et al. 
2000). Plm degrades fibrin and fibrinogen with the highest specificity. Termed fibrinolysis, 








Figure 1.5 Simplified diagram of the fibrinolytic system and potential interactions between the 
plasminogen activation and matrix metalloproteinase systems. The synthesis of tissue 
plasminogen activator (tPA), urokinase plasminogen activator (uPA), matrix metalloproteinases 
(MMPs) and their inhibitors are regulated by hormones, growth factors and cytokines. tPA and uPA 
stimulate the conversion of plasminogen into active plasmin (plm), and are inhibited by plasminogen 
activator inhibitor type-1 and -2 (PAI-1 / PAI-2). The main enzyme of the fibrinolytic system is plm, 
which can degrade some components of the extracellular matrix (ECM), convert pro-matrix 
metalloproteinases into active MMPs (also capable of degrading the ECM), and degrade fibrin into 
small soluble plm-generated protein fragments (PGPFs). Plm is inhibited by alpha-2 antiplasmin 
(A2AP) and alpha-2 macroglobulin (A2M). Modified from Andreasen et al., 2000, Ny et al., 2002 
and Mathias, 2007. 
 
Synthesised in the liver and found in plasma and most extracellular fluids as a inactive 
zymogen, plg is maintained at a stable plasma concentration of 2 μM (Ponting et al. 1992). 
Plg contains five homologous lysine-binding sites dubbed “kringle” domains which are 
responsible for interaction with fibrin and other lysine residues of tissue cell surface receptors 
and target molecules (Hoover et al. 1993; Menhart et al. 1995; Nilsen et al. 1999; Law et al. 
2012). The kringle domains bind to free lysine groups and lysine-like compounds such as 
trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (also known as tranexamic acid; TXA), 
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tPA is synthesised by endothelial cells and secreted in its pro-enzyme, single chain form into 
the intravascular space often close to a blood clot, with the primary role of preventing 
uncontrolled clot propagation (Vassalli 1991; Yepes 2008; Gebbink et al. 2009). Upon 
binding to a fibrin clot, tPA undergoes a conformational change leading to an increase in 





 peptide bond (Andreasen et al. 2000; Castellino and Ploplis 2005). Plm is 
capable of degrading the fibrin clots into small soluble fragments (van Zonneveld 1986; 
Cesarman-Maus and Hajjar 2005) and can be inhibited by the action of serine protease 
inhibitor(s) [serpin(s)] PAI-1 and PAI-2 (Alessi et al. 1991; Andreasen et al. 2000; Castellino 
and Ploplis 2005). In vivo, the serpins PAI-1 and PAI-2 block the conversion of plg to plm by 
inhibiting the activity of tPA through blocking of the active site and disposal of the formed 
tPA:PAI complex via internalisation by receptor-mediated endocytosis (Alessi et al. 1991; 
Andreasen et al. 2000; Castellino and Ploplis 2005). A2AP is the main physiological plm 
inhibitor in mammalian plasma, and like PAI-1 and PAI-2, is a serpin. It inhibits plm very 
rapidly by forming an inactive 1:1 stoichiometric complex with plm (Collen 1976; Collen and 
Wiman 1978; Lijnen 1982). 
 
The fibrinolytic system is safeguarded to ensure that the degradation of proteins by plm is 
kept local. Circulating tPA is cleared by the liver and has a short half life, and most tPA in its 
single chain form is bound to its inhibitor PAI-1. However once tPA has bound to fibrin it is 
refractory to inhibition by PAI-1 and 2 (Mathias 2007). tPA has roles beyond fibrinolysis, as 
plm is capable of degrading extracellular matrix proteins such as laminin and activating 
metalloprotease precursors, which can potentiate further degradation of extracellular proteins 
and trigger inflammatory responses (Vassalli 1991) as well as the ability to modulate the 
toxicity of fibrillar protein aggregates in Alzheimer’s disease by their degradation in vivo 
(Tucker 2000; Tucker et al. 2000).  
 
1.4.2 Further roles of tPA-mediated plg activation 
The blood brain barrier (BBB) is an interface which regulates the movement of substances 
between the brain and the intravascular space (Yepes 2008). tPA may regulate the 
permeability of the BBB, particularly following ischemic injury (such as in stroke), by 
activating plm which in turn regulates the activity of MMPs (Cuzner 1999; Aoki 2002; 
Kidwell 2008; Yepes 2008). MMPs are a family of endopeptidases that can modify and 
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cleave components of the extracellular matrix (ECM) and are activated by plm via proteolytic 
cleavage (Figure 1.5) (Cuzner 1999; Egeblad 2002). The ECM is important as it provides 
scaffolds for tissues, forms barriers between tissue compartments, and turn-over of the ECM 
is involved in wound healing. Thus, alterations of this matrix can result in breakdown of the 
BBB and neuronal degeneration. Laminin is an important component of the ECM and may be 
degraded by tPA-activated plm, or by plm-activated MMPs (Chen et al. 1997; Indyk 2003).  
Interestingly some of the main inhibitors of MMPs in tissue fluids are the ECs A2M and 
CLU. A2M:MMP complexes are cleared via LRP-mediated endocytosis (Egeblad 2002), 
while CLU is a negative regulator of MMP-6 produced by neutrophils and brain tumours 
(Matsuda 2003) and has been shown to bind to and inhibit the activities of MMP-3 and 
MMP-7 in vitro, and MMP-9 in epithelial cells (Jeong et al. 2012). This serves to protect host 
tissue from MMP-mediated degradation. 
 
The tPA system may also play a role in protecting neurons from damage in Alzheimer’s 
disease by regulating Aβ levels. Aβ can stimulate tPA activity, with the plm generated able to 
degrade both non-aggregated Aβ and Aβ fibrils (Tucker 2000), and Aβ may be cleared via 
association with α2M and internalisation by LRP (Hughes et al. 1998). Additionally, the 
inhibitors of tPA (PAI-1 and PAI-2) are increased in patients with Alzheimer’s disease, 
suggesting a “feed forward” model where Alzheimer’s disease increases the expression of 
tPA inhibitors, which reduces tPA and plm activation allowing more Aβ to accumulate, 
which produces even more tPA inhibitors (Akiyama et al. 1993; Melchor and Strickland 
2005). Like fibrin and amyloid proteins, stressed denatured proteins have also been found to 
serve as substrates and activators of the fibrinolytic system (Radcliffe and Heinze 1981). 
Thus, the tPA system can have both beneficial and detrimental actions. It can aid in the 
degradation of protein aggregates, or cause neurodegeneration by directly or indirectly 
degrading the ECM and BBB.  
 
1.4.3 Activation of tPA by protein aggregates 
As mentioned above, fibrin, the Aβ peptide, and non-native proteins can activate and be 
substrates for the tPA system, yet the structures of each of these are quite different. To 
investigate a possible common structure among ligands capable of binding to, and activating 
tPA, fibrin derived peptides were tested for their ability to stimulate tPA-mediated 
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plasminogen activation. It was found that the peptides able to activate tPA had an almost 
100% β-sheet structure (a structure indicative of amyloid fibrils) (Kranenburg et al. 2002). It 
has been reported that the conversion of fibrinogen to fibrin is associated with a general 
increase in β-sheet structure and that polymerised fibrin can bind amyloid dyes, suggesting 
amyloid properties (Marx 1979; Gebbink et al. 2009; Gebbink 2011)(Marx et al., 1979; 
Gebbink et al., 2009). Finally, injury induced protein cross-linking has been shown to form 
protein aggregates rich in β-sheet structure which can enhance tPA-mediated plg activation 
(Samson et al. 2009; Samson et al. 2012). These results suggest that tPA is a multiligand 
cross-β structure receptor. Cross-β sheets may act as cofactors, promoting the interaction 
between tPA and plg, resulting in the removal of β-sheet containing proteins by plm-
mediated degradation, regardless of amino acid sequence (Kranenburg et al. 2002; Samson et 
al. 2009). It is currently unclear whether the activation of the tPA system prevents toxicity by 
degrading and removing aggregates, or if the soluble fragments produced are toxic and can 
themselves cause damage to cells.  
 
1.4.4 Toxicity of fragments released by plm-mediated degradation 
Plm degradation of fibrin produces soluble products containing fragments from the central E-
domain and D-dimer of the fibrin molecule (Guo et al. 2009). Research investigating the 
toxicity of these plm-generated protein fragments (PGPFs), as well as fragments from other 
protein aggregates, is of great interest and is important for developing new therapeutic 
strategies for protein deposition diseases and stroke. It has been noted, that fibrin deposition 
on the surface of placental cells was associated with apoptosis which could be prevented by 
inhibiting fibrinolysis, suggesting that cell death was caused by the degradation of products 
of fibrin (Isermann et al. 2003). This work was expanded by Guo et al. (2009) who found that 
the Aα-chain in the fibrin fragment E (FnE) was responsible for apoptosis in placental 
trophoblast cells (metastasising cells of the placenta) after internalisation into the cytoplasm 
via caveolin-1-dependent endocytosis. Internalisation of the fibrin fragments activated the 
mitochondrial cell death pathway, resulting in a reduction of mitochondrial activity and 
electrochemical potential difference across the inner mitochondrial membrane (Guo et al. 
2009). Although the concentration of FnE used by Guo et al. (2009) was higher than 
circulating levels of FnE in humans, local concentrations of PGPFs near trophoblast cell 
surfaces are high enough to induce apoptosis, and similar conditions are present during 
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wound healing, tissue remodelling, and thrombotic injury in blood vessels. It is thought that 
apoptosis induced by PGPFs may be beneficial by aiding in clearing damaged cells from 
injury sites, but have deleterious cytotoxic effects when produced excessively, such as in 
acute lung injury and chronic lung disease (Siao and Tsirka 2002; Gando et al. 2004; Guo et 
al. 2009). The degradation of fibrin by plm is vital for the maintenance of haemostasis, yet 
despite the apparent toxicity of the fragments produced, biological functions are not impaired 
under normal conditions. This suggests the existence of mechanisms which protect cells from 
toxicity during the plm-mediated degradation of proteins.  
 
1.5 The synergy of extracellular chaperones and proteases to maintain extracellular 
proteostasis 
The discovery and characterisation of abundant ECs has led to the development of a model 
for extracellular proteostasis where chaperones defend against PDDs by binding to and 
preventing the aggregation of misfolded proteins (section 1.3.3). Building upon this, the 
proposed model (Figure 1.6) includes an additional protease arm of quality control that may 
function in tandem with ECs as part of a larger system to maintain proteostasis. In this new 
system protein aggregates activate and are subsequently degraded by tPA-activated plm. ECs 
then form a complex with the resulting PGPFs which are recognised by scavenger-like cell 
surface receptors, internalised via receptor mediated endocytosis and directed to lysosomes 
for degradation. This new theory is supported by research demonstrating that amyloid fibrils 
and denatured proteins can act as activators and substrates for the tPA and the plg activation 
system (Radcliffe and Heinze 1981; Tucker et al. 2000; Kranenburg et al. 2002; Samson et 
al. 2009) (section 1.4.3 and 1.4.4). In addition it has been shown that A2M associates with 
plasmin-degraded fibrin in vitro (Zammit 2009). However this experiment was only 
preliminary and further experiments should be conducted to determine if other ECs associate 
with PGPFs from fibrin and amorphous protein aggregates. Additionally, if PGPFs produced 
from plm-mediated degradation of aggregates are cytotoxic, the involvement of ECs presents 
a way in which plm can break down proteins while keeping the body protected from toxicity. 
Increased knowledge of these mechanisms could lead to the development of new therapeutics 
for the treatment of PDDs, such as Alzheimer’s disease and ALS. 




Figure 1.6 Hypothetical model for maintenance of extracellular proteostasis. Under normal 
conditions a) misfolded proteins or soluble oligomers can bind directly to scavenger receptors; b) 
extracellular chaperones can form stable complexes with misfolded proteins and/or soluble oligomers, 
keeping them soluble and facilitating their transport to scavenger receptors, and c) insoluble protein 
aggregates activate proteases, and extracellular chaperones interact with the soluble fragments 
produced, facilitating their transport to scavenger receptors. The chaperone:client complexes are then 
internalised via receptor-mediated endocytosis and delivered to lysosomes for degradation. Modified 
from Dabbs et al., 2013.  
 
1.6 Conclusions 
The folding of an amino acid sequence into its correct native three dimensional structure is 
vital for a protein to perform its normal function. As a result of various stress conditions, 
proteins may unfold and form aggregates, a process associated with many harmful protein 
deposition diseases such as Alzheimer’s disease. Thus the body has evolved intra- and 
extracellular systems of protein quality control to maintain proteostasis, with relatively little 
known about the processes that operate in the extracellular environment. ECs such as CLU 
and A2M bind to exposed hydrophobic residues on misfolded proteins and form soluble 
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complexes with them which can then be disposed of via receptor-mediated endocytosis. 
Furthermore, physiological stresses may induce A2M to adopt more chaperone-active 
quaternary structures (dimers and monomers) to enhance its ability to safely dispose of 
misfolded proteins (see Chapter 3). Synergy between the plg activation system and ECs may 
form a critical pillar, functionally underpinning the extracellular proteostasis system. 
Amyloid fibrils, fibrin and denatured proteins can all act as substrates and activators for tPA, 
and the extracellular chaperone A2M can bind to toxic fibrin-derived PGPFs. More detailed 
analysis of the interactions between ECs and the tPA system, and the toxicity and fate of the 
resulting EC:PGPFs complexes, will provide a better understanding of the mechanisms of 
extracellular proteostasis, and aid in the development of new therapeutics to treat serious 
protein deposition diseases. 
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CHAPTER 2 : GENERAL MATERIALS AND METHODS 
 
2.1 Cell lines and established tissue culture 
EOC-13.31 microglial-like, SVEC4-10 endothelial-like and LADMAC cell lines were 
obtained from the American Type Culture Collection. Cell lines were grown in DMEM/F12 
media (Life Technologies) containing 10 % (v/v) foetal calf serum (FCS) at 37°C/5%CO2, 
and subcultured when they reached 80% confluency. EOC-13.31 cells were additionally 
supplemented with 20% (v/v) LADMAC conditioned media containing colony stimulating 
factor-1 (CSF-1), which is secreted by the cell line. LADMAC conditioned media was 
harvested from LADMAC cell tissue culture supernatant by centrifugation at 500 x g for 5 
min, and sterile filtration. For experiments involving the addition of chaperones, cells were 
incubated with treatments in DMEM/F12 containing 1% (v/v) FCS at 37°C/5%CO2 in an 
effort to limit the effects of residual chaperone which may be present in the FCS.  
 
2.2 Purification of primary polymorphonuclear neutrophils 
Fresh human blood was obtained from members of the Wilson lab, with the addition of 200 
µL of 1M sodium citrate per 20 mL of whole blood to prevent coagulation. Blood was slowly 
layered above 20 mL of Polymorphprep (Fisher Biotec) and then centrifuged at 500 x g for 
35 min at room temperature (20˚C), with deceleration set to 0 (no assisted-braking) in a 
multifuge X3R centrifuge (ThermoFisher). Simultaneously, 3 mL of plasma (purified as per 
2.6) was heated to 55˚C for 30 min to inactivate complement factors. Heat inactivated plasma 
was then placed on ice for 30 min and cleared of precipitation by centrifugation at 2,500 x g 
for 10 min at 4˚C. Once the whole blood was fractionated into distinct layers, the 
polymorphonuclear neutrophil (PMN) layer was gently removed (as outlined in the SOP 9.2 
of the Sanderson-Smith lab) and washed twice with saline (5 mM sodium phosphate and 85 
mM NaCl, pH 8) to remove any contaminating erythrocytes using osmolytic stress, by 
centrifugation at 180 x g for 10 min at room temperature (20˚C), with deceleration set to 0. 
PMNs were quantified using a hemocytometer and resuspended to a concentration of 1.0 x 
10
6
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2.3 Bicinchoninic acid (BCA) assay  
1% (w/v) BCA was dissolved in a sufficient volume of solution A (20 g/L sodium carbonate, 
1.6 g/L sodium tartrate, 9.5 g/L sodium bicarbonate, pH 11.25 with NaOH). Solution B (4% 
(w/v) CuSO4 in H2O) was added to a ratio of 1:50 (v/v) to solution A, yielding solution C. 
Bovine serum albumin (BSA) of known concentration (80 µg/mL) in phosphate-buffered 
saline (PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4) was 
serially diluted in triplicate in a 384 well microtitre plate (Greiner Bio-one) to produce a set 
of protein standards. Similarly, protein(s) of unknown concentration were also serially diluted 
with PBS to give a final volume of 50 µL in each well. Solution C was then thoroughly 
mixed by vortexing (Super-mixer; Lab-line instruments, Inc.), and 50 µL added to each well. 
The plate was then incubated at 60˚C for 15 min to allow colour development and the 
absorbance at 562 nm measured using a Spectramax Plus 382 plate reader (Molecular 
Devices). The concentration of unknown protein(s) was interpolated from the standard curve 
constructed using the BSA standards. 
 
2.4 Biotinylation of proteins 
A stock solution of biotin-LC-N-hydroxysuccinimide (Biotin-LC-NHS; ThermoFisher) was 
prepared at 40 mg/mL in dimethyl sulfoxide (DMSO). Sufficient biotin stock was added to 
protein (at 1-2 mg/mL in 0.1 M sodium bicarbonate, pH 8.5) to give a ratio of 0.25 mg biotin-
LC-NHS per mg of protein and incubated for 2 h at room temperature with gentle shaking. 
Excess, un-reacted biotin-LC-NHS was removed by dialysing the mixture against three 
changes of PBS/0.1 % Az at 4˚C. Protein concentration was subsequently determined using a 
BCA assay. 
 
2.5 Fluorophore (CF-488) labelling of proteins 
Proteins at a concentration of 1 mg/mL were buffer exchanged into PBS either by dialysis or 
by using protein desalting spin columns (Amicon Ultra-0.5 mL Ultracel 3k; Merck-
Millipore). 1M sodium bicarbonate pH 8.3, 10% (v/v) was added to adjust the pH to optimise 
labelling efficiency. CF-488 SE dye (Biotium) dissolved in 25 µL anhydrous DMSO and 
reacted with protein for 1 h at room temperature in the dark, with gentle rocking. Excess, 
unreacted CF-488 SE dye was removed by gel filtration using a 5/20 Sephadex G-25 column 
equilibrated in PBS/0.1% Az (GE Healthcare) and eluted fractions were collected using an 
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ÄKTA FPLC system (GE Healthcare). Fractions containing CF-488 labelled protein were 
pooled and the protein concentration was determined using a BCA assay. 
 
2.6 Preparation of human plasma from whole blood 
Fresh human blood used in this study was donated by healthy consenting volunteers under the 
approval of the University of Wollongong and Illawarra Shoalhaven Local Health District 
Health Medical Human Research Ethics Committee (HE02/080). Blood was obtained from 
Wollongong Hospital and supplemented with 10 mM sodium citrate to prevent coagulation. 
Citrated whole blood was centrifuged at 1300 x g for 30 min at 4˚C in an X3R multifuge 
(ThermoFisher). Plasma was gently decanted from the pelleted red blood cells, pooled, and if 
not used immediately stored at -20˚C for later use. Prior to protein purification steps, frozen 
plasma was thawed and one crushed tablet of Complete Protease Inhibitor (Roche) was 
dissolved in approximately 400 mL of cleared plasma. Plasma was then filtered cold through 
GF/C glass fibre filters (Whatman) to remove cell debris and subsequently through 0.45 µm 
nitrocellulose filters (Sartorius). Citrated plasma was used as source material for the 
purification of clusterin (section 4.2.1), plasminogen (section 4.2.2), and immunoglobulin-G 
(section 4.2.3). Plasma used in the purification of alpha-2 macroglobulin (section 3.2.1) was 
prepared in a similar manner with the following exceptions; to 50 mL of whole blood, 100 µL 
of 1000 IU/mL of heparin (to prevent coagulation) and half a tablet of EDTA-free Complete 
Protease Inhibitor cocktail (Roche) were added. Following centrifugation and decanting 
steps, the heparinised plasma was supplemented with 1 M NaCl and 200 mM HEPES prior to 
subsequent purification steps. 
 
2.7 SDS-PAGE 
Gel electrophoresis was performed on polyacrylamide gels using the method of Laemmli 
(Laemmli 1970). Purified proteins were analysed under reducing and non-reducing 
conditions. Samples containing 10 µg of protein were prepared by diluting 1 in 2 with 2X 
SDS-PAGE loading buffer (100 mM Tris-HCl, 20% (v/v) glycerol, 4% (w/v) SDS, 0.2% 
(w/v) bromophenyl blue, pH 6.8) and adding 1% (v/v) 2-mercaptoethanol for reduced 
samples. The samples were then heated for 5 min in 100˚C heating block before being loaded 
onto the gel. The acrylamide gels used are characterised by the total percentage concentration 
(#%) of both monomers (acrylamide and the crosslinker bisacrylamide) (Hjerten 1962). Gels 
were prepared by layering a 5% stacking gel layer atop a resolving gel layer between 8-12%, 
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dependant on the separation range required for the protein samples being analysed. The 
resolving gel layer was buffered using a final concentration of 375 mM Tris-base at pH 8.8, 
while the stacking gel layer was buffered using 126 mM Tris-base at pH 6.8. Both gel layers 
contained 0.1% (w/v) SDS and 0.1% (w/v) ammonium persulfate. Polymerisation of the 
resolving gel layer was initiated by adding 4 µL of TEMED. The mixture was transfered to 
the gel cassettes; and filled to approximately 1.5 cm from the top of gel cassette (which is 
reserved for the stacking gel) and gently overlayed with a small volume (0.5 mL) of 100% 
absolute ethanol to remove bubbles. Gel was polymerised for 30 min at room temperature 
and the layer of ethanol removed for addition of the stacking gel. The stacking gel layer was 
polymerised by adding 5 µL of TEMED and transferred to the gel cassettes and a comb 
inserted with the required number of wells and polymerised for 30 min at room temperature. 
The cast gel was then transferred to a “Mighty Small II Mini Vertical Electrophoresis Unit” 
(Hoefer Inc.) and clamped into position. The reservoir was filled with SDS-PAGE running 
buffer (192 mM glycine, 3.5 mM SDS, 25 mM Tris-base) and electrophoresis carried out at 
constant voltage at 150 V for 90 min using a PowerPac Basic (Bio-Rad) or until the dye front 
had migrated out from the bottom of the gel. Gels were stained with Coomassie Blue Stain 
(40% (v/v) methanol, 10% (v/v) acetic acid, 0.15% (w/v) Coomassie Blue R250) at room 
temperature for an hour before being destained (40% (v/v) methanol and 10% (v/v) acetic 
acid). 
 
2.8 Flow cytometry 
All flow cytometry was conducted with a LSRII flow cytometer (BD) (excitation at X nm, 
emission collected at X ± X nm). Data was acquired using BD FacsDiva software v8.0.1 and 
analysed post-acquisition using FlowJo v5.0 software. Specific wavelengths (denoted by X) 
are identified in the appropriate methods sections. Dead cells stained with 3 µM propidium 
iodide (PI) were electronically excluded from the analyses unless stated otherwise. 
 
 




CHAPTER 3 : THE CHAPERONE ACTIVITIES OF DIFFERENT QUATERNARY 
STRUCTURES OF A2M, AND A2M:PROTEASE COMPLEXES  
 
3.1 INTRODUCTION 
Alpha-2 macroglobulin (A2M) is a 720 kDa glycoprotein homotetramer (four 180 kDa 
identical monomers; with 10% carbohydrate by mass) formed from two disulfide-linked 
dimer pairs which are associated by non-covalent interactions (Jensen and Sottrup-Jensen 
1986). In the native A2M, dimer pairs are arranged around a large central cavity in an open 
cage-like structure, to yield the final quaternary structure (Figure 3.1) (Marrero et al. 2012). 
A2M is a broad-spectrum inhibitor of extracellular proteases with a unique mode of action 
that functions in haemostatic and inflammatory reactions (Harpel 1973; Imber 1981; LaMarre 
et al. 1991). Proteases cleave A2M internally within a peptide stretch termed the bait region, 
which contains recognition sequences for serine proteases such as trypsin and plasmin as well 
as other protease families (Figure 3.1B) (Sottrup-Jensen 1989). Cleavage of the bait region by 
a protease exposes internal beta-cysteinyl-gamma-glutamyl thiol esters - activation of two 
ester bonds results in covalent binding of the protease (Saunders et al. 1971) and induces a 
large conformational change converting the open cage-like structure to a closed 
conformation, trapping the protease in a steric cage (Cummings et al. 1984; Feldman et al. 
1985). These changes, collectively referred to as “activation”, result in the formation of an 
A2M:protease complex, and are accompanied by exposure of a binding-site for the cell-
surface receptor low density lipoprotein receptor-related protein (LRP) (Roche and Pizzo 
1987; Roche and Pizzo 1988). Depending on the size of the protease, A2M can bind up to 
two protease molecules in a ternary complex (Howell et al. 1983; Christensen and Sottrup-
Jensen 1984). The central cavity in activated A2M is 60 Ǻ in diameter and approximately 
167,000 Ǻ
3
, allowing the trapping of proteases that total up to approximately 90 kDa in mass 
(Marrero et al. 2012). This allows for the formation of A2M:protease complexes containing 
two trypsin (23.3 kDa) or one plasmin (83 kDa) molecule, respectively. Despite being 
sterically trapped, the bound protease(s) are active and can cleave small molecules which are 
able to enter the A2M:protease complex through openings in the structure (Ganrot 1966; 
Barrett and Starkey 1973). Small nucleophiles such as amines (e.g. methylamine, ammonium 
ions) can also induce A2M to adapt the closed, active conformation, by reacting directly with 
the internal thiol ester bonds (Imber 1981). 




Figure 3.1 Schematic structure of A2M monomer subunit and activation by protease cleavage 
(A) The A2M monomer is 180 kDa in size and is comprised of seven macroglobulin-like domains 
(MG1-MG7), a thioester domain (TED) flanked by two structural motifs (CUB; complement protein 
subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1) and a 
receptor binding domain (RBD) with recognition-sites for LRP. N-linked glycosylation sites are 
marked (black asterix). Within MG6 is the flexible bait region domain (residues690-728) which contains 
the cleavage site for a broad-spectrum of proteases. The thioester motif (CGEQ; residues972-975) is 
located within the TED. Image modified from Neves, D. et al. (2012). (B) In A2M the disulfide-
linked (S-S) dimer pairs are arranged around a large central cavity (purple dashed lines) containing 
four bait regions (blue rectangles) and thioester bonds (green loops) in close proximity to one another. 
Cleavage of one or more bait regions by a protease (plg in red) results in emergence of thioester 
bonds. Breaking of thioester bonds induces a large conformational change resulting in the activated 
form of A2M, sterically trapping the protease and exposing LRP-binding sites. Image modified from 
Boisset, N. et al. (1996). (C) The conformational change induced by activation of A2M results in the 
lateral compression and lengthening of the quaternary structure (arrows). The state of A2M activation 
can be distinguished electrophoretically due to these structural changes, based on their speed of 
migration through a polyacrylamide gel matrix. Native A2M migrates slower (Slow-form) in 
comparison to activated A2M (Fast-form). The central cavity (60 Ǻ in diameter as indicated by scale 




bar) can accommodate up to two trapped proteases based on their size (single plg shown). Image 
modified from Law, R. et al. (2012).  
Like other ECs, A2M is a secreted glycoprotein abundant in human plasma, which protects 
proteins from stress induced precipitation by binding to them via hydrophobic interactions 
(French et al. 2008). This ATP-independent holdase mechanism is similar to that of 
intracellular sHSPs. A2M-client protein complexes can be bound by cell-surface LRP, 
internalised by receptor-mediated endocytosis and subsequently degraded (French et al. 
2008). PDDs, including several neurodegenerative diseases, cardiomyopathy, and arthritis-
related diseases, are associated with reductive and oxidative (redox) stress which can induce 
protein misfolding and aggregation. Protein aggregates, in turn, compound the pathology by 
inducing inflammation (Papp et al. 2003; Tabner et al. 2005), which results in the release of 
oxidants, proteinases, and cytokines (Casserly and Topol 2004). A2M helps mediate 
inflammatory responses by binding and regulating the biological activities of a number of 
inflammatory cytokines and growth factors including; interleukins-1β and 6, transforming 
growth factor-β1 and 2, tumor necrosis factor-α, platelet derived growth factor, nerve growth 
factor, and fibroblast growth factor (LaMarre et al. 1991; Feige et al. 1996). The clearance of 
several cytokines is increased by their non-covalent binding to activated A2M, receptor 
mediated endocytosis via LRP and subsequent degradation in lysosomes (LaMarre et al. 
1991; Crookston et al. 1994; Gonias et al. 1994). In addition, following internalisation of 
A2M-peptide complexes by LRP-mediated endocytosis, fragments of the peptide are 
presented on the cell surface serving a valuable immunological role - a similar role is played 
by exogenous (normally intracellular) HSPs (Binder et al. 2002).  
 
A2M was recently shown to have an extracellular chaperone activity similar to that of CLU 
(French et al. 2008). A2M is synthesised mainly in the liver, and locally by leukocytes 
(White et al. 1980), while gene expression is induced by a variety of factors in an acute phase 
dependant manner (Milosavljevic et al. 2002). The acute phase response is a non-specific 
inflammatory state which results in the increased expression and release of important 
mediators of the inflammatory cascade including oxidants, proteinases, cytokines and A2M 
(which shows a 2-fold increase in humans) (Schreiber et al. 1982; Koenig and Rosenson 
2002; Casserly and Topol 2004; Tabner et al. 2005). In plasma under physiologically-
relevant shear-stress, A2M was found to bind to four aggregating client proteins 
(ceruloplasmin, fibrinogen, alpha-1-acid glycoprotein and complement component 3) all of 
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which are acute phase proteins (Wyatt et al. 2013). Conditions which induce acute phase 
responses such as increased local temperature, low pH and generation of reactive oxygen 
species are likely to enhance protein unfolding. Strikingly, these conditions are also likely to 
induce dissociation of the A2M tetramer (Barrett et al. 1979; Wyatt et al. 2014). 
 
A2M is found in the plasma and CSF of healthy humans mainly as a tetramer. However, in 
different species A2M can exist as tetrameric, dimeric and monomeric forms, all of which 
can function as protease inhibitors (Sottrup-Jensen 1989). In humans, under physiological 
conditions 4-5% of the extracellular A2M pool is in the form of circulating disufide-linked 
dimers (Ozawa et al. 2011). A2M dimers have been found to be dissociated by oxidative 
conditions often related with PDDs such as rheumatoid arthritis (Wu and Pizzo 2001) and 
Alzheimer’s disease (Cocciolo et al. 2012), and by hypohalous acids released by 
inflammatory-stimulated leukocytes (Reddy et al. 1989; Reddy et al. 1994) as well as 
hypochlorite released by neutrophils and microglia (Wyatt et al. 2014). In humans, A2M 
monomers in plasma have been identified as a clinical biomarker in patients with diabetes 
(Takada et al. 2013). Takada et al. (2013) report a ~2-fold increase of A2M monomer to 1 – 
1.7 µM in diabetic patients with retinopathy, and a ~1.5-fold increase in diabetic patients with 
nephropathy, relative to healthy controls. In addition, monomeric A2M, also referred to as 
‘cardiac isoform of A2M’, serves as an early molecular marker for cardiac hypertrophy 
(Rajamanickam et al. 1998), myocardial infarction in diabetes, (Annapoorani et al. 2006), 
and cardiac diseases (Rathinavel et al. 2005; Ramasamy et al. 2006). Reportedly, in all cases, 
the plasma concentration of A2M monomer is increased ~2-fold, relative to healthy controls. 
In addition to these diseases there are several conditions such as stresses in aging (Squier 
2001; Papp et al. 2003; Morimoto 2006), and the acute phase response (which is 
accompanied by inflammation, pH and temperature changes, and redox stress), that could 
induce the formation of A2M monomers (Barrett et al. 1979; Schreiber et al. 1982; Koenig 
and Rosenson 2002; Casserly and Topol 2004; Tabner et al. 2005; Wyatt et al. 2014). 
 
While native tetrameric A2M has been shown to exert a potent chaperone-like activity akin to 
the sHSPs against diverse client proteins (French et al. 2008; Yerbury et al. 2009), 
hypochlorite at physiologically relevant concentrations has been shown to dissociate A2M to 
dimers, and increase the ability of A2M (relative to the tetramer) to inhibit the aggregation of 




several client proteins (Wyatt et al. 2014). The ability of A2M monomer to inhibit protein 
aggregation has not previously been studied.  
 
Collectively, A2M has been shown to bind to many diverse ligands and proteases, influence 
the immune response, and inhibit the amorphous or amyloid aggregation of many different 
client proteins. It is possible that A2M may alter its chaperone activity in response to changes 
in the extracellular environment.  
 
The aims of the work described in this chapter were to investigate whether: 
1. A2M can adopt different quaternary forms (dimers and monomers) in response to 
oxidative or reductive conditions, and whether these dimeric and monomeric forms 
exhibit different levels of chaperone activity compared to the native A2M tetramer 
2. Proteolytically activated A2M can inhibit protein aggregation, and whether the level 









3.2.1 Alpha-2 macroglobulin purification 
3.2.1.1     Zn
2+ 
affinity chromatography 
Two 5 mL HiTrap chelating columns (GE Healthcare) were connected in tandem to an 
ÄKTA FPLC system (GE Healthcare) and recharged with zinc prior to use. Zn
2+
 affinity 
columns were recharged by first equilibrating in binding buffer (20 mM HEPES, 1 M NaCl, 
pH 7.4) at a flow rate of 5 mL/min, stripped with 50 mL of zinc stripping buffer (20 mM 
HEPES, 0.5 M NaCl, 50 mM EDTA, pH 7.4), washed with 100 mL of milli-Q H2O and 
recharged using 10 mL of zinc recharge solution (0.1 M ZnSO4) at a rate of 1 mL/min. The 
columns were re-equilibrated using 100 mL of binding buffer and loaded with 50 mL of 
filtered, heparinised plasma (section 2.6), at a rate of 1 mL/min. A2M was eluted step-wise 
by first using elution buffer 1 (20 mM HEPES, 0.5 M NaCl, 20 mM imidazole, pH 7.4) to 
wash loosely bound protein contaminants from the columns before eluting the bound A2M 
with elution buffer 2 (20 mM HEPES, 0.5 M NaCl, 0.5 M imidazole, pH 7.4). The eluate 
containing A2M was collected and dialysed against three changes of PBS/0.1% Az, prior to 
subsequent size exclusion chromatography. 
 
3.2.1.2     Size exclusion chromatography 
A2M equilibrated in PBS/0.1% Az (section 3.2.1.1) was then further purified by size 
exclusion chromatography (SEC) using a HiPrep 16/60 Sephacryl S-200 HR column (GE 
Healthcare) equilibrated in PBS/0.1% Az and connected to an ÄKTA FPLC system (GE 
Healthcare). The sample was applied to the column at a rate of 0.5 mL/min. Fractions of 1 
mL were collected and analysed by 8% SDS-PAGE (section 2.7). Those containing pure 
A2M were pooled and concentrated using an Amicon Ultra-15 filter unit (Merck Millipore; 
30 kDa cut-off) and stored at 4˚C. Protein concentration was determined using a BCA assay 
(section 2.3). 
 
3.2.2 Generation of dimeric and monomeric alpha-2 macroglobulin 
A2M was purified as per section 3.2.1 and dissociated into dimers or monomers by 
incubating in PBS under either oxidising or reducing conditions, respectively. A2M was 
dissociated into stable dimers by oxidation-mediated disruption of non-covalent interactions 
between dimer pairs, in the presence of 500 µM NaOCl (Wyatt et al. 2014) for 8 h or 1.6-1.8 




M NaSCN (Shanbhag et al. 1996) for 1 h at room temperature and dialysed against three 
changes of PBS at 4˚C. NaOCl-treated A2M tetramer and dimer were separated by SEC 
using a BioSep-SEC-s3000 (Phenomenex) equilibrated in PBS connected to an ÄKTA FPLC 
system (GE Healthcare). Samples were applied over the column at a flow rate of 0.5 mL/min 
and the absorbance of the eluate at 280 nm (A280) continuously monitored to identify the 
elution of proteins. 150 µL fractions of column eluate were collected and separated into 
tetramer and dimer species, which correspond to the two observed peaks in Figure 3.2B. The 
two separated tetramer and dimer fractions were then analysed for purity by Native-PAGE 
(section 3.2.4) and subsequently dialysed against three changes of PBS at 4˚C. The region of 
overlap between the peaks corresponding to tetramer and dimer species was estimated by 
overlaying chromatographs of NaOCl-treated A2M and untreated native A2M. The 
difference in the area under the curve was calculated from these peaks excluding the region 
of overlap. A2M was dissociated into stable monomers by reduction of disulfide-bonds 
between subunits, and carboxymethylation to prevent oxidative re-association into tetramer 
during storage (Barrett et al. 1979). A2M was reduced by step-wise reaction with 1 mM 
dithiothreitol (DTT) in PBS for 30 min, and carboxymethylation with 1 mM iodoacetic acid 
for a further 45 min at room temperature, then dialysed against three changes of PBS at 4˚C. 
The quaternary structure of resulting A2M preparations was analysed by Native-PAGE 
(section 3.2.4) and SDS-PAGE (section 2.7). The A2M species generated were stable for 
several weeks when stored in PBS/0.1% Az, pH 7.4 at 4˚C, as assessed by Native-PAGE and 
SDS-PAGE. 
 
3.2.3 In vitro generation and purification of activated alpha-2 macroglobulin:protease 
complexes  
Pure native A2M (section 3.2.1) was activated by incubation with either ammonium cations 
or a serine protease (trypsin or plasmin). Native A2M was activated with 100 mM 
ammonium sulphate in PBS for 1 h at room temperature and immediately analysed, without 
dialysis, by NativePAGE. Activated A2M:protease complexes were formed by incubation 
with either trypsin or plasmin at a three times molar excess in PBS for 1 h at room 
temperature to ensure all A2M had been activated (and had trapped the maximum amount of 
protease). Unreacted protease was then inhibited by adding a four times molar excess of 
soybean trypsin inhibitor, relative to protease, and incubating in PBS for 1 h at room 
temperature. Free, unreacted protease and soybean trypsin inhibitor were removed via 
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multiple centrifugal concentration steps at 15,000 x g and 4˚C using a Vivaspin 500 
(Sartorius; 100 kDa cut-off) and PBS as diluent, in a Heraeus Fresco 21 (ThermoFisher) 
bench-top centrifuge. Using a method established by Nelles et al., 1980, the state of A2M 
activation was analysed by Native-PAGE (section 3.2.4) and SDS-PAGE (section 2.7) which 
compared activated A2M:protease complexes to native and ammonium-activated A2M. 
A2M:protease complexes were stable for several weeks when stored in PBS/Az, pH 7.4 at 
4˚C, as assessed by both Native-PAGE and SDS-PAGE. 
 
3.2.4 Native-PAGE analysis 
Native-PAGE was used to separate native proteins on the basis of differences in their mass 
and charge. This technique was used to analyse the activation state of A2M incubated with 
ammonium ions or in complex with proteases (section 3.2.3) and the extent to which A2M 
had dissociated following oxidation or reduction (section 3.2.2). Samples containing 
approximately 20 µg of total protein were prepared by mixing an equivalent volume of 
sample with that of 2 X Native-PAGE loading buffer (50 mM Tris-base, 400 mM glycine, pH 
8.3), under non-reducing conditions. Samples were then loaded onto the gel as described in 
section 2.7 (SDS-PAGE) with the following modifications. Gels were prepared by layering a 
4% stacking gel atop a 5% resolving gel layer. The resolving gel layer was buffered using a 
final concentration of 167 mM Tris-base at pH 8.3, while the stacking gel layer was buffered 
using 125 mM Tris-base at pH 6.8. Both gel layers contained no SDS. The reservoir was 
filled with Native-PAGE running buffer (40 mM Tris-base, 40 mM boric acid, pH 8.6) and 
electrophoresis carried out at a constant voltage of 150 V for 1 h and stained using Coomassie 
Blue Stain (section 2.7). Native-PAGE analysis performed under these conditions results in 
bands that are not as visually sharp and defined as in SDS-PAGE but that appear somewhat 
broad and streaky. 
 
3.2.5 Measure of exposed-hydrophobicity – bisANS binding assays 
NaOCl-dissociated A2M tetramer and dimer, NaSCN-dissociated dimer and reduced and 
carboxymethylated monomer were diluted in PBS to give a final concentration of 5 M and 
compared to an equal amount of native A2M tetramer (w/v) and 5 M BSA (used as a 
positive control) also in PBS. All samples were supplemented with 100 M 4,4′-bis(1-
anilino-8-naphthalene sulfonate) (bisANS; Sigma-Aldrich) and the relative bisANS-




associated fluorescence recorded using a POLARstar spectrophotometer (BMG Labtech); 
excitation and emission band pass filters used were 355 ± 5 nm and 490 ± 5 nm, respectively. 
 
3.2.6 In vitro chaperone activity assays 
The effects of native tetrameric A2M (section 3.2.1), dimeric and monomeric forms of A2M 
(section 3.2.2), and activated A2M:protease complexes (section 3.2.3) on the aggregation of 
client proteins were measured over time using either changes in turbidity (absorbance at 360 
nm; for amorphous aggregation) or changes in thioflavin-T (ThT)–associated fluorescence 
(for amyloid aggregation) with excitation and emission band pass filters of 440 ± 5 nm and 
490 ± 5 nm, respectively. Both were measured using a FLUOstar or POLARstar 
spectrophotometer (BMG Labtech). Creatine phosphokinase (CPK), citrate synthase (CS) and 
reduced and carboxymethylated α-lactalbumin (RCM α-lact) have been used as client proteins 
by numerous laboratory groups to measure the activity of chaperones. RCM α-lact is a 
disordered form of the protein with three of four disulfide bridges reduced, and is susceptible 
to fibrillation at physiological temperature and pH (Goers et al. 2002). The conditions 
(concentration, buffer, and temperature) and duration of incubation used to induce 
aggregation of client proteins is given below in Table 3.1. 
 















9.4 0.75 80 PBS 43 2 
Citrate Synthase 
(CS) 





100 1.4 14 PBS 37 12 
 
Client proteins CPK and RCM α-lact in PBS, and CS in TE buffer (50 mM Tris-base, 2 mM EDTA, 
pH 8.0) were heated at the temperature indicated to induce aggregation. 
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To measure amorphous protein aggregation, CPK or CS were incubated at 43˚C in 384-well 
plates (100 µL final volume) while continuously measuring turbidity in the absence or 
presence of: native A2M tetramer, or NaSCN- or NaOCl-dissociated dimer, or DTT-
dissociated A2M monomer (at equal mass concentration to the tetramer), or the non-
chaperone control protein ovalbumin (Ova; at the highest mass concentration of native A2M 
tested). For comparisons of the relative chaperone activities of A2M tetramer, dimer and 
monomer, the "subunit molar ratio" (SMR) of A2M to client (A2M:client) was used, which is 
calculated as the ratio of the number of moles of A2M monomer (regardless of whether the 
A2M is present as tetramer, dimer or monomer) to the moles of protein client. In this way, 
direct comparisons could be made at the same SMR between the relative chaperone abilities 
of different A2M forms (present at the same total mass concentration). Percent inhibition of 
aggregation was calculated by (i) subtracting background measurements of buffer and 
chaperone controls from their corresponding samples, (ii) from the differences in end-point 
turbidity, or ThT-associated fluorescence between client protein incubated alone, and client 
protein in the presence of chaperone, as shown in the equation below.  
 
% Inhibition = [(client alone - client with chaperone) / client alone] * 100 
 
In similar experiments using CPK and CS as amorphously aggregating client proteins, the 
ability of A2M tetramer to inhibit protein aggregation was compared with that of both Trp 
and Plm activated A2M:protease complexes and the non-chaperone control protein Ova. 
When using SMR to compare the chaperone activity of A2M:protease complexes tested, the 
molecular mass of the trapped protease was excluded in calculations. In other related 
experiments, the effects of native A2M, A2M:protease complexes, and the non-chaperone 
control protein Ova on amyloid formation by reduced and carboxymethylated α-lact (RCM α-
lact) was measured using ThT-associated fluorescence. At the completion of these assays, the 
microplates containing the samples were stored at -20˚C for subsequent analysis to assess 
proteolytic degradation of the client protein by SDS-PAGE. The effects of increasing reaction 
time between A2M and Trp (1 – 24 h) on the resulting chaperone activity of A2M:Trp 








3.2.7  SDS-PAGE analysis of proteolytic degradation of client proteins by 
A2M:protease complexes 
Samples taken from chaperone activity assay end-points were analysed for proteolytic 
degradation of the client proteins to ascertain whether inhibition of protein aggregation by 
A2M:protease complexes is influenced by the action of the sterically-trapped protease. 
Aliquots were removed and centrifuged at 15,000 x g and 4˚C for 20 min. The pellet fractions 
were washed in PBS, centrifuged once more under the same conditions and solubilised in 100 
µL 2X SDS-PAGE loading buffer containing 10% (v/v) 2-mercaptoethanol. The samples 
were then heated for 10 min at 100˚C before being loaded onto the gel. SDS-PAGE was 
performed under reducing conditions on 10 – 15% resolving gel (section 2.7). The gels were 
stained with Coomassie Blue Stain at room temperature for an hour before being destained. 
 
3.2.8  Densitometry analysis of Native- and SDS-PAGE images  
Images of gels (sections 3.2.4 and 3.2.7) were captured by a Gel Logic 212 Pro (Carestream, 
USA) imaging system and saved as high quality .tif files for subsequent densitometry 
analysis. 8-bit monochromatic images were background subtracted and analysed with ImageJ 
1.49a (National Institute of Health, USA) using the “Integrated density” function, and the 
intensity of bands measured. From this, the amount of protein in individual bands of interest 
was calculated as a percent of the total intensity of all bands within the lane.  
 
3.2.9  Statistical Analysis 
Data presented in the results was analysed using a one-way ANOVA and a Bonferroni 
multiple comparison post-test using GraphPad Prism v5.0, unless stated otherwise. The extent 
of significance between samples is denoted by the amount of asterix present in the graphs 
(*p<0.05, **p<0.01 and ***p<0.001).   





3.3.1 Treatment with NaOCl and NaSCN induces dissociation of native tetrameric 
A2M into stable dimers  
A2M preparations were analysed by both Native-PAGE and SEC and conditions were 
optimised to successfully generate pure species. Native A2M tetramer was treated under 
conditions previously described by Wyatt et al. (2014) and Shanbhag et al. (1996), and 
optimised to generate A2M dimers which could then be purified and analysed (section 3.2.2). 
A2M was treated with NaOCl, which aims to replicate the hypochlorite released by activated 
neutrophils and microglia during inflammation (Wyatt et al. 2014). A2M was also treated 
with NaSCN, previously used in structural studies to distrupt non-covalent interactions 
between A2M dimer pairs (Shanbhag et al. 1996), to later compare whether A2M dimers 
formed by different treatments would vary in their properties and chaperone activities 
(sections 3.3.4 – 3.3.5). Incubation of purified human A2M with NaOCl or NaSCN resulted 
in the dissociation of native A2M tetramer into dimers as expected, which was visualised by 
Native-PAGE (Figure 3.2A). The remaining tetramer species migrated at the same rate as the 
native slow-form of A2M, demonstrating that chemical dissociation by either NaOCl or 
NaSCN did not induce a conformational change to the fast-form (for diagrams of slow- and 
fast-form A2M refer to Figure 3.1C) (Barrett et al. 1979). Treatment with 500 µM NaOCl 
resulted in the dissociation of approximately 50% of the tetramer to dimer (Figure 3.2A). 
Comparatively, 1.6 – 1.8 M NaSCN resulted in dissociation of approximately 90% of the 
tetramer to dimer (Figure 3.2A). At 1.8 M (Figure 3.2A) or higher concentrations of NaSCN 
(data not shown), an A2M species with higher electrophoretic mobility than the dimer was 
present. This was thought to be monomer and comprised approximately 40% of the total 
protein. The A2M dimers generated by treatment with 500 µM NaOCl can be purified by 
SEC (Figure 3.2B); the difference in the area under the curve suggests that approximately 
30% of the total protein present in solution was dimer. However, there was inefficient 
separation between tetramer and dimer due to the limited resolving power of the SEC column 
used. The region of overlap between the tetramer and dimer peaks was not used in chaperone 
activity assays. Taken together, these data demonstrate the successful generation of pure 
species of dimeric A2M, produced by two different methods.  
           
















Figure 3.2 Sodium hypochlorite and sodium thiocyanate induce dissociation of native A2M 
tetramer into stable dimers. (A) Image of 4% native polyacrylamide gel showing A2M treated with 
either 500 µM NaOCl or 1.6-1.8 M NaSCN for 1 h at room temperature. Tetramer and dimer species 
of A2M are indicated by arrows as shown. (B) Purified native A2M was incubated in the absence or 
presence of 500 µM NaOCl for 8 h at room temperature then fractionated by SEC and eluate fractions 
monitored continuously by A280 measurement. The scale bar (top left) indicates three milli-absorbance 
units (mAU). The elution volumes of molecular weight standards are indicated by black arrows at the 
top of the figure. The positions of peaks corresponding to tetramer and dimer species of A2M are 
indicated by either bracket or arrow, respectively. The eluate fractions were analysed by Native-
PAGE (section 3.2.4), pooled and separated into purified tetramer and dimer species as shown by 4% 
native polyacrylamide gel (right).  
 
3.3.2 Protease- and ammonium-induced activation of A2M. Reduction and alkylation 
of A2M to form stable monomers  
Native A2M tetramer was treated under conditions previously described by French et al. 
(2008) and optimised to either generate purified A2M:protease complexes (section 3.2.3). 
Plm was selected as a suitable protease to generate A2M:Plm complexes to compare to 
A2M:Trp complexes, previously described by French et al. (2008), due to its larger relative 
molecular weight and the physiological relevance of A2M:Plm complexes (Harpel 1973; 
Imber 1981), in order to later assess whether A2M:protease complexes formed by activation 
with different proteases would vary in their properties and chaperone activities (sections 3.3.4 
and 3.3.6). Native A2M was also treated under conditions first described by Barrett et al. 
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(1979) to generate stable A2M monomers (section 3.2.2). Native A2M was also activated by 
treatment with ammonium ions (NH4
+
), serving as a positive control to compare the extent of 
activation of A2M:protease complexes as described (section 3.2.4), and analysed by Native-
PAGE; the resulting species migrated as a single band of electrophoretically fast-form of 
A2M species, equivalent to the activated conformation (Figure 3.3A). In the same analysis, 
the lane containing A2M:Trp complexes showed a single band migrating slightly faster than 
the NH4
+
-activated A2M, having undergone a complete conformational change induced by 
cleavage of all four thioester bonds, and steric trapping of two molecules of Trp (Saunders et 
al. 1971; Marrero et al. 2012). The lane containing A2M:Plm complexes showed two bands 
which migrated to equivalent positions to the NH4
+
-activated fast-form (73%; calculated as 
described in section 3.2.8), and A2M:Trp complexes (27%), suggesting the steric trapping of 
a single large molecule of Plm. It is currently thought that the two bands differ in migration 
speeds due to the inefficient trapping of Plm within the molecular cage of A2M, the 
conversion to a “fully activated/closed” conformation (as diagrammed in Figure 3.1) 
equivalent to that of A2M:Trp complexes; occurring at a much slower rate due to the size of 
the protease, requiring gradual re-arrangement of the monomeric subunits of A2M to 
accommodate the large protease (Kolodziej et al. 1998; Marrero et al. 2012). Reduction of 
the disulfide-bonds of native A2M and carboxymethylation of the resulting free thiol groups 
to prevent oxidative re-association of subunits produced stable monomers which migrated as 
a single band, much faster than activated A2M tetramer. To confirm their structure, activated 
A2M and monomer samples were then analysed by SDS-PAGE under non-reducing and 
reducing conditions (Figure 3.3B). A2M monomer was visualised as a major band at ~180 
kDa (equivalent to a monomeric subunit), as well as a faint band (visible only under reducing 
conditions) at ~120 kDa, corresponding to the product of heat-induced A2M cleavage of the 
thioester bond in A2M (Sottrup-Jensen 1989). NH4
+
-activated A2M analysed under reducing 
conditions showed a major band at ~180 kDa, corresponding to a dissociated A2M monomer. 
Thioester bond cleavage was indicated by faint bands at ~120 kDa detected in analyses of 
both NH4
+
-activated A2M and A2M:Plm complexes. Analyses of A2M activated with either 
Trp or Plm but not NH4
+
 showed a band at ~90 kDa, visible only under reducing conditions, 
indicative of proteolytic cleavage of one or more bait-region(s), located at the approximate 
centre of an A2M subunit (Harpel et al. 1979; Sottrup-Jensen 1989). When analysed under 
non-reducing conditions both protease- and NH4
+
-activated A2M samples showed a band at > 
200 kDa which did not completely enter the gel matrix, consistent with the intact 720 kDa 
A2M tetramer. No proteolytic degradation of A2M was detected in preparations of A2M 




reacted with molar excess of either Trp or Plm, demonstrating that the process of inhibiting 
and removing the excess protease (as outlined in section 3.2.3) allows production of intact 
A2M:protease complexes. The above data demonstrate the successful generation of pure 




Figure 3.3 Images of (A) 4% Native-PAGE and (B) 8% SDS-PAGE analyses of the effects of 
various treatments on the electrophoretic mobility of A2M. Purified native A2M (N) was activated 
by incubation with 100 mM ammonium sulfate (NH4) or either trypsin (Trp) or plasmin (Plm) for 1 h 
at room temperature. Free, un-reacted protease was inhibited by soybean trypsin inhibitor and 
removed by ultrafiltration. A2M was dissociated into monomer (Mon) by reduction and 
carboxymethylation. (A) Native-PAGE was performed under non-reducing conditions, (B) SDS-
PAGE was performed under both non-reducing and reducing conditions. The molecular weight 
standards (Lane M; BioRad) indicated in kDa. 
 
3.3.3 Ammonium activation of A2M stabilises it against chemical dissociation into 
dimer and monomer species 
In vivo, A2M can circulate either as native tetramers or in an activated state complexed with 
proteases (Zhabin and Zorin 1995), and also as dimers (Ozawa et al. 2011) and monomers 
(Takada et al. 2013); which may dissociate in response to extracellular environmental 
conditions. To test whether the conformational state of A2M affects its ability to dissociate 
into dimers and monomers, A2M was activated with NH4
+
 and compared to native A2M by 
Native-PAGE. It was shown before that treatment of native A2M with NaSCN (section 3.3.1) 
or reduction and carboxymethylation (section 3.3.2) generates A2M dimers and monomers, 
respectively. However, NH4
+
 activated A2M was found to be resistant to dissociation into the 
A B 
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dimers and monomers that otherwise result from treatment by NaSCN or reduction (Figure 
3.4). Native-PAGE analysis indicated that (i) approximately 65% (calculated as described in 
section 3.2.8) of NH4
+
-treated native A2M had been activated into the fast-form (lane 1 – 2), 
(ii) native A2M was almost completely dissociated into dimer by NaSCN treatment (lane 3), 
this effect was completely inhibited by previous NH4
+
-activation of A2M (lane 4), and (iii) 
reduction and carboxymethylation induced almost complete dissociation of native A2M to 
monomers (lane 5) but previous NH4
+
-activation of A2M prevented dissociation to 
monomers altogether (lane 6). However, a small amount of dimer was detected. 
 
 
Figure 3.4 Pre-activation by NH4+ inhibits dissociation of A2M into dimers and monomers. 
Purified native A2M was activated by incubation with NH4
+ 
(+) or not (-) as previously described to 
induce activation and transition to an electrophoretically fast-form. A2M was either left untreated 
(Controls) or subsequently treated with NaSCN or DTT/carboxymethylation as previously described, 
then analysed by 4% Native-PAGE. The positions of A2M tetramer (Slow- or Fast-form), dimer and 
monomer are indicated to the right, and sample identity and treatments are indicated below the image, 










3.3.4 Dissociation of native A2M into dimers and monomers, and the formation of 
A2M:protease complexes, is associated with increased exposed hydrophobicity  
The activity of extracellular chaperones, including A2M, depends on hydrophobic 
interactions between the chaperone and normally buried hydrophobic residues of the 
unfolding client protein leading to the formation of chaperone:client protein complexes 
(French et al. 2008; Wyatt et al. 2009; Dabbs et al. 2013). bisANS was used as a probe for 
levels of exposed hydrophobicity on native A2M, A2M dimers and monomers (section 3.2.2), 
and complexes formed between A2M and Trp or Plm (section 3.2.3) (Figure 3.5). BSA was 
included as a positive control for bisANS fluorescence. Dissociation of A2M into dimers by 
treatment with 1.6 M NaSCN and 500 µM NaOCl significantly increased hydrophobicity by 
5.3 ± 0.04 and 3.4 ± 0.4 fold respectively, when compared to the native A2M tetramer 
(Figure 3.5A and B). However, there was no significant difference in hydrophobicity between 
the NaOCl-oxidised tetramer (separated from dimer species by SEC; Figure 3.2B) and the 
native tetramer. This suggests that dissociation itself, rather than oxidation, is responsible for 
the observed increase in hydrophobicity. Furthermore, dissociation of A2M into stable 
monomers significantly increased hydrophobicity by 4.5 ± 0.04 fold, when compared to the 
native tetramer (Figure 3.5A). Reaction of native A2M with Trp and Plm yielded activated 
A2M:protease complexes with significantly increased surface hydrophobicity relative to 
native A2M (Figure 3.5C); there was a 2.3 ± 0.1 fold increase for A2M:Trp and 2.0 ± 0.1 for 
A2M:Plm, respectively. Trp or Plm alone did not show significantly increased 
hydrophobicity compared to background bisANS levels. Therefore, it appears that the 
increase in relative hydrophobicity is due to the conformational change associated with 
proteolytic activation of A2M. Similar effects have been reported for the methylamine-
mediated activation of A2M (Wyatt et al. 2013).   






















































































Figure 3.5 bisANS fluorescence assays showing that relative to native A2M, A2M dimers 
(formed by treatment with either NaOCl or NaSCN), monomers (formed by RCM) and 
A2M:protease complexes have increased exposed hydrophobicity. bisANS-associated 
fluorescence was used to measure exposed hydrophobicity for A2M samples and BSA (positive 
control) diluted to 5 M in PBS. (A) Dimeric and monomeric A2M produced by NaSCN or RCM. (B) 
Oxidised (NaOCl-treated, as previously described) A2M tetramer and dimer (purified by SEC). (C) 
A2M:Trp and A2M:plm complexes produced by reaction of A2M with Trp or Plm, or protease alone. 
Bars represent the mean of triplicate measurements and are representative of separate experiments 








3.3.4 Stable dimers and monomers of A2M are more chaperone-active than native 
A2M 
3.3.4.1    NaSCN-dissociated dimer, and RCM monomer 
Both native tetrameric A2M and hypochlorite-dissociated dimers have been shown to have a 
potent chaperone activity akin to the sHSPs against a variety of client proteins (French et al. 
2008; Yerbury et al. 2009; Wyatt et al. 2014). The ability of NaSCN-dissociated dimers to 
inhibit protein aggregation has not previously been tested. The client protein CPK was 
precipitated by heating at 43˚C in the absence or presence of different concentrations of either 
A2M tetramer, NaSCN-dissociated dimer or monomer (or non-chaperone control protein 
Ova) (Figure 3.6). Heating native CPK to 43˚C in the absence of A2M resulted in extensive 
and rapid protein precipitation, shown by an increase in turbidity (A360) after a lag phase of 
15 min, reaching a maximum at approximately 75 min. The initial drop in A360 occurs in all 
chaperone assays involving CPK as the client protein and is likely an artefact, and may be 
result from heating the client from room temperature to 43˚C required to induce aggregation. 
The A2M tetramer inhibited protein aggregation in a dose-dependent manner as expected 
(Figure 3.6A). A subunit molar ratio (SMR; section 3.2.6) of tetramer:CPK = 1:3 and 1:5 
reduced the end-point turbidity by 62.3 ± 4 % and 12.94 ± 7%, respectively compared to CPK 
alone. A SMR of 1:50 induced a small (but insignificant) increase in protein aggregation 
relative to CPK alone. In contrast, both A2M dimer and monomer, at a SMR of 
chaperone:CPK = 1:10 and 1:50 resulted in either complete (97.6 ± 5% and 100.1 ± 6%, 
respectively for SMR = 1;10), or partial but significant inhibition (19.6 ± 10% and  18.0 ± 
8%, respectively for SMR = 1:50) of CPK aggregation, (Figure 3.6 B and C). This indicates 
that A2M dimers and monomers are more potent chaperone molecules than the intact A2M 
tetramer. In all cases, the presence of Ova had no significant effect on the end-point turbidity. 




dissociated A2M dimers 
and A2M monomers 
inhibit CPK aggregation 
to a greater extent than 
A2M tetramers. CPK (9.4 
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experiment measurements 




3.3.4.2    NaOCl-dissociated dimer, and RCM monomer 
To investigate the chaperone activity of NaOCl-dissociated A2M dimer and contrast that to 
the activity of NaSCN-dissociated A2M dimer, and monomer, the ability of these species to 
inhibit the amorphous aggregation of CPK and CS was compared with that of A2M tetramer, 
NaOCl-dissociated dimer and monomer, and the non-chaperone control protein Ova (Figure 
3.7A). A2M tetramer, dimer and monomer significantly inhibited the stress-induced 
aggregation of CPK and CS (Figure 3.7). In CPK aggregation assays, at SMRs of 


















































tetramer:CPK from 1:31 to 1:4.5, A2M tetramer inhibited CPK aggregation from 0.6 ± 4% to 
29 ± 2%, respectively (Figure 3.8). By comparison, at equivalent SMRs, CPK aggregation 
was inhibited by (i) NaOCl-dissociated dimer from 71.4 ± 1% to 100.3 ± 7.1%, and (ii) by 
A2M monomer from 55.9 ± 2% to 63 ± 9%. When compared at a CPK concentration of 1.5 
µM, A2M dimer, monomer and tetramer inhibited CPK aggregation by 93.4 ± 7%, 63.2 ± 9%, 
and 22. 0 ± 1%, respectively (Figure 3.7A – C). Whether dissociated by treatment with 
NaSCN (Figure 3.6) or NaOCl (Figure 3.7 and 3.8), when tested at similar SMRs, the A2M 
dimers produced had near identical chaperone activities. In CS aggregation assays, A2M 
tetramer, dimer and monomer all showed dose-dependent inhibition of CS aggregation. 
SMRs of tetramer:CS from 1:4 to 1:0.6 dose-dependently inhibited protein aggregation, 
ranging from zero to 49.0 ± 1%, respectively (Figure 3.8). In comparison, at equivalent 
SMRs, NaOCl-dissociated dimer inhibited CS aggregation by from 49.0 ± 4% to 94.0 ± 1%, 
and monomer inhibited CS aggregation by from zero to 94.5 ± 2%. When compared at a 
concentration of 1.5 µM, A2M dimer, monomer and tetramer inhibited CS aggregation by 
58.3 ± 8%, 69.0 ± 3% and 25.6 ± 5%, respectively (Figure 3.7D – F). 













































































Figure 3.7 NaOCl-dissociated dimers, and monomers of A2M, inhibit stress-induced CPK and 
CS aggregation to a greater extent than A2M tetramers. CPK (9.4 µM; A – C) and CS (1.2 µM; 
D – F) were induced to aggregate by heating at 43˚C in the absence or presence of increasing molar 
concentration and different SMR of A2M species (indicated at top left of each panel), or non-
chaperone control protein, Ova (equivalent to the highest mass concentration of A2M used). The 
ratios shown in the table below the key are SMR of A2M:client protein. The effects of stable A2M 
NaOCl-dissociated dimers or monomers (produced as described previously) on CPK and CS 
precipitation were compared to an equal amount of native A2M tetramer. Data points represent the 
mean ± SD (n=9) of three separate experiments, where in each experiment measurements were 
performed in triplicate.  









































Figure 3.8 Inhibition of client protein aggregation at assay end-point as a function of SMR. The 
% inhibition of protein aggregation at assay end-point (data from Figure 3.7 and 3.8) is plotted as a 
function of the SMR of A2M tetramer, dimer or monomer to client protein (SMR was calculated as 
per section 3.2.6). The identity of each client protein is indicated at the top left of the respective 
panels. Lines between data points indicate a trend and have no theoretical significance. Data points 
represent the mean ± SD (n=9) of three separate experiments, where in each experiment 
measurements were performed in triplicate. In some cases, the error bars are too small to be visible. 
 
3.3.6 The formation of A2M:protease complexes enhances the ability of A2M to inhibit 
protein aggregation 
As mentioned previously (section 3.1), activation of A2M by proteolytic cleavage of the bait-
region induces a conformational change which both traps the protease within a steric cage 
and covalently binds it by interaction with the thioester bond. The volume of the 
intramolecular cavity of A2M allows for the trapping of proteases with a total mass of up to 
90 kDa (Marrero et al. 2012). This allows for the formation of (tetramer) A2M:protease 
complexes incorporating two trypsin (Trp; 23.3 kDa) or one plasmin (Plm; 83 kDa) molecule, 
respectively. As mentioned previously (section 3.1), the active site of the protease itself is not 
affected and can cleave small substrates, inhibitors and proteins of 6 – 9 kDa (Ganrot 1966; 
Barrett and Starkey 1973). However, prolonged incubation with soybean Trp inhibitor (20.1 
kDa) has been found to inhibit A2M-trapped Trp (Bieth et al. 1981). Computer modelling by 
Marrero et al. (2012) using a crystal structure of a complex of A2M:Trp:soybean Trp 
inhibitor (Song and Suh 1998) suggests this may occur through re-arrangement of the 
monomeric subunits of A2M allowing entry and inhibition of the protease active site of 
A2M-trapped Trp (Marrero et al. 2012). A2M-trapped Plm occupies a large majority of the 
intramolecular cavity, making further re-arrangement of A2M subunits surrounding the 
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cavity unlikely (Kolodziej et al. 1998) which limits the entry of proteins of up to 7 kDa 
(cavity size limits of 90 kDa minus the 83 kDa for plasmin). Thus if proteins limited to ≤ 20.1 
kDa for A2M:Trp and ≤ 7 kDa for A2M:Plm diffuse into the intramolecular cavity, the 
protease(s) may still be able to degrade them, which could affect the progress of client protein 
aggregation (Barrett and Starkey 1973; Marrero et al. 2012). Previous work by French et al., 
2008 suggested that pre-activation with Trp abolished the chaperone action of A2M.  
 
The chaperone activity of protease activated A2M was investigated using amorphously 
aggregating CPK, CS and amyloid fibril forming RCM α-lact as client proteins. 
A2M:protease complexes were produced as previously described (section 3.2.3). All A2M 
species tested significantly inhibited the heat-induced aggregation of CPK and CS (Figure 
3.9). In all cases, the non-chaperone control protein Ova had no significant effect on end-
point turbidity. In CPK aggregation assays, 2.1 µM native A2M (SMR of A2M:CPK = 1:4.5) 
inhibited protein aggregation by approximately 29 ± 2% (Figure 3.9 and 3.11). Under 
identical conditions, both A2M:Trp and A2M:Plm inhibited CPK aggregation by 
approximately 94.4 ± 11% and 91.7 ± 3%, respectively. A2M:Trp inhibited CPK aggregation 
by 55.5 ± 2% when [A2M:Trp] = 0.3 µM and SMR (A2M:Trp):CPK = 1:31.3, while at an 
equivalent concentration native A2M did not significantly inhibit CPK aggregation. 
A2M:Plm complexes  completely inhibited CPK aggregation at all concentrations tested. In 
CS aggregation assays, 1.5 µM native A2M (SMR of A2M:CS = 1:0.8) inhibited protein 
aggregation by approximately 40.0 ± 10% (Figure 3.9 and 3.11). Under identical conditions, 
both A2M:Trp and A2M:Plm inhibited CS aggregation to a similar extent as native A2M,  by 
approximately 54.0 ± 8% and 26.1 ± 3%, respectively.  














































































Figure 3.9 Native A2M and A2M:protease complexes inhibit heat-induced aggregation of CPK 
and CS. CPK (9.4 µM; A – C) and CS (1.2 µM; D – F) were induced to aggregate by heating at 
43˚C in the absence or presence of increasing molar concentration and different SMR of native A2M, 
A2M:Trp and A2M:Plm complexes (indicated at top left of each panel), or non-chaperone control 
protein, Ova (equivalent to the highest mass concentration of A2M used). The ratios shown in the 
table below the key are SMR of A2M:client protein. The effects of A2M:protease complexes on CPK 
and CS precipitation were compared to an equal amount of native A2M tetramer. Data points 
represent the mean ± SD (n=9) of three separate experiments, where in each experiment 
measurements were performed in triplicate. In some cases, the error bars are too small to be visible. 
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Native A2M was previously shown to inhibit amorphous and fibrillar aggregation of a range 
of proteins (French et al. 2008; Yerbury 2009). To determine if A2M:protease complexes can 
also prevent fibril formation, we compared the ability of A2M:protease to inhibit the amyloid 
aggregation of RCM α-lact to that of native A2M. Heating RCM α-lact at 37˚C induced, from 
40 – 1100 min, a dramatic increase in β-sheet content and a characteristic increase in ThT-
associated fluorescence accompanying fibrillar aggregation (Figure 3.10). Native A2M (2 
µM; SMR of A2M:client protein = 1:50) significantly inhibited this aggregation by 
approximately 21.2 ± 4 %; no further increase in inhibition was obtained at higher molar 
concentrations (and lower SMR) of native A2M to client protein (Figure 3.10 and 3.11). By 
comparison, at an equivalent concentration (and SMR), A2M:Trp and A2M:Plm complexes 
inhibited the protein aggregation by approximately 78.1 ± 3% and 44.3 ± 3%, respectively; 
There was no further inhibition at higher ratios of A2M:Plm to client protein, while A2M:Trp 
(20 µM; SMR of A2M:Trp complex:client protein = 1:5) there was complete inhibition of 
aggregation. Although at 10 – 20 µM A2M:Plm (SMR range from 1:10 – 1:5) there was a 
notable increase in the lag phase of the reaction from zero to 180 min. A2M:Trp complexes 
inhibited the aggregation of RCM α-lact to a greater degree than either native A2M or 
A2M:Plm. In all cases, the non-chaperone control Ova had no significant effect on end-point 
turbidity.  
 
In summary, A2M:protease complexes were found to inhibit the aggregation of both CPK 
and RCM α-lact to a greater extent than native A2M over a lower SMR of chaperone:client 
proteins, with A2M:Plm having the greatest effect on CPK aggregation, and A2M:Trp having 
the greatest effect on RCM α-lact aggregation (Figure 3.11). All A2M species were found to 
inhibit the aggregation of CS to slightly differing degrees, with A2M:Trp complexes being 
more potent than A2M:Plm and native A2M over a lower SMR of chaperone:CS (Figure 
3.11). 





































































Figure 3.10 Native A2M and A2M:protease complexes inhibit heat-induced fibrillar 
precipitation of RCM α-lact. RCM α-lact (100 µM) was induced to aggregate by heating at 37˚C in 
the absence or presence of increasing molar concentration and different SMR of native A2M, 
A2M:Trp and A2M:Plm complexes (indicated at top left of each panel), or non-chaperone control 
protein, Ova (equivalent to the highest mass concentration of A2M used). The ratios shown in the key 
are SMR of A2M:CPK. Amyloid aggregation of RCM α-lact was measured using ThT-fluorescence. 
The effects of A2M:protease complexes on CPK and CS precipitation were compared to an equal 
amount of native A2M tetramer. Data points represent the mean ± SD (n=9) of three separate 
experiments, where in each experiment measurements were performed in triplicate. In some cases, the 
error bars are too small to be visible. 




















































Figure 3.11 Inhibition of heat-induced aggregation of client proteins by native A2M and 
A2M:protease complexes, as a function of SMR. The % inhibition of protein aggregation at assay 
end-point (data from Figure 3.7 and 3.8) is plotted as a function of the SMR of A2M or A2M:protease 
complex to client protein (SMR was calculated as per section 3.2.6). The identity of each client 
protein is indicated at the top left of the respective panels. Lines between data points indicate a trend 
and have no theoretical significance. Data points represent the mean ± SD (n=9) of three separate 
experiments, where in each experiment measurements were performed in triplicate. In some cases, the 
error bars are too small to be visible. 
 
End-point samples (prepared as in section 3.2.7) taken from protein aggregation assays 
containing (or not) native A2M, or A2M:Trp or A2M:Plm complexes were subsequently 
analysed by SDS PAGE to assess any proteolytic degradation of the client proteins. Samples 
from CPK aggregation assays containing A2M:protease complexes showed low molecular 
weight bands (<30 kDa in size) corresponding to proteolytic degradation products (~20% of 
the total protein by intensity) (Figure 3.12A, lane 3 and 4), and was coincident with a 
reduction in the intensity of monomeric CPK bands (~ 42 kDa). Analysis of samples from 
RCM α-lact aggregation reactions containing A2M:Plm complexes (but not other species) 
showed the appearance of lower molecular weight fragments (~30% of the total protein by 
intensity) (Figure 3.12B; lane 4), and was also coincident with a reduction in the intensity of 




monomeric RCM α-lact (~ 14 kDa). A similar reduction in intensity was seen for samples 
containing A2M:Trp complexes (Figure 3.12B; lane 3), however, no degradation products 
were observed. These lower molecular weight bands were absent in samples from 
aggregation reactions containing native A2M (Figure 3.12A, B). Analysis of samples from 
CS aggregation assays (containing only CS) showed no degradation of CS during any of the 
assays conducted (Figure 3.12C). The minor bands present in samples containing A2M and 
A2M:protease complexes (lane 2 – 4) are also present in control samples on native A2M 
alone (lane 5). Suggesting these bands to be artefacts of the samples taken from these particular CS 








Taken together, the results of chaperone activity assays (Figures 3.9 – 3.11) and SDS-PAGE 
analysis of proteolytic degradation of client proteins by trapped protease(s) (Figure 3.12), 
suggests that A2M:protease complexes are in most cases more efficient at inhibiting protein 
Figure 3.12 A2M:protease complexes proteolytically 
degrade CPK and RCM α-lact, but not CS. Samples 
(prepared as in section 3.2.7) taken from the end point of 
protein aggregation assays incubated in the absence (client 
protein; lane 1 in all panels) or presence of 0.7 µM of 
native A2M (lane 2 in all panels), A2M:Trp (lane 3 in all 
panels) or A2M:Plm (lane 4 in all panels) complexes, were 
analysed for proteolytic degradation of the client protein 
by reducing 10 – 15% SDS PAGE. Known molecular 
weight markers (M; BioRad) indicated in kDa. (A) CPK 
and (B) RCM α-lact incubated in the presence of A2M:Trp 
and A2M:Plm (but not native A2M), showed limited 
proteolysis of the client protein (degradation products 
indicated by red arrows). (C) CS incubated in the presence 
of A2M and A2M:protease complexes (lanes 2 – 4) 
showed the appearance of minor bands or greater and 
lower apparent mass than CS. Similar bands are also 
present in a control sample of native A2M alone (lane 5). 
Suggesting these bands to be artefacts of the samples taken 
from these particular CS chaperone assays and not 
degradation products formed by the action of 
A2M:protease complexes. 
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aggregation than native A2M. Small full-length client proteins such as α-lact (not shown) and 
RCM α-lact (14 kDa), as well as larger clients such as CPK (~42 kDa monomers) are bound 
and cleaved by A2M:protease complexes regardless of whether they aggregate via 
amorphous or fibrillar pathways.  
 
Even though the monomers of CPK (~42 kDa) and CS (~45 kDa) are of similar molecular 
weights, only CPK was able to be cleaved, and both exceed the theoretical size limitations for 
diffusion into the intramolecular cavity of A2M as mentioned previously (section 3.3.6), with 
≤ 20.1 kDa for A2M:Trp and ≤ 7 kDa for A2M:Plm (Barrett and Starkey 1973; Marrero et al. 
2012). The ability of CPK to undergo limited proteolysis may be due to how the protein 
unfolds and binds to A2M:protease complexes, perhaps allowing unfolded flexible portions 
of the protein to enter the steric cage and be degraded by the trapped protease(s). However, 
this does not explain why CS did not undergo measurable proteolytic degradation. Although 
given the fact that in humans, A2M:protease complexes are bound by cell-surface receptors 
and rapidly cleared in vivo within minutes (Gliemann et al. 1985; Roche and Pizzo 1987; 
Roche and Pizzo 1988) the extent of any short-term minor proteolytic degradation of the 
client is likely to be of negligible physiological significance.  
 
3.3.7 Prolonged activation of A2M by trypsin decreases the ability of A2M:protease 
complexes to inhibit stress-induced protein precipitation 
As mentioned earlier (section 3.3.6), French et al. (2008) demonstrated that activation of 
A2M with Trp abolishes the chaperone action of A2M, whereas here it has been shown that 
complexes formed between A2M and either Trp or Plm are in fact chaperone active. There 
were methodological differences which may contribute to the discrepancies between the 
findings of this thesis and work by French and colleagues. These were in the preparation of 
A2M:Trp complexes, where  French et al. incubated a six times molar ratio of Trp with 
native A2M for two hours (concentration, and incubation period of soybean trypsin inhibitor 
not stated), versus in this study where a three times molar ratio of Trp was incubated with 
A2M for one hour, and free protease was inactivated with a four times molar excess of 
inhibitor for one hour (section 3.2.3). The effects of (i) were tested for by incubating native 
A2M with Trp over 24 h, and producing purified A2M:Trp complexes which were 
subsequently tested for chaperone activity using in vitro aggregation assays (section 3.2.6). 
Following extended times of incubation of Trp with A2M, the ability of A2M:Trp complexes 




to inhibit CS aggregation decreased (Figure 3.13). Proteolytic degradation of A2M by over-
exposure to Trp may have been overlooked by French et al., as only Native-PAGE analysis 
was used to verify activation of A2M by Trp (SDS-PAGE analysis of A2M:Trp complexes is 
necessary to reveal limited degradation by Trp). This points to the conclusion that over-
exposure of A2M to Trp is the most likely source of the discrepancies between studies. 





























Figure 3.13 Prolonged activation of A2M by trypsin leads to decreased chaperone activity. A2M 
was incubated at room temperature with Trp for a range of times (1 – 24 h). Any remaining free 
trypsin was inhibited with trypsin inhibitor and A2M:Trp complexes were purified (section 3.2.3). CS 
(6 µM) was induced to aggregate by heating at 43˚C and incubated in the absence or presence of 
A2M:Trp at SMR of 1:4. Inhibition of aggregation at assay end-point is plotted as a function of Trp 
incubation time. Lines between data points indicate a trend and have no theoretical significance. Data 
points represent the mean ± SD (n=9) of three separate experiments, where in each experiment 
measurements were performed in triplicate.  
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3.4 DISCUSSION  
 
3.4.1 Chaperone activity of A2M dimers  
A2M dimers were shown to potently inhibit the stress-induced aggregation of a variety of 
proteins; this activity was more potent than that of the native A2M tetramer (Figure 3.6 and 
3.7). Ozawa et al. (2011) demonstrated that SDS-induced dissociation of A2M into dimer 
pairs resulted in increases in both surface hydrophobicity and the ability to inhibit the 
aggregation of β2-microglobulin. The in vivo aggregation of β2-microglobulin is associated 
with dialysis-related amyloidosis (Gejyo et al. 1985). At normal physiological levels, human 
plasma A2M concentrations are in the range 2.8 – 5.6 µM (Gourine et al. 2002) and 4 – 5% 
of this extracellular A2M pool is in the form of circulating disulfide-linked dimers (Ozawa et 
al. 2011). It was previously shown that when native A2M was exposed to oxidative 
conditions (100 µM CuSO4, 4 mM H2O2) it was able to potently inhibit the in vitro 
aggregation of both lysozyme and alpha-synuclein (French et al. 2008); these conditions are 
likely to have induced dissociation of native A2M into dimers. 
 
Oxidation by neutrophil- and eosinophil-generated hypohalous acids (HClO, HBrO), N-
chloramines (RNCl) and N-haloamines has been shown to dissociate native A2M 
homotetramer into two pairs of disulfide-linked dimers (Reddy et al. 1989; Reddy et al. 
1994). Increased oxidative modification (carbonylation) of A2M has been shown in the 
plasma of patients with rheumatoid arthritis (accompanied by a two-fold higher expression of 
A2M) (Wu and Pizzo 2001) and Alzheimer’s disease (Cocciolo et al. 2012). Rheumatoid 
arthritis and Alzheimer’s disease are both associated with extracellular protein aggregation of 
IgG and Aβ peptide, respectively; as well as increased myeloperoxidase activity (Green et al. 
2004; Stamp et al. 2012). The myeloperoxidase-H2O2-chloride system is used by neutrophils 
(or microglia) of the immune system to kill bacteria by oxidising bacterial proteins, however 
during inflammation the local concentration of OCl
-
 can reach high-µM or low-mM levels, 
damaging nearby proteins and tissues (Weiss 1989; Hampton et al. 1998; Vlasova et al. 
2011). Consistent with these concentrations, disulfide-bonded A2M dimers were generated 
by treatment of native A2M tetramers with 500 µM NaOCl (Reddy et al. 1994) which 
disrupts the non-covalent interactions normally holding the two paired dimers together. The 
dimers produced are stable and do not re-associate (Figure 3.4). Furthermore, Wyatt et al. 
(2014) have reported dissociation of A2M into dimers by physiologically relevant OCl
-
 




concentrations in plasma (Wyatt et al. 2014). These findings support the possibility that OCl
-
 
dissociation generated A2M dimers are in vivo, and is consistent with the observation that 4 – 
5% of the extracellular A2M pool is in the form of circulating disulfide-linked dimers 
(Ozawa et al. 2011).  
 
It is conceivable that A2M dimers may function as a physiologically important EC in 
rheumatoid arthritis and Alzheimer’s disease given their significantly increased chaperone 
potency compared to that of native A2M (Figure 3.6 – 3.8), and this role may extend to other 
protein deposition diseases involving oxidative modification (OCl
-
-induced) of proteins, 
including osteoarthritis (Steinbeck et al. 2007), atherosclerosis (Hazell et al. 1994), kidney 
disease (Malle et al. 1997), and chronic lung disease (Buss et al. 2003). 
 
3.4.2 Chaperone activity of A2M monomers  
Stable monomers were generated under mild-reduction of native A2M with DTT and 
alkylating free S-H groups with iodoacetic acid (to prevent oxidative re-association) - 
producing identical monomeric subunits ~180 kDa (Figures 3.3) (Gonias and Pizzo 1983; 
Roche et al. 1988; Moncino et al. 1991). A2M monomers were shown to potently inhibit the 
stress-induced aggregation of CPK and CS; this activity was more potent than that of the 
native A2M tetramer (Figures 3.6 – 3.8). Diseases such as diabetes and cardiomyopathy 
induce acute phase protein responses. Diabetes is associated with both micro- and 
macrovascular complications that can lead to significantly elevated incidence of retinopathy, 
nephropathy, neuropathy, myocardial infarction and stroke (McAlpine et al. 2010). As 
mentioned in section 3.1, increased levels of A2M monomers have been found to be 
associated with reductive stress and with protein deposition in diabetic patients with 
retinopathy and nephropathy (Takada et al. 2013), myocardial infarction in diabetes 
(Annapoorani et al. 2006), cardiac hypertrophy (Rajamanickam et al. 1998), and cardiac 
diseases (Rathinavel et al. 2005; Ramasamy et al. 2006). Diabetes, diabetic nephropathy and 
cardiomyopathy all involve extracellular protein aggregation and deposition of: islet amyloid 
polypeptide from pancreatic β-cells in diabetes (Hoppener et al. 2000), complement C1q (Joh 
et al. 1990), and Tamm-Horsfall urinary glycoprotein (Rampoldi et al. 2003; Bleyer et al. 
2005) in diabetic nephropathy, and αB-crystallin and cytoskeletal components in 
cardiomyopathy (Rajasekaran et al. 2007; Kannan et al. 2013). In addition, diabetes (Nardai 
et al. 2003), diabetic nephropathy (Ma et al. 2014), and cardiomyopathy (through sustained 
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activation of nuclear erythroid-2 like factor-2) (Rajasekaran et al. 2007; Kannan et al. 2013) 
are also associated with the unfolded protein response and shifts in endoplasic reticulum (ER) 
redox environment to a more reducing state, which may provide a pathophysiological 
mechanism by which A2M monomers are formed.  
 
Thioredoxin is a small disulfide oxidoreductase and reduces disulfide bonds on target 
proteins, including the reduction of A2M to monomers (Larsson et al. 1988), which is 
secreted by lymphocytes in response to oxidative stress and inflammation (Kondo et al. 2004; 
Nakamura et al. 2006), providing a mechanism not directly related to any particular disease 
by which monomers can be generated extracellularly in vivo and may contribute to 
extracellular proteostasis. 
 
The presence of A2M monomers in diseased patients, and the observation that misfolded 
proteins are a hallmark of these same diseases, suggests that A2M monomers may function as 
an EC in a physiologically relevant manner in diabetes (and diabetes-associated diseases) and 
cardiac disease, and possibly other protein deposition diseases involving redox stress of the 
extracellular environment, such as liver disease (Papp et al. 2006) and Alzheimer's (Garg et 
al. 2011). 
 
3.4.3 Relationship between exposed hydrophobicity and the chaperone activity of 
A2M 
Native A2M dissociated into dimers by treatment with either NaOCl or NaSCN, and into 
monomers by RCM, produced species with dramatically increased exposed hydrophobicity 
relative to the native or oxidized tetramer (Figure 3.5A, B). Based on the crystal structure of 
activated A2M, the contact surfaces between non-covalently bonded disulfide-linked dimer 
pairs are rich in hydrophobic residues (Marrero et al. 2012). Dissociation is thought to 
involve disruption of hydrophobic interactions between A2M subunits (Sjoberg et al. 1992); 
the dimer-dimer interface then becomes solvent exposed, effectively increasing the area 
available for A2M to bind to hydrophobic patches on misfolded proteins. The ability of 
extracellular chaperones, including A2M, to inhibit protein aggregation depends on 
hydrophobic interactions between the chaperone and the normally buried hydrophobic 
residues of misfolded client proteins, which results in the formation of chaperone:client 
protein complexes (French et al. 2008; Wyatt et al. 2009; Dabbs et al. 2013). Collectively, 




these observations, together with the results of chaperone activity assays comparing A2M 
tetramers, dimers and monomers (Figures 3.6 – 3.8), suggest that the level of A2M chaperone 
activity strongly correlates with the level of surface-exposed hydrophobicity. This study did 
not examine whether A2M dimers and monomers formed soluble complexes with the 
misfolding client proteins, which is another aspect of extracellular chaperone activity. In 
summary, a central observation reported in this chapter, that exposure to sufficient levels of 
oxidative or reductive stress induces the dissociation of native A2M tetramers into dimers 
and monomers, respectively, that have enhanced exposed hydrophobicity and chaperone 
activity, may be of considerable physiological importance.  
 
A2M dimers and monomers have been shown to function as protease inhibitors in avians, 
reptiles, amphibians and mammals (Sottrup-Jensen 1989; Rubenstein et al. 1993). Homologs 
of native A2M exist in humans, as extracellular dimers (pregnancy zone protein) and 
monomers (A2M like-1), in plasma and the granular layer of the epidermis, respectively 
(Galliano et al. 2006). Due to their predicted structural similarities with A2M (based on 
sequence homology) these molecules may also act as extracellular chaperones. 
 
3.4.4 Chaperone activity of A2M:protease complexes  
Activation of native A2M by reaction with either a nucleophile or a protease (Trp or Plm) 
induced a large conformational conversion to the fast-form (Figure 3.3) (Saunders et al. 
1971; Barrett et al. 1979; Imber 1981). For diagrams of slow- and fast-form A2M refer to 
Figure 3.1C. This transition is accompanied by proteolytic cleavage of A2M which can be 
detected by the appearance of additional smaller bands in SDS-PAGE (Figure 3.3) (Harpel et 
al. 1979). As shown previously (section 3.4.2), DTT-induced dissociation of A2M generates 
monomers with increased chaperone activity relative to the native tetramer (Figure 3.6B). 
However, NH4
+
-activation of A2M conformationally stabilised and protected A2M from 
chemically-induced dissociation into dimeric and monomeric species (Figure 3.4). 
Intramolecular non-covalent interactions are stronger in the fast-form than the slow-form 
(Gonias et al. 1993; Shanbhag et al. 1996). Thus, A2M:protease complexes are highly 
unlikely to dissociate under conditions which would otherwise lead to the formation of 
chaperone active dimers or monomers in vivo. They are also rapidly cleared from circulation 
in vivo. 
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Native A2M inhibits the aggregation of a number of different amorphously aggregating and 
amyloid-forming proteins by interacting with transient species early in fibril formation, 
suppressing protein aggregation and mature fibril formation, and protecting cells from the 
toxicity associated with protein aggregates (Du et al. 1998; Yerbury 2009). A2M has been 
previously shown to have discrete binding sites for misfolded proteins and proteases, 
demonstrated by the fact that soluble A2M:protein client complexes can subsequently react 
with and trap proteases (Narita 1997; French et al. 2008). In the current study, A2M activated 
with either Trp or Plm prior to incubation with misfolding client proteins, was shown to 
potently inhibit the stress-induced aggregation of a variety of proteins. In the cases of the 
amorphous aggregation of CPK and amyloid formation by RCM α-lact, this activity was 
more potent than that of native A2M (Figure 3.9 – 3.11). Both A2M:protease complexes and 
native A2M inhibited the amorphous aggregation of CS to a similar extent (Figures 3.9 – 
3.11). Proteolytic activation of A2M by either Trp or Plm produced complexes with a 
significantly more exposed hydrophobicity than the native tetramer (Figure 3.5C). It was 
previously shown that activation of A2M with methylamine or chymotrypsin significantly 
increases surface exposed hydrophobicity relative to native A2M (Birkenmeier et al. 1989). 
The ability of methylamine-activated A2M to inhibit protein aggregation has also been shown 
to be independent of a trapped protease (Wyatt et al. 2013). These results suggest that, as 
appears to be the case for A2M tetramers/dimers/monomers, the level of chaperone activity 
of A2M species incorporated into A2M:protease complexes may also correlate with the level 
of surface-exposed hydrophobicity. Methylamine-activated A2M, but not native A2M, has 
been shown to bind to and decrease the levels of soluble β-amyloid peptide (both 1 – 40 and 
1 – 42 forms) associated with toxic, fibrillar aggregate formation in Alzheimer’s disease by 
internalisation via receptor-mediated endocytosis (Narita 1997). In activated A2M, β-
Amyloid binds to a discrete site in the RBD (residues1314 – 1365; Figure 3.1A) (Mettenburg et 
al. 2002), and is disposed of by LRP-mediated endocytosis in cortical neurons (Narita 1997; 
Du et al. 1998; Qiu et al. 1999).  
 
As mentioned earlier (section 3.1), sterically trapped proteases remain active and are able to 
degrade molecules which are small enough to diffuse into the intramolecular cavity of 
A2M:protease complexes. A2M:protease complexes were able to proteolytically degrade 
CPK and RCM α-lact, but not CS (Figure 3.12). A2M:protease complexes have also been 
shown to proteolytically degrade β-amyloid peptide (~4 kDa) in vitro, which may further 




reduce concentrations of aggregation-prone peptide (Lauer et al. 2001; Wyatt et al. 2013). It 
is currently unknown whether A2M:protease complexes degrade proteins in vivo, but is likely 
not physiologically relevant in humans as, A2M:protease complexes are bound by cell-
surface receptors and internalised within minutes (Gliemann et al. 1985; Roche and Pizzo 
1987; Roche and Pizzo 1988). 
 
A2M:protease complexes are responsible for approximately 3% of the total A2M pool of 2.8 
– 5.6 µM, in blood plasma and sera (Zhabin and Zorin 1995). The concentration of 
circulating A2M:protease complexes is increased in many disease states including acute 
pancreatitis (Banks et al. 1990; Banks et al. 1991), arthritis (Abbink et al. 1991), diabetic 
retinopathy (Sanchez et al. 2007), multiple sclerosis (Gunnarsson et al. 2000) and sepsis (de 
Boer et al. 1993). As mentioned earlier, arthritis and diabetic retinopathy are both associated 
with extracellular protein aggregation. Moreover, acute pancreatitis (Schiesser et al. 2001; Ho 
et al. 2006), multiple sclerosis (Dasgupta et al. 2013; Stoffels et al. 2013; David and Tayebi 
2014), and sepsis (Bodas et al. 2010) also present with extracellular deposits of insoluble 
protein aggregates. The increase in circulating A2M:protease complexes is mostly attributed 
to increased extracellular protease secretion and activity associated with these diseases, but 
may also include a response to protein aggregation. It is unknown whether A2M is involved 
in binding to and forming soluble A2M:client complexes with misfolded/unfolded proteins in 
these diseases in vivo. Protease activation of A2M after the formation of soluble A2M:client 
complexes has been shown to expedite disposal by LRP, and may facilitate clearance of 
misfolded client proteins via LRP in these diseases.  
 
3.4.5 A2M and proteases in extracellular proteostasis 
As mentioned previously, A2M can mediate the clearance of both misfolded proteins and 
proteases in diseases (section 3.1). Interestingly, amyloid fibrils, fibrin and 
denatured/misfolded proteins can bind to and stimulate initiation of extracellular proteolytic 
cascades, including the kallikren-kinin system and in particular the plg activation system 
(which will be explored in Chapter 4) (Kranenburg et al. 2002; Kranenburg et al. 2005; Maas 
et al. 2008; Gebbink et al. 2009; Gebbink 2011). Tissue plasminogen activator (tPA) is 
secreted from neurons and microglia following aggregate-induced excitotoxic injury, such as 
in Alzheimer’s disease and spongiform encephalopathies (Fischer et al. 2000; Siao and 
Tsirka 2002; Siao 2003). tPA has been shown to bind to and become activated by structural 
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components of amyloid fibrils and aggregating proteins – which can act as both a co-factor 
and substrate (Kranenburg et al. 2002; Gebbink et al. 2009). This activated form of tPA 
cleaves plasminogen into the active serine protease Plm which can then degrade protein 
aggregates into plm-generated protein fragments (PGPFs; Chapter 5) (Lijnen 1982; Gebbink 
et al. 2009). A2M is synthesised by microglia and has been shown to accumulate near 
amyloid plaques in Alzheimer’s disease (Hughes et al. 1998; Lauer et al. 2001). A2M can 
either function as a protease inhibitor and remove free Plm not bound to aggregates, and/or 
bind to misfolded/unfolded proteins (or PGPFs) and dispose of these via LRP receptor-
mediated endocytosis – which can further stimulate secretion of both tPA and A2M by 
microglia. A2M:Plm complexes can bind to aggregating proteins or PGPFs and promote their 
disposal, while simultaneously stimulating the synthesis and secretion of A2M and Plg by 
mononuclear cells (Zhabin et al. 1995). Thus, the local concentrations of A2M, proteases and 
A2M:protease complexes in protein deposition diseases such as Alzheimer’s disease may be 




Collectively, A2M has been shown to bind to many diverse ligands and proteases, influence 
the immune response, and inhibit the amorphous and fibrillar aggregation of client proteins. 
Collectively, the established literature and the results presented here show that the chaperone 
activity of A2M can be changed in response to a variety of conditions related to diseases, 
such as reductive/oxidative stress, inflammation, the acute-phase response, and increased 
protease secretion. A model is presented to describe the potential physiological significance 
of these findings; incorporating A2M tetramers/dimers/monomers and A2M:protease 
complexes into an extracellular quality control mechanism (Figure 3.14). In conclusion, the 
significance of the findings in this Chapter may be far-reaching. A greater understanding of 
the mechanisms by which A2M is able to prevent protein aggregation and facilitate the 
disposal of misfolded protein molecules could, in future, provide potential therapeutic targets 
for a host of degenerative conditions. 
 





Figure 3.14 Hypothetical model of overlapping physiological roles of the chaperone and 
protease-trapping activities of A2M. Native tetrameric A2M can be dissociated by reductive or 
oxidative (redox) stress to form A2M monomers and dimers, respectively. A2M species can inhibit 
aggregation by binding to misfolded and aggregating proteins via hydrophobic interactions, thereby 
facilitating their removal via LRP receptor-mediated endocytosis. tPA-generated Plm can either (i) 
bind to and degrade protein aggregates into Plm-generated protein fragments (PGPFs), or (ii) be 
inhibited by forming A2M:Plm complexes, which expose LRP-binding sites. Once formed, A2M:Plm 
complexes can subsequently bind to misfolded proteins or PGPFs and be disposed of via LRP-
mediated endocytosis, which in turn induces increased expression and secretion of (i) tPA and A2M 
from microglia, and (ii) Plg and A2M from mononuclear cells. Collectively, these interactions provide 
a feed-forward mechanism to co-localise chaperones and proteases at sites of protein aggregation, 
which act together to facilitate return of the system to normal healthy proteostasis. 
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CHAPTER 4 : THE INTERACTION OF AMORPHOUS AGGREGATES WITH THE 
PLASMINOGEN ACTIVATION SYSTEM AND EXTRACELLULAR CHAPERONES 
 
4.1 INTRODUCTION 
A complex and well characterised network of protein quality control mechanisms have 
evolved intracellularly to preserve proteostasis, involving a combination of two strategies 
that: (i) ensure correct protein folding and maintain solubility (Buchner 1996; Fink 1999), 
and (ii) degrade non-native or aggregated proteins. Both proteases and chaperones are key 
players in this context (Buchner 1996; Kaufman 2002). Corresponding extracellular 
mechanisms of proteostasis are much less well understood, even though many protein 
misfolding diseases present with pathologies characterised by the extracellular deposition of 
protein aggregates (Chapter 1; Table 1.1). Synergy between proteolytic systems and 
extracellular chaperones may be a functionally critical mechanism in extracellular 
proteostasis (Wyatt et al. 2013). 
 
It has recently become apparent that, like in the intracellular environment, extracellular 
amyloid fibrils, fibrin and denatured/misfolded proteins can trigger responses from both 
chaperone and protease systems (Gebbink et al. 2009; Wyatt et al. 2010) and that the 
extracellular chaperone A2M can bind to toxic plasmin generated protein fragments (Zammit 
2009). It is interesting to note that A2M is an extracellular chaperone, an immune-modulator, 
and also a well characterised protease inhibitor and modulator of plm activity (Sottrup-Jensen 
1989; LaMarre et al. 1991; Feige et al. 1996). 
 
The plg activation system may play an important role in maintaining extracellular 
proteostasis. tPA has been shown to bind to, and become activated by structural components 
of amyloid fibrils and aggregating proteins, acting as both a co-factor and substrate 
(Kranenburg et al. 2002; Gebbink et al. 2009; Samson et al. 2009). This activated form of 
tPA converts plg into plm which can then degrade protein aggregates (Lijnen 1982; Gebbink 
et al. 2009). This is akin to the dissolution of macromolecular fibrin-clots and re-modelling of 
the extracellular matrix by the plg activation system. Additionally, the altered expression of 
tPA, PAI-2 and other members of the plg activation system have been shown to deleteriously 
impact the brain during traumatic brain-injury-induced cell death and in Alzheimer’s disease 
(Akiyama 1993 ; Dietzmann et al. 2000; Medcalf 2011). While amyloid fibrils have been 
shown to undergo limited proteolytic degradation by plasmin (Tucker et al. 2000), the 
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degradation of amorphously aggregating proteins have been poorly studied. It is currently 
unknown whether (i) amorphous aggregates can bind tPA and enhance plg activation, (ii) plm 
can clear these by proteolytically degrading them into fragments, and (iii) what biological 
impact this might have.  
 
Many protein conformational disorders result in the pathological deposition of amorphous 
protein aggregates in the extracellular space. The G93A mutant of SOD, and IgG are two 
proteins deposited extracellularly (Chapter 1; Table 1.1). SODG93A is associated with familial 
cases of amytrophic lateral sclerosis, and while normally occurring as intracellular deposits, 
has been shown to be actively released into the extracellular environment following cell 
death/lysis, which may explain the prion-like spread of the disease (Adachi et al. 2000; Wang 
et al. 2002; Swash 2013). Extracellular deposits of aggregated and/or oxidised IgG are 
associated with corneal dystrophy, heavy chain deposition disease, multiple myeloma, and 
rheumatoid arthritis (Matthews 1983; Shultz et al. 1987; Aucouturier et al. 1993; Aucouturier 
et al. 1993; Khamlichi et al. 1995; Khamlichi et al. 1995; Truscott 2005). The plg activation 
system has been implicated in several of these diseases. Ovotransferrin (Ovo) has been 
routinely used as a client protein to assess the chaperone activity of ECs such as CLU and 
A2M (Poon et al. 2000; French et al. 2008). 
 
The aims of the work described in this chapter were to investigate whether: 
1. Amorphous aggregates formed by Ovo, SOD and IgG bind tPA and enhance plg 
activation. 
2. The resulting plm generated is subject to inhibition by PAI-2 and A2AP. 
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4.2.1    Clusterin purification 
4.2.1.1     Immunoaffinity chromatography 
Immunoaffinity columns (approximately 5 ml bed volume each) containing G7 and 41D anti-
clusterin monoclonal antibodies (mAbs) coupled to Sepharose beads, produced by Mark 
Wilson’s laboratory group (Illawarra Health and Medical Research Institute) (Wilson and 
Easterbrook-Smith 1992), were connected in tandem and equilibrated in PBS/0.1% Az at a 
flow rate of 0.5 mL/min using a Bio-Rad Econo-pump. Approximately 400 mL of filtered, 
citrated plasma as prepared in section 2.6, was applied over the columns at a rate of 0.5 
mL/min or less, followed by PBS/0.1% Az to wash the columns. Non-specifically bound 
material was eluted from the columns by further washing with 50 mL 0.5% (v/v) Tx-100 in 
PBS followed by 50 mL of 200 mM sodium acetate containing 0.5 M NaCl, pH 5.0. Bound 
clusterin was eluted using 50 mL of  2 M GdHCl in PBS and dialysed into three changes of 3 
L of PBS/0.1% Az followed by an additional two changes of 20 mM MES, pH 6.0.  
 
4.2.1.2     Cation-exchange chromatography 
Clusterin in 20 mM MES, pH 6.0 (section 4.2.1.1) was then further purified by cation 
exchange chromatography using a 1 mL HiTrap SP XL column (GE Healthcare) connected to 
a ÄKTA FPLC system (GE Healthcare). The column was equilibrated in 20 mM MES, pH 
6.0 and the sample twice passed over the column at 0.5 mL/min to allow contaminants to 
bind. The flow through containing the unbound clusterin was collected. The bound 
contaminants were subsequently eluted using 1 M NaCl in 20 mM MES, pH 6.0. Clusterin 
was then concentrated using an Amicon Ultra-15 filter unit (Merck Millipore) with a 
molecular weight cut-off of 30 kDa and dialysed into three changes of PBS/0.1% Az and 
stored at 4˚C. Protein purity was assessed by 10% SDS-PAGE and protein concentration was 
determined by BCA assay (section 2.3). 
 
4.2.2 Purification of plasminogen by Lys-affinity chromatography 
Lysine-Sepharose 4B (GE Healthcare) was equilibrated in PBS as per manufacturer’s 
instructions and 5 mL aliquots mixed with approximately 400 mL of filtered, citrated plasma 
(section 2.6) and incubated at 4˚C for 2 h with gentle mixing by inversion at 4 rpm, using a 
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rotory mixer (Ratek) at 4˚C. The Lysine-Sepharose 4B slurry (to which plasminogen was 
bound) were then washed with PBS by centrifugation (200 x g for 10 min at 4˚C) and 
resuspended in PBS containing 5 mM EDTA and 1 mM PMSF. The re-equilibrated slurry 
was then poured and allowed to settle into an empty XK 16/40 chromatography column (GE 
Healthcare) and connected to a Bio-Rad Econo-pump. Loosely bound proteins were then 
washed from the column at 0.5 mL/min using (i) 200 mL of PBS containing 5 mM EDTA 
and 1 mM PMSF, and then (ii) 100 mL of 0.5 M NaCl, 50 mM Na2HPO4, pH 7.4. Bound 
plasminogen was then eluted at 0.5 mL/min using 200 mM ε-aminocaproic acid in PBS, 
collecting 2.5 mL fractions. Three main protein peaks were eluted corresponding to Glu-
plasminogen, a mixture of Glu- and Lys-Plasminogen and a mixture of plasminogen and 
plasmin. These fractions were immediately dialysed against three changes of PBS to remove 
ε-aminocaproic acid and stored at -80˚C. Protein purity was assessed by 10% SDS-PAGE 
under non-reducing and reducing conditions and protein concentration was determined by 
BCA assay (section 2.3).  
 
4.2.3 Purification of IgG by protein G affinity chromatography 
A 5 mL HiTrap Protein G HP column (GE Healthcare) was equilibrated in 20 mM NaH2PO4, 
pH 7.0, before 20 mL of filtered, citrated plasma (section 2.6) was passed over the column at 
1 mL/min. The column was subsequently washed with firstly 20 mM NaH2PO4, pH 7.0, and 
then 0.5 M NaCl, 50 mM sodium acetate, pH 5.0. Finally, the bound IgG was eluted with 10 
mL of 0.1 M glycine-HCl, pH 2.3, and 1.5 mL fractions were collected in tubes containing 
200 µL of 1 M Tris-HCl, pH 9.0 to neutralise the acidity of the eluate. Fractions were then 
analysed by 8% SDS-PAGE and those containing IgG were pooled and dialysed against three 
changes of PBS and stored at -20˚C. Protein concentration was determined by BCA assay 
(section 2.3). 
 
4.2.4  Expression and purification of recombinant superoxide dismutase-1  
4.2.4.1     Culture of transformed bacteria and lysis 
The expression vector pACA-forward yCCS SOD1 (Lindberg 2004) containing the gene for 
the G93A mutant of Cu/Zn- superoxide dismutase 1 (SOD) was transformed into the 
Escherichia coli strain DH5α, a single colony was selected for and amplified on plates of LB 
agar containing 0.1 mg/mL carbenicillin (Carbenicillin direct) as a selective agent. Starter 
Chapter 4: The interaction of amorphous aggregates with the plasminogen activation 
system and extracellular chaperones 
71 
 
cultures of 20 mL of 2 x LB (20 g/L sodium chloride, 20 g/L bactotryptone and 10g/L yeast 
extract) containing 0.1 mg/mL carbenicillin (20 mL, per 1 L flask) were inoculated with a 
transformed colony and grown overnight at 37˚C with shaking at 180 rpm. Overnight starter 
cultures were transferred to two flasks containing 1 L of 2 x LB and 0.1 mg/mL carbenicillin 
and incubated at 37˚C with shaking (Bioline-8000) at 180 rpm until reaching an OD of 0.5. 3 
mM CuSO4 and 40 µM ZnSO4 was added to 1 L cultures for incorporation into the catalytic 
active sites of SOD. Cultures were then induced with a final concentration of 0.5 mM IPTG 
and grown at 18˚C overnight with shaking at 180 rpm. Bacteria were harvested by 
centrifugation at 6,000 x g for 10 min at 4˚C, in a Sorvall RC 6+ centrifuge (ThermoFisher). 
The bacterial pellets containing SOD were resuspended in 25 mL of 50 mM Tris, pH 7.5 
containing 0.01 mg/mL each of DNase (Roche) and RNase (Sigma Aldrich) and twice treated 
with an EmulsiFlex-C5 high pressure homogenizer (Avestin) at a pressure of 75-150 MPa to 
lyse the cells. The lysate was centrifuged (Sorvall RC 6+) at 40,000 x g for 20 min at 4˚C to 
remove cell debris and the supernatant collected for subsequent purification. 
 
4.2.4.2     Ammonium sulfate precipitation 
The bacterial supernatant containing the G93A mutant of SOD (section 4.2.4.1) was heat 
denatured in a water bath at 55˚C for 30 min. The precipitated material was then removed via 
centrifugation at 40,000 x g for 20 min at 4˚C and discarded. Ammonium sulfate was then 
added to the supernatant fraction, slowly and with continuous stirring at 4˚C, to 60% of 
saturation. The saturated mixture was allowed to stir for a further two hours before the 
precipitated material was then removed by centrifugation at 40,000 x g for 20 min at 4˚C. 
Further ammonium sulfate was added to the supernatant fraction as before, to 90% of 
saturation. The saturated mixture was then incubated overnight with continuous stirring at 
4˚C. The precipitate was harvested by centrifugation at 40,000 x g for 20 min at 4˚C and the 
supernatant carefully discarded. The pelleted material was washed gently by rinsing with 
distilled H2O and redissolved in 150 mM NaCl, 50 mM Tris, pH 7.5 for subsequent 
purification. 
 
4.2.4.3     Size exclusion chromatography 
The ammonium sulfate fraction containing G93A SOD (section 4.2.4.2) was further purified 
by size exclusion chromatography (SEC) using a XK 16/70 column packed with Superdex 75 
prep grade gel filtration medium (GE Healthcare) equilibrated in 150 mM NaCl, 50 mM Tris, 
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pH 7.5. The fraction was passed over the column at a rate of 1 mL/min. 1 mL fractions were 
collected using an ÄKTA FPLC system (GE Healthcare) and analysed by 12% SDS-PAGE. 
Those containing SOD and other contaminants were pooled and dialysed against three 
changes of 10 mM Tris, pH 8.0 and stored at 4˚C prior to further purification.  
 
4.2.4.4     Anion-exchange chromatography 
SEC-purified G93A SOD (section 4.2.4.3) was further purified by anion exchange 
chromatography using a 5 mL HiTrap Capto-Q column (GE Healthcare) connected to an 
ÄKTA FPLC system (GE Healthcare). The column was equilibrated in 10 mM Tris, pH 8.0 
and SEC-purified G93A SOD (in the same buffer) loaded onto the anion exchange column at 
1.0 mL/min. 50 mL of 10 mM Tris, pH 8.0 was used to wash the column before eluting the 
bound SOD with a salt gradient of 0-200 mM NaCl in 10 mM Tris, pH 8.0 at 1 mL/min over 
60 mL. 1 mL fractions were collected and analysed by 12% SDS-PAGE. Those containing 
G93A SOD were pooled and concentrated using an Amicon Ultra-15 filter unit (Merck 
Millipore; 10 kDa molecular weight cut-off), dialysed against three changes of PBS/0.1% Az 
and stored at 4˚C. Protein concentration was determined by BCA assay (section 2.3). 
 
4.2.5  Protein aggregation assays 
Amorphous aggregation of proteins in 96-well microplates (100 µL/well) was measured as 
turbidity (changes in absorbance at 360 nm) using a FLUOstar or POLARstar 
spectrophotometer (BMG Labtech). Ovotransferrin (Ovo), immunoglobulin G (IgG) and 
Cu/Zn superoxide dismutase 1 (SOD) were selected as suitable target proteins for further 
experiments to elucidate the structural properties of aggregated proteins which activate 
extracellular proteases. Ovo (1.5 mg/mL, 13.2 µM) in PBS was induced to aggregate by 
heating at 60˚C for 120 min. IgG (1 mg/mL, 6.8 µM) in PBS was induced to aggregate by 
incubation with 500 µM NaOCl at 37˚C for 8 h. SOD (1.4 mg/mL, 44 µM) in PBS was 
induced to aggregate by incubation with 50 mM DTT and 5 mM EDTA at 37˚C for 24 h. For 
Ovo, aggregation mixtures were snap-frozen in liquid nitrogen at different time points over 
90 min for use in later experiments. In separate experiments, to test whether chaperone:client 
complexes could enhance tPA-mediated plg activation, Ovo was heat-stressed to aggregate at 
60˚C in the absence or presence of increasing SMR of CLU:Ovo to form high molecular 
weight (HMW) chaperone:client complexes. SMR and percent inhibition of aggregation was 
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calculated as described in section 3.2.6; except that the SMR was calculated assuming a CLU 
"subunit" to be comprised of the 80 kDa heterodimer form. 
 
4.2.6 bisANS fluorescence assays 
bisANS assays were performed as described in section 3.2.5; except fluorescence was 
measured spectrophotometrically over time measuring changes in exposed hydrophobicity of 
the client proteins under conditions which would induce their unfolding and aggregation 
(described in 4.2.5).  
 
4.2.7 Thioflavin T fluorescence assays 
Thioflavin T assays were performed as described in section 3.2.6, except fluorescence 
measurements were made using samples taken at different time points during the time course 
of protein aggregation assays. BSA was used as a negative control at equi-molar 
concentrations. Fibrillar aggregates of the SH3 domain (5 µM) of the p85α subunit of bovine 
phosphatidylinositol 3-kinase [kindly donated by Dr Justin Yerbury; (Kumita et al. 2007)] 
were used as a positive control.  
 
4.2.9 Circular dichroism spectroscopy 
Changes in secondary structure of aggregated protein samples were determined by Far-UV 
spectroscopy using a Jasco Model J-810 spectropolarimeter. Samples taken from protein 
aggregation assays (section 4.2.2) at reaction end-point (or in the case of Ovo, from 0-72 
min) were diluted to 0.1 mg/mL and dialysed against 10 mM NaH2PO4, pH 7.4. 
Measurements of mdeg (θ) were made over 180-250 nm and the molar ellipticity was 
calculated using the following equation (Schmid, 1989): 
 
[θ] = θ*100*molecular weight / concentration (mg/mL)*distance*number of amino acids 
 
The percentage of α-helix for each protein was estimated from ellipticity at 222 nm using the 
following formula (Phillips et al., 1981): 
% α-helix = - (θ222 nm – 4,800) / 45,400 
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4.2.8 Size exclusion chromatography of protein aggregates 
Native IgG (1 mg/mL, 6.8 µM) in PBS was incubated with 0-1000 µM NaOCl overnight (~8 
h) or 500 µM for 0-7 days at room temperature. 100 µL of protein was injected onto a 10/300 
Superose 6 GL (GE Healthcare) SEC column equilibrated in PBS connected to an ÄKTA 
FPLC system (GE Healthcare). Samples were run over the column at a flow rate of 0.3 
mL/min and the absorbance of the eluate at 280 nm (A280) continuously monitored. 150 µL 
fractions of oxidised IgG were collected and separated into HMW and monomeric species 
(corresponding to the two observed peaks in Figure 4.5) and in later experiments assayed for 
their ability to enhance the activation of plasminogen. The region of overlap between the 
peaks corresponding to HMW and monomeric species was estimated by overlaying 
chromatographs of IgG treated with increasing concentrations of NaOCl and untreated IgG. 
The difference in the area under the curve was calculated from these peaks excluding the 
region of overlap. 
 
 
4.2.9 Scanning electron microscopy 
Samples taken from the end-points of protein aggregation assays (section 4.2.2), or in the 
case of Ovo at a range of time points, were resuspended at a total protein concentration of 0.1 
mg/mL in PBS and 2 µL of each sample was blotted onto formvar resin (with carbon coating) 
nickel mesh grids (Proscitech), incubated for 5 min at room temperature, washed three times 
with filtered dH2O, and negatively stained with 1% (w/v) uranyl acetate in Milli-Q H2O. The 
specimens were then examined using a JSM7500FA cold Field Emission Gun Scanning 
Electron Microscope (JEOL) with an acceleration voltage of 20.0 kV and a working distance 
of 8 mm (spot size setting of 8). The detector used was a transmission electron detector 
mounted beneath the specimen platform (JEOL). Secondary electron images were taken with 
a semi in-lens detector at a working distance of 8.0 mm.  
 
4.2.10  Plasminogen activation assays 
Samples taken either at various time points or at the endpoints of the protein aggregation 
assays (section 4.2.5), were dialysed into HBST (10 mM HEPES, 150 mM NaCl, 0.01% (v/v) 
Tween 20, pH 7.4) and quantified by BCA assay (section 2.3) prior to subsequent 
experimentation. In the case of Ovo and SOD, aggregates were also centrifuged (Heraeus 
Chapter 4: The interaction of amorphous aggregates with the plasminogen activation 
system and extracellular chaperones 
75 
 
Fresco 21; ThermoFisher) at 15,000 x g for 30 min at 4˚C for separation into insoluble and 
soluble fractions and dialysed as above. The samples were then analysed for their ability to 
enhance tPA-mediated plg activation to plasmin by measuring changes in absorbance 
resulting from the conversion of the plasmin-specific chromogenic substrate H-D-norleucyl-
hexahydrotyrosol-lysine-para-nitroanilide diacetate (SPEC-PL; American Diagnostica 
Incorporated) to para-nitroaniline. 500 nM of aggregated or native non-aggregated protein 
sample or fibrin (positive control) in ice-cold HBST was incubated with 250 nM plg (in some 
experiments in the absence or presence of 10 mM tranexamic acid (TXA), a competitive 
lysine-binding site inhibitor of plg) and 500 nM SPEC-PL in a 96-well polystyrene 
microplate (Greiner Bio-one) at a total volume of 60 µL per well. The reaction was initiated 
by adding 10 µL of recombinant human tPA (Actylise; Boehringer-Ingelheim, Australia) to a 
final concentration of 5 nM per well.  Absorbance at 405 nm (A405) was read on a Spectramax 
Plus 382 plate reader (Molecular Devices) for 120 min at 37˚C with measurements taken at 
30 s cycles with 3 s of shaking between cycles. To determine whether A2AP (Calbiochem) or 
recombinant PAI-2 [kindly donated by Prof. Marie Ranson; (Cochran et al. 2009)] could 
inhibit plg activation by protein aggregates, ternary complexes were first allowed to form 
between tPA, plg and the aggregate sample for 30 min in HBST at 37˚C, and then incubated 
(or not) with either 400 nM A2AP or 200 nM PAI-2 for a further 15 min, prior to measuring 
plasmin activity.  
 
Various background controls for plm activity in the absence of fibrin or aggregated proteins 
(eg. tPA/SPEC-PL, plg/SPEC-PL, SPEC-PL alone) were included in all assays and subtracted 
from the raw data. These were essentially negative/zero indicating the absence of 
contaminating plm in the tPA, plg or SPEC-PL components. Background controls for assays 
conducted in the presence of fibrin or aggregated proteins (e.g., Ovo/SPEC-PL, 
Ovo/plg/SPEC-PL, Ovo/tPA/SPEC-PL) were also included and subtracted from the 
appropriate raw data. All experiments for Ovo were performed at once, but on separate days 
for SOD and IgG. Solubilised fibrin stock (25 mg/mL) was prepared as per the 
manufacturer’s instructions by addition of 1 M NaOH to powdered fibrin (Sigma-Aldrich, 
USA), and then aliquoted and stored at -20˚C. Different aliquots were used for each series of 
experiments. Comparison of the effects of amorphous aggregates on plg activation were 
plotted as the change in A405 against time (t). The change in A405 is a function of SPEC-PL 
substrate cleavage by plasmin, generated during the tPA-mediated activation of plg. For 
quantitative analyses the initial rate of change of plm activity (initial rate of reaction) was 
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 was used to linearise the 
curves and simplify calculation). Data transformation and linear regressions were performed 
using GraphPad Prism v5.0 (GraphPad Software). 
 
 
4.2.11  Statistical Analysis 
Data presented in the results was analysed using a one-way ANOVA and a Bonferroni 
multiple comparison post-test using GraphPad Prism v5.0, unless stated otherwise. The extent 
of significance between samples is denoted by the amount of asterix present in the graphs 
(*p<0.05, **p<0.01 and ***p<0.001).  
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4.3.1 Heat or chemical stress treatments of ovotransferrin, G93A mutant superoxide 
dismutase-1 and immunoglobulin-G produces amorphous protein aggregates 
Hyper-physiological temperatures and oxidative stress are often associated with human 
diseases and can induce proteins to unfold from their native structure and subsequently 
aggregate to form either elongated amyloid fibrils or large amorphous clumps (Stranks et al. 
2009). Heating native ovotransferrin (Ovo) at 60˚C resulted in extensive and rapid 
precipitation of the protein, shown by an increase in turbidity (measured as absorbance at 360 
nm (A360)) after a lag phase of 20 min, followed by a rapid increase in absorbance to reach a 
maximum at approximately 120 min (Figure 4.1). Chemical denaturation of the G93A mutant 
of superoxide dismutase-1 (SOD) by chelation of metals using EDTA and reduction with 
DTT resulted in gradual precipitation of the protein after a lag phase of 250 min, followed by 
a rapid increase in turbidity to reach a maximum at 1100 min (Figure 4.1). In contrast, there 
was only a small linear increase in turbidity measured for oxidatively-stressed 
immunoglobulin-G (IgG), reaching a maximum at 1100 min (Figure 4.1).  
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Figure 4.1 Heat and chemical stress-induced aggregation of Ovo, IgG and SOD. Ovo, SOD and 
IgG were induced to aggregate as described in section 4.2.5. Aggregation was measured as increasing 
turbidity (changes in absorbance at 360 nm) over time. Data points represent the mean ± SD (n=9) of 
three separate experiments, where in each experiment measurements were performed in triplicate.  
 
A hallmark of protein aggregation is the exposure of normally buried hydrophobic residues 
during unfolding, which then allows the protein molecules to self-associate into an 
aggregation nucleus. The nucleus continues to grow in size (measured as an increase in 
turbidity; (Moreno et al. 2000)) until large insoluble aggregates are formed. The extent to 
which protein molecules exposed hydrophobicity to solution during stress induced 
aggregation was probed using bis-ANS fluorescence. During the heat-induced unfolding of 
Ovo, a dramatic increase in bisANS-associated fluorescence was measured over time, 
reaching a plateau at 60 min and a maximum value at 90 min (Figure 4.2). Chemical 
denaturation of SOD resulted in an increase in bisANS-associated fluorescence after a lag 
phase of 100 min, followed by a further rapid increase to reach a plateau at 300 min, followed 
by a slight linear reduction in fluorescence until the end of the time course (Figure 4.2). 
When the kinetics of changes in bisANS fluorescence are related to turbidity measurements 
in Figure 4.1, for both SOD and Ovo, normally buried hydrophobic residues are exposed 
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before there is a measurable increase in turbidity. During oxidation, IgG produced a small 
linear increase in bisANS fluorescence following a lag phase of 300 min (Figure 4.2). 
 



















































Figure 4.2 Aggregation of Ovo, SOD and IgG results in increased exposed hydrophobicity. Ovo, 
SOD and IgG were induced to aggregate as described in section 4.2.5. Exposed hydrophobicity was 
measured as mean bisANS-associated fluorescence intensity over time. Data points represent the 
mean ± SD (n=9) of three separate experiments, where in each experiment measurements were 
performed in triplicate. 
 
Samples of Ovo were taken at increasing times during the aggregation time course and snap-
frozen in liquid nitrogen for use in later experiments. These samples were also examined for 
changes in secondary and tertiary structure using far-UV circular dichroism (CD) 
spectroscopy and thioflavin-T (ThT) fluorescence measurements, respectively. Furthermore, 
samples of SOD were taken at reaction end-point and measured for ThT fluorescence. The 
far-UV CD spectra of Ovo samples taken at various intervals during the aggregation reaction 
time were virtually superimposable; deconvolution of the spectra into their α-helical, β-sheet, 
β-turn and unordered structures showed that there were no significant changes over time 
(Figure 4.3). The relative ThT fluorescence (an indicator of cross-beta sheet structure) 
associated with Ovo  samples taken throughout the aggregation time-course reaction and end-
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point SOD samples was similar to native BSA and ThT alone, and significantly lower than 
that measured for fibrillar aggregates of the SH3 domain (p < 0.001; Figure 4.4). This 
indicated that heat-denatured Ovo and chemically-denatured SOD do not form fibrillar 
aggregates associated with cross-beta structure. 
 

































Figure 4.3 Heat-stress induced aggregation of Ovo does not result in significant changes to 
secondary structure content. CD spectra of Ovo aggregate samples (0.1 mg/mL) taken at increasing 
lengths of time from an aggregation reaction. The data shown are means of three scans; mean molar 
ellipticity is plotted (θ), calculated for Ovo (section 4.2.9), assuming a molecular weight of 76 kDa.  
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Figure 4.4 Ovo and SOD aggregates are not rich in beta-sheet content. Ovo (5 µM) and control 
proteins in PBS were heated at 60˚C. 25 µM Thioflavin-T was incubated in the absence (ThT; purple 
bar) or presence of samples of Ovo aggregates taken over the reaction time course (time is indicated) 
and the level of beta-sheet content was measured as the relative mean ThT fluorescence intensity (490 
nm). Data points represent the mean ± SD (n=9) of three separate experiments, where in each 
experiment measurements were performed in triplicate. Fibrillar aggregates of SH3 (red bar) and 
native BSA (blue bar) were used at equi-molar concentrations as positive and negative control 
proteins, respectively. 
 
Relative to SOD and Ovo, oxidatively-stressed IgG showed only minor changes in turbidity 
and exposed hydrophobicity. To confirm the presence of larger high molecular weight 
(HMW) species, indicative of protein aggregates, size exclusion chromatography was 
performed (Figure 4.5). The oxidation of IgG by NaOCl (0 – 7 days) did not produce 
aggregates of a size large enough to scatter visible light (therefore little change in turbidity 
was measured, Figure 4.1). SEC shows that monomeric species of IgG (normally ~150 kDa) 
can be induced to form larger HMW species, seen as a broad peak eluting from the column 
earlier, interpolated to be an average ~ 356 kDa in size (Figure 4.5 A). The difference in the 
area under the curves between IgG incubated in the absence or presence of NaOCl, suggests 
that approximately 60% of the protein formed larger species which are most likely in the 
form of soluble aggregates (Figure 4.5 A). Incubating IgG for a prolonged time (>24 h) did 
not result in an increase in HMW species being formed (data not shown for day 2-7). IgG 
incubated with increasing concentrations of NaOCl for 8 h showed increasing amounts of 
HMW species as a percentage of the total protein present in solution, ranging from ~ 5% (0 
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µM NaOCl) to a maximum of ~ 46% for 1000 µM NaOCl (Figure 4.5 B). A concentration of 
500 µM NaOCl was chosen for use in later plasminogen activation experiments as a 
compromise between the amount of HMW generated and physiologically relevant NaOCl 
concentration (Bergt et al. 2001).  










Oxidised IgG (24 h)





































[NaOCl] (µM) 0 250 500 750 1000
% of Total Area 
Under the Curve
5.16 15.94 31.87 35.72 46.22
 
Figure 4.5 Oxidation of IgG produces soluble high molecular weight protein species. Native IgG 
(1 mg/mL, 6.8 µM) in PBS was incubated with (A) 500 µM NaOCl for 24 h or (B) 0-1000 µM NaOCl 
overnight (~ 8 h) then analysed by SEC and A280 monitored continuously during elution. The 
positions of molecular weight standards in (A) are indicated by black arrows at the top of the figure. 
The molecular weight interpolated using a standard curve is indicated by a blue arrow centred over a 
high molecular weight peak. The position of monomeric species of oxidised IgG in (B) is indicated by 
a black arrow at the top of the figure, while the position of high molecular weight (HMW) species is 
indicated by a capped bar below the traces. The vertical dashed line indicates the volume at which the 
two species were separated into fractions. The table beneath (B) indicates the % of the total protein 
comprised of HMW species at each corresponding concentration of NaOCl.   
A 
B 
Chapter 4: The interaction of amorphous aggregates with the plasminogen activation 
system and extracellular chaperones 
83 
 
Scanning electron microscopy allowed visualisation of aggregates (Figure 4.6), with samples 
taken either at end points (for SOD and IgG; Figure 4.6 F, H, respectively) or at increasing 
lengths of time (from an Ovo aggregation reaction; Figure 4.6 A-D). Micrographs of Ovo, 
SOD and IgG displayed clumps of disorganised “amorphous” protein aggregates. Ovo 
aggregates increased in complexity and size with increasing aggregation reaction time. The 
structure of IgG was less complex than Ovo and SOD, and the protein aggregates were of a 
smaller and more compact size (much smaller than 1 µm), consistent with the observation 
that oxidation of IgG did not elicit large changes in turbidity (Figure 4.1). Micrographs of the 
corresponding native Ovo (0 min), SOD and IgG did not show any detectable aggregated 
protein (Figure 4.6 A,E,G).  
 




Figure 4.6 Representative scanning electron micrographs of native Ovo, SOD and IgG and their 
amorphous aggregates. Ovo aggregate samples (A-D) were taken from an aggregation reaction at 0 
(A), 10 (B), 34 (C) and 72 (D) min. (E) Native SOD. (F) End-point samples of SOD aggregates taken 
post-aggregation (20 h). (G) Native IgG. (H) End-point samples of SEC purified HMW oxidized IgG 
aggregates following 8 h incubation with 500 µM NaOCl. White scale bars represent 1 µm in all 
cases.    
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4.3.2  Amorphous aggregates but not native proteins enhance the activation of 
plasminogen to plasmin  
The plg activation system may play an important role in maintaining extracellular 
proteostasis (Yerbury et al. 2005; Gebbink et al. 2009). Tissue plasminogen activator (tPA) 
has been previously shown to bind to the cross-beta structure of fibrillar protein aggregates 
(Kranenburg et al. 2002). However, the ability of amorphous aggregates to interact with and 
activate elements of the plg activation system was previously unknown. The ability of 
amorphous aggregates to activate plg to plm in the presence of tPA was measured indirectly 
using the plm-specific chromogenic substrate SPEC-PL.  As expected the positive control 
protein fibrin, by colocalising tPA and plg, considerably enhanced the activation rate of plg 
compared to tPA and plg alone (i.e., in solution) (Figure 4.7). Amorphously aggregated Ovo, 
SOD and IgG taken from the end-points of protein aggregation assays were also capable of 
enhancing tPA-mediated plg activation but were less efficient than fibrin (Figure 4.7). Native 
protein and oxidised monomeric IgG did not significantly enhance plg activation above that 
of tPA/plg alone in solution (Figure 4.7).   
 
The initial rates of change of plasmin activity (refer to section 4.2.10 for method of analysis) 
were then calculated for the purpose of quantitative comparisons.  Fibrin generated the fastest 
initial rate of change of plm activity with values ranging between assays from 80.0 ± 1.1 to 
135.1 ± 1.2 µA405.min
-2
 (101 ± 30; n=9). By direct comparison to the intra-assay plg 
activation control (tPA/plg in the absence of cofactor) this equated to an average fold-
increase of ~ 7.1 ± 1.7 (across three replicates). The corresponding calculated initial rates of 
change in plm activity for Ovo, SOD and HMW oxidised IgG aggregates ranged from 53.1 ± 
2.2 to 28.2 ± 0.9 µA405.min
-2
 (36.4 ± 14.5 µA405.min
-2
; n=9), respectively. However, when 
expressed as a fold-increase compared to tPA/plg alone, all amorphous protein aggregates 
elicited similar increases in plg activation (mean fold-increase = 2.5 ± 0.4, n=3). This 
suggests that analogous to fibrin, amorphous aggregates likely colocalise tPA and plg, 
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Figure 4.7 Amorphous aggregates of Ovo, IgG and SOD enhance tPA-mediated plasminogen 
activation. 500 nM of aggregated or native non-aggregated protein sample or fibrin (positive control) 
was pre-incubated in the presence of 250 nM plg and 500 nM SPEC-PL. The reaction was initiated by 
the addition of 5 nM tPA and the level of plm activity was measured spectrophotometrically (A405) at 
37C for 120 min. Fibrin and tPA/plg alone served as interassay controls for plg activation in the 
presence or absence of cofactor. Data points represent the mean ± SD (n=9) of three separate 
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4.3.3  Plasminogen activation is enhanced by both insoluble and soluble Ovo 
aggregates  
It is unknown which biophysical characteristics of amorphous aggregates mediate plg 
activation. To investigate this, the effects on plg activation of (i) the size and quantity of 
protein aggregates and (ii) the level of exposed hydrophobicity of aggregates were examined. 
Both soluble and insoluble protein species were examined. Ovo aggregate (Ovo Agg.) 
samples taken at various time points from an aggregation reaction were assayed for their 
ability to enhance tPA-mediated plg activation. Ovo Agg. samples taken at increasing time 
points (10 – 72 min) from the aggregation reaction elicited exponentially increasing initial 
rate of change of plm activity. The t=0 min sample did not enhance plg activation above 
tPA/plg alone (Figure 4.8); this is probably due to the absence of aggregated material, as 
visualised by SEM (Figure 4.6). The initial rate of change of plm activity correlated 
significantly with each of the following: aggregation time (Figure 4.8A; Pearson r =0.939; p 
=0.0001), hydrophobicity (Figure 4.8B; Pearson r =0.833; p =0.001), and turbidity (Figure 
4.8C; Pearson r =0.748; p =0.005), the latter two after a lag phase. The greatest increase in 
initial rate of change of plm activity was seen using protein samples from 48 – 72 min of 
aggregation time, effectively doubling rates from 42.8 ± 2.6 to 72.3 ± 3.3 µA405.min
-2
. These 
time points correspond to the plateau phase of the turbidity curve shown in Figure 4.1.  
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Figure 4.8 Initial rate of change of plm activity increases with the extent of Ovo aggregation, 
exposed hydrophobicity and turbidity. 500 nM of Ovo aggregate (Ovo Agg.) samples taken at 
increasing lengths of time from an aggregation reaction were dialysed against HBST and assayed for 
their ability to enhance tPA-mediated plg activation. The initial rate of change of plm activity was 
calculated as per section 4.2.10 and plotted versus: (A) The corresponding time at which the aggregate 
sample was collected from the reaction (section 4.2.5). (B) Exposed hydrophobicity of these samples 
(measured as bisANS-associated fluorescence). (C) Turbidity of these samples. The level of tPA-
mediated plg activation in the absence of aggregates (tPA/plg alone) is indicated by the dashed black 
line. Data points represent the mean ± SD (n=9) of three separate experiments, where in each 
experiment measurements were performed in triplicate.  
 
In parallel experiments, the same samples were centrifuged and separated into insoluble and 
soluble protein fractions. The initial rate of change of plm activity was measured and plotted 
against aggregation time (Figure 4.9). Insoluble aggregates sampled from after 10 min 
aggregation time elicited an overall higher rate of change of plm activity compared to soluble 
aggregates, reaching maximal rates of 124.5 ± 10.9 µA405.min
-2
 (48 min sample), versus 88.3 
± 2.8 µA405.min
-2
 (72 min sample) ( p < 0.01) (Figure 4.9), respectively. Taken together these 
data indicate that the ability of Ovo Agg. to stimulate plg activation is dependant on the 
extent of protein aggregation (turbidity), and correlates with the extent of exposed 
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hydrophobicity present (Figure 4.8). Lastly, it appears that the larger insoluble aggregates are 
more efficient at generating plm than smaller soluble aggregates (Figure 4.9).  









































Figure 4.9 Both insoluble and soluble Ovo aggregates can activate plg. 500 nM of Ovo Agg. 
samples taken from an aggregation reaction (section 4.2.5) were separated into insoluble (red squares) 
and soluble (blue circles) fractions by centrifugation, dialysed against HBST and assayed for their 
ability to enhance tPA-mediated plg activation. Data points represent the average initial rate of change 
of plm activity ± SD and correspond to the time at which the aggregate sample was collected from the 
reaction (on the x-axis). Data points represent the mean ± SD (n=9) of three separate experiments, 
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4.3.4 The ability of oxidised IgG to activate plasminogen increased with the 
concentration of NaOCl used and increasing amounts of high molecular weight species 
generated 
To investigate the possible role of tPA-mediated plg activation in inflammatory protein 
deposition diseases, IgG was first incubated with increasing concentrations of NaOCl for 8 h 
to produce increasing amounts of HMW species and then tested for their ability to enhance 
tPA-mediated plg activation. In some experiments, the oxidized IgG was fractionated by SEC 
into monomeric IgG and HMW species (Figure 4.5) before testing in the same assay.  HMW 
oxidised (ox.) IgG induced tPA-mediated plg activation - this ability increased with the 
concentration of HMW ox. IgG (Figure 4.10 and 4.11). The ability of unfractionated mixtures 
of ox. IgG to enhance tPA-mediated plg activation increased with exposure to greater 
concentrations of NaOCl (Figure 4.12). In the case of 1 mg/mL IgG oxidized by exposure to 
500 µM NaOCl, the level of plm activity elicited was similar to that elicited by the fibrin 
control (Figure 4.12). Neither native IgG nor ox. monomeric IgG (purified by SEC; Figure 
4.5) were able to increase plm activation above background levels (Figure 4.10 and 4.11). A 
Michaelis-Menten equation was fitted to the data using GraphPad Prism v5 to determine the 
kinetic constants of tPA-mediated plg activation (Figure 4.11). For HMW ox. IgG, these 
analyses gave values for Vmax of 40.1 ± 2.1 µA405.min
-2 and a corresponding value for Km 
of 1195 ± 170 nM, a value similar to the Km for plg activation in the presence of fibrin (990 
± 169 nM) (Fleury and Angles-Cano 1991). 
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Figure 4.10 Increasing concentrations of high molecular weight but not monomeric ox. IgG 
enhance tPA-mediated plg activation. IgG was oxidised with 500 µM NaOCl in PBS, separated into 
high molecular weight (HMW) and monomeric species by SEC and dialysed against HBST. 
Increasing concentrations of both HMW and monomeric oxidised IgG (ox. IgG) and untreated native 
IgG (from 0.075 - 1 mg/mL) were incubated in the presence or absence of tPA and plg and substrate 
SPEC-PL and the level of plm activity measured. Fibrin was used as a positive control. Data points 
represent the mean ± SD (n=9) of three separate experiments, where in each experiment 
measurements were performed in triplicate.   
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Figure 4.11 Michaelis-Menten curve fit to plot of initial rate of change of plm activity as a 
function of concentration of HMW ox. IgG. Initial rates from measurements of plm activity in 
Figure 4.11 were plotted against the concentrations of HMW and monomeric ox. IgG and native IgG. 
A Michaelis-Menten equation was fitted to the data to determine kinetic constants for HMW ox. IgG 
induced, tPA-mediated plg activation. Data points represent the mean ± SD (n=9) of three separate 
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Figure 4.12 The effect of IgG oxidised with varying concentrations of NaOCl on initial rate of 
change of plm activity. (A) IgG was oxidised with varying concentrations of NaOCl (0-1000 µM) in 
PBS, dialysed and diluted to 500 nM in HBST and incubated in the presence or absence of tPA and 
plg and substrate SPEC-PL to measure the level of plm activity. Fibrin was used as a positive control. 
(B) Initial rate of change of plm activity in (A) was plotted against the concentration of NaOCl (µM) 
incubated with IgG. Levels of tPA-mediated plm activation (i.e. tPA/plg alone in the absence of IgG) 
are shown by the dashed black line. The red dashed line in (B) indicates the level of activation elicited 
by fibrin. Data points represent the mean ± SD (n=9) of three separate experiments, where in each 
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4.3.5 Plasmin associated with insoluble aggregates of Ovo and SOD was resistant to 
inhibition by alpha-2-antiplasmin but not when associated with soluble aggregates 
Plm bound to intact fibrin is protected from inhibition by the potent protease inhibitor alpha-
2-antiplasmin (A2AP), allowing plm to perform a primary role - the efficient dissolution of 
fibrin-clots (Lijnen et al. 1982). To investigate whether plm generated in the presence of 
amorphously aggregated proteins was inhibited by A2AP, Ovo and SOD Agg. were separated 
into insoluble and soluble fractions by centrifugation and ternary complexes between plg, 
tPA and aggregate fractions formed before being incubated (or not) with A2AP and assayed 
for plm activity. 
 
As shown previously in section 4.3.3 (Figure 4.9), both soluble and insoluble aggregates of 
Ovo and SOD taken at aggregation reaction end-points greatly increased plg activation 
relative to tPA/plg alone levels (Figure 4.13). In a manner similar to fibrin, insoluble protein 
aggregates of both Ovo and SOD were found to shield plm from inhibition by A2AP, while 
soluble aggregates did so to a significantly lesser extent (Figure 4.13). For samples of Ovo 
Agg. taken at 72 min of aggregation, A2AP inhibited the activity of plm associated with 
insoluble Ovo Agg. by 15.5 ± 3.1 %; in contrast, when bound to soluble Ovo Agg., A2AP 
inhibited plm activity by 60.6 ± 2.0 %. Similarly, for end-point samples of SOD Agg., A2AP 
inhibited plm associated with insoluble SOD Agg. by 12.78 ± 2.3 % compared with 66.9 ± 
5.6 % inhibition for plm associated with soluble SOD Agg.  
 
Taken together these results indicate that insoluble amorphous protein aggregates induce 
tPA-mediated activation of plg to plm, and like fibrin, shields substrate-bound plm from 
inhibition by A2AP. This would allow for the continued degradation of large insoluble 
protein aggregates into smaller fragments by bound plm, while keeping the plm activity 
restricted to the aggregate surface. 
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Figure 4.13 Effects of alpha-2-antiplasmin on tPA-mediated plasminogen activation induced by 
soluble and insoluble aggregates of Ovo and SOD. Soluble (blue bars) and insoluble (green bars) 
fractions prepared from samples taken at different times from an Ovo aggregation reaction (Ovo Agg.; 
A) and end-point (20 h) samples of a SOD aggregation reaction (SOD Agg.; B) were tested for their 
ability to activate plg in the presence or absence of 400 nM alpha-2-antiplasmin (± A2AP). tPA, plg 
and samples were allowed to form a ternary complex and and assayed for the ability to activate plm 
either prior to or after the addition of A2AP. Bar graphs showing plm activity at the end of 120 min 
time courses, with the type of aggregate and aggregation time indicated above. Data points represent 
the mean ± SD (n=9) of three separate experiments, where in each experiment measurements were 
performed in triplicate.  Asterixes placed immediately above error bars indicate that the sample is 
significantly different to the corresponding sample lacking A2AP. Asterixes above horizontal brackets 
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4.3.6 tPA and lysine-binding mediates the activation of plasminogen by Ovo and SOD 
aggregates. 
The co-localised binding of plg and tPA to lysine residues in fibrin/ogen results in the 
enhanced activation of plg to plm, with fibrin/ogen acting as both a cofactor and a substrate 
for plm (Suenson and Petersen 1986). To further investigate the structural elements of the 
aggregates responsible for the enhanced plg activation observed above, the lysine-like analog 
tranexamic acid (TXA), which competes against plg for lysine-binding sites on target 
molecules (see Chapter 1; section 1.4) was used. PAI-2 (an active site inhibitor of tPA) is 
highly expressed in amyloid-containing microglial conglomerations associated with plaques 
in Alzheimer’s disease patients (Akiyama et al. 1993). Therefore the question of whether the 
plm activity elicited by amorphous protein aggregates is, as for fibrin, shielded from 
inhibition by PAI-2 (Lobov and Ranson 2011) was also investigated (see Chapter 1; section 
1.4). TXA significantly inhibited tPA-mediated plg activation induced by end-point Ovo and 
SOD aggregates by 97.7 ± 0.2 and 46.8 ± 1.2 %, respectively, compared to controls in the 
absence of TXA. In the case of fibrin-induced activation, inhibition was 62.0 ± 1.5 % of 
controls (Figure 4.10 A,B). In parallel experiments, TXA was found to significantly inhibit 
plg activation induced by samples from all Ovo aggregation reaction time points (ranging 
from 92.0 ± 2.3 to 102.2 ± 0.6 % inhibition; Figure 4.10 D). Thus, similar to fibrin-bound 
tPA, direct binding of tPA and plg to protein aggregates via lysine residues appears to be 
essential for efficient tPA-mediated plg activation. 
 
PAI-2 significantly inhibited plm activity induced by end-point Ovo and SOD aggregates by 
83.2 ± 0.7 and 77.1 ± 0.5 % respectively, compared to controls in the absence of PAI-2. A 
similar effect was found for fibrin-induced plm activity (64.6 ± 1.4 % inhibition) (Figure 4.10 
A,B). In parallel experiments, PAI-2 was found to significantly inhibit tPA-mediated plg 
activation (expressed as initial rate of change of plm activity) induced by samples from all 
Ovo aggregation reaction time points; inhibition ranged from approximately 51 – 52% for 0-
10 min samples to 71 – 83% inhibition for subsequent time point samples (Figure 4.10 C). 
Thus, aggregates partially shield bound tPA from inhibition by PAI-2, similar to fibrin-bound 
tPA. 
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Figure 4.14 Effects of plasminogen activator inhibitor type-2 (PAI-2) and tranexamic acid 
(TXA) on tPA-mediated plasminogen activation elicited by Ovo and SOD aggregates. (A,B) Bar 
graphs of plasmin activity elicited by fibrin (positive control) or time course end-point samples of (A) 
Ovo and (B) SOD aggregates (both at 500 nM) in the absence or presence of PAI-2 (200 nM) or TXA 
(10 mM). (C,D) Graphs of the initial rate of Ovo Agg.-induced plasmin activity (measured as 
described in 4.2.10) as a function of Ovo aggregation time, in the presence or absence of (C) PAI-2 
and (D) TXA. Data points represent the mean ± SD (n=9) of three separate experiments, where in 
each experiment measurements were performed in triplicate. In D, the error bars on the lower plot are 
too small to be visible. Significant differences between samples incubated in the presence of either 
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4.3.7 Chaperone:client complexes of clusterin:Ovo enhance tPA-mediated 
plasminogen activation  
Chaperones such as clusterin (CLU) are known to form high molecular weight complexes 
with partly unfolded proteins (clients) under stress conditions (Humphreys et al. 1999; Carver 
et al. 2003). These complexes are mostly soluble and can be purified from precipitated 
protein material by means of post-reaction centrifugation and SEC. The ability of soluble 
chaperone:client complexes to interact with and affect plg activation is unknown. To 
investigate this, CLU:Ovo complexes were formed by co-incubating CLU and Ovo at 60˚C at 
different molar ratios of client to chaperone. Heating native Ovo in the absence of CLU 
resulted in its rapid and extensive precipitation, shown by an increase in turbidity after a lag 
phase of 20 min, reaching a maximum at approximately 110 min (Figure 4.10). CLU 
inhibited the extent of Ovo precipitation by 67.9 ± 7.8 % and 83.6 ± 4.8 % at molar ratios of 
chaperone:client of 1:8 and 1:2, respectively, and formed soluble chaperone:client complexes 
as demonstrated previously by (Humphreys et al. 1999; Poon et al. 2000) (Figure 4.11 A).  
 
Purified complexes formed at various CLU:Ovo ratios were then analysed for their ability to 
enhance tPA-mediated plg activation. It is unclear whether altering the ratio of CLU:Ovo 
alters the stoichiometry of the HMW complexes formed by their interaction therefore, 
different ratios of CLU:Ovo were tested. Soluble HMW complexes of CLU:Ovo were shown 
to enhance tPA-mediated plg activation similar to Ovo aggregates alone (Figure 4.11 B). 
Complexes formed using a ratio of 1:2 CLU:Ovo displayed a lower initial rate of change of 
plm activity (16.1 ± 0.1 fold-increase above background) when compared with complexes 
formed in the presence of higher concentrations of Ovo relative to CLU (SMR of 1:8 and 1:4 
CLU:Ovo gave an average 82.1 ± 11 fold-increase above tPA/plg alone). The initial rate of 
change of plm activity elicited by CLU:Ovo complexes was greater than corresponding levels 
obtained for Ovo Agg. end-point samples (57.4 ± 2.0 fold). The in vivo relevance of the 
activation of plg by CLU:client complexes is unknown. 
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Figure 4.15 CLU:Ovo complexes enhance tPA-mediated plasminogen activation. (A) Turbidity 
(measured as A360) as a function of time for Ovo (11.6 µM) in PBS, induced to aggregate by heating 
at 60˚C in the presence of different molar ratios of chaperone:client (CLU:Ovo, indicated in key). (B) 
75 µg/mL of purified CLU:Ovo complexes (see section 4.2.5) dialysed against HBST, were assayed 
for their ability to enhance tPA-mediated plg activation. Complexes formed using molar CLU:Ovo 
ratios of 1:12 and 1:24 elicited similar levels of plg activation as complexes formed using CLU:Ovo 
at 1:8 and thus are not shown for clarity. Data points represent the mean ± SD (n=9) of three separate 
experiments, where in each experiment measurements were performed in triplicate. 
 
  




Previous studies have shown that tPA can bind to chemically- and heat-stressed protein 
aggregates, which act as a cofactor for plg activation, and a substrate for plm (Table 4.3) 
(Radcliffe 1981; Radcliffe 1983; Machovich and Owen 1997; Samson et al. 2009; Gebbink 
2009 ). The structural properties of these aggregates were not clearly established by these 
previous studies. The conditions used to denature the proteins (acidic or basic pH and 
heating), however, are similar to those often used to produce amorphous aggregates.  
 
Table 4.1 Chemical and heat stressed proteins which have been shown to enhance tPA-mediated 
plasminogen activation. 
Plasma Cytosolic-secretory Connective 






































   Pepsin2 RNase2     
Fibrinogen
1,2
   Pyruvate kinase2     
 α2-Macroglobulin1   
 
      
α1-Protease inhibitor
1
         
 Immunoglobulins1,2           
Plasminogen
2
         
  
Stressed proteins are divided into columns based on their distribution (for example, plasma), and their 
ability to initiate tPA-mediated plg activation. Proteins were either able to induce plg activation 
without further treatment (Active), or required pre-treatment and partial proteolysis with plm prior to 
being assayed, before they could activate plg (Pre-treated). Heating was used to denature albumin, 
antithrombin, A2M, and α1-protease inhibitor, while acidic pH was used to denature apoferritin. The 
conditions used to denature the other proteins were heat and acidic or basic pH. However, the details 
of these treatments were not fully described in the corresponding publications. 
1
Machovich, R. and 
Owen, W.G. (1997), 
2
Radcliffe, R. and Heinze, T. (1981), 
3
Stack, S. et al. (1990). 
 
Heat or reduction were used to generate amorphous aggregates from Ovo, SOD and IgG. 
Analysis of their biophysical characteristics established that the products were hydrophobic 
and structurally disordered amorphous aggregates. The stressed proteins yielded a 
heterogenously sized and structurally disorganised mixture of aggregates (Figure 4.6), 
growing in size and complexity over time into material either sufficiently large enough to 
Chapter 4: The interaction of amorphous aggregates with the plasminogen activation 
system and extracellular chaperones 
101 
 
scatter light (Ovo and SOD, Figure 4.1) or detectable as soluble HMW species (Ox. IgG, 
Figure 4.5). Soluble HMW Ox. IgG species were found on average to equate in size to cross-
linked IgG dimers (~ 356 kDa).  
 
Like fibrin, amorphous SOD, Ovo and Ox. IgG aggregates, but not their native protein 
counterparts, were able to enhance tPA-mediated activation of plg. In agreement with 
previous studies (Table 4.3), these aggregates acted as both cofactors (probably by 
colocalising both tPA and plg to their surface) to generate plm (Figure 4.7). Aggregates of all 
three proteins induced similar levels of plg activation. Disease relevant amyloid proteins have 
also been shown to activate tPA in a similar manner (Tucker 2000). Interestingly, the ability 
of ox. IgG to activate plasminogen increased with the amount of high molecular weight 
species, but neither oxidized monomeric IgG nor native IgG induced activation of plg (Figure 
4.12). 
 
Plg activation also increased with the concentration of NaOCl used to oxidise IgG (Figure 
4.14), most likely due to increasing amounts of HMW species formed at higher NaOCl 
concentrations (Figure 4.5). It is interesting to note that plg has previously been shown to 
bind to solid-phase-immobilised IgG (Harpel et al. 1989). Soluble and insoluble aggregates 
of IgG have been shown to trigger an immunogenic response by activating neutrophils to 
secrete oxidants and granule enzymes and induce the secretion of plasminogen activator by 
macrophages (it was not established whether this was uPA or tPA; (Pestel et al. 1984; 
Robinson et al. 1993). This may create a feed forward mechanism, potentially increasing the 
pool of oxidised proteins and co-factors able to further activate plg.  
 
The extent of plg activation was dependent on the amount and extent of hydrophobic, 
aggregated material produced. Increases in turbidity correlated with an increase in aggregate 
size (Moreno et al. 2000). SEM micrographs indicated an increase in the size of amorphous 
Ovo aggregates at later time points (taken from the plateau region of the turbidity curve, 
Figure 4.1), which strongly correlated with an increased capacity to activate plg (Figure 4.8). 
The heterogenously sized aggregates were able to reproducibly activate plg and this was 
accomplished by both soluble and insoluble Ovo aggregates. Overall, insoluble aggregates 
were found to be more efficient at enhancing plg activation than soluble aggregates (Figure 
4.9). Previous studies have shown that an increase in aggregate particle size correlated with 
enhanced plg activation, and that there was a minimal requirement for the size of the cofactor 
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(about 10 nm radius) (Galantai et al. 2006). Differences in aggregate size may account for the 
observations that (i) amorphous ox. IgG aggregates are smaller than Ovo and SOD 
aggregates, and have a lower ability than the latter to activate plg (the latter have comparable 
abilities to activate plg, Figure 4.7), and (ii) soluble aggregates are smaller in size than 
insoluble protein aggregates. Differences in the relative ability of protein aggregates to 
activate plm may also be dependent upon the number of binding sites available to tPA and 
plg, which would be more numerous on larger protein aggregates.   
 
The exposure of normally buried hydrophobic residues to solution is a general phenomenon 
associated with protein aggregation (Dobson 2003). While the correlation between greater plg 
activation and the increased hydrophobicity of aggregates may be simply attributable to the 
extent of aggregation rather than increased binding of tPA and plg to hydrophobic residues, it 
should be noted that the kringle domains of both tPA and plg are dominated by a core cluster 
of hydrophobic residues, with kringle 2 (tPA) and kringle 4 (plg) having been shown to 
facilitate hydrophobic binding to fibrin (van Zonneveld 1986) and dimeric αs2-casein (one of 
a group of phosphoproteins found in mammalian milk) (Heegaard et al. 1997). Thus tPA and 
plg may bind to amorphous protein aggregates via hydrophobic interactions. Furthermore, 
circulating extracellular chaperones “sense” denatured/misfolded proteins by virtue of their 
exposed hydrophobicity (Poon et al. 2002; Wyatt et al. 2013), a mechanism which may allow 
interplay and cooperation between proteases and chaperones. 
 
The minimum chaperone:client ratio required to substantively inhibit the formation of large 
turbid Ovo species was an SMR 1:8 (CLU:Ovo), comparable to previously reported values 
(Figure 4.11) (Humphreys et al. 1999; Poon et al. 2000). CLU and other chaperones 
preferentially bind to small misfolded oligomeric species during amyloid aggregation (this 
has not yet been established for amorphous aggregation) to maintain their solubility, inhibit 
their further aggregation and toxicity, and facilitate their bulk uptake and degradation via 
receptor-mediated endocytosis (Yerbury et al. 2005; Wyatt et al. 2013). Chaperones such as 
CLU are known to form high molecular weight complexes with partly unfolded client 
proteins under stress conditions (Humphreys et al. 1999; Carver et al. 2003). In protein 
deposition diseases there is a pathophysiological presentation of misfolded proteins as large 
insoluble protein deposits, meaning these systems of extracellular protein quality control are 
overcome by the disease state. CLU has been found associated with such extracellular protein 
deposits (Wilson et al. 2008). Soluble HMW complexes of CLU:Ovo were shown to enhance 
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tPA-mediated plg activation similar to Ovo aggregates alone (Figure 4.11). HMW complexes 
generated by the binding of CLU with misfolded citrate synthase, fibrinogen and glutathione 
S-transferase are comprised of an approximate mass ratio of 1:2 CLU:client protein (Wyatt et 
al. 2009). However, the mass ratio of the two proteins in CLU:Ovo complexes has has not 
been established. Complexes formed using a ratio of 1:2 CLU:Ovo elicited less activation of 
plg to plm than complexes formed using higher ratios of CLU:Ovo (SMR of 1:8 and 1:4, 
CLU:Ovo). 
 
Speculatively, this may be due to complexes formed using a large excess of Ovo relative to 
CLU resulting in increased accessibility of tPA and plg binding sites present on the CLU:Ovo 
complex. Uncomplexed CLU was able to enhance plg activation to approximately 2.5 times 
above that of background levels (tPA/plg alone), but this is unlikely to have significance in 
vivo as the plm activity was relatively small when compared to either aggregate- or fibrin-
stimulated plg activation. In addition to the removal of circulating HMW CLU:client protein 
complexes by hepatocytes (Wyatt et al. 2011), plg activation by HMW CLU:client protein 
complexes may assist in the removal of large extracellular protein aggregates.  
 
The results with TXA (Figure 4.10) suggest that, as is the case for fibrin (Wiman and Wallen 
1977), binding of tPA and plg to lysine residues is important in the activation of plg elicited 
by amorphous protein aggregates. Plg binding to (structurally uncharacterised) denatured 
proteins has previously shown to be mediated via lysine residue binding (Radcliffe 1983). 
This is likely due to binding of both plg and tPA to the protein aggregates via kringle-
domains. Plg is also known for its ability to distinguish between conformationally different 
prion proteins (i.e. disease relevant and native forms); again, the lysine binding site 1 
(kringles 1-3) are involved (Fischer et al. 2000). Interestingly, while TXA almost completely 
inhibited the binding of tPA and plg to Ovo aggregates, binding to SOD aggregates was far 
less affected (Figure 4.10). tPA has been shown to bind to substrates by several lysine-
independent mechanisms: (i) to fibrin via hydrophobic interaction with the kringle 2 domain 
(Urano et al. 1991) (ii) to cofactors through the fibronectin type 1 domain (Maas et al. 2008), 
and (iii) to amyloid fibrils through interaction with their “cross-beta” structure (Kranenburg 
et al. 2002). For amyloid fibrils it has been argued that cross-beta structure is not essential for 
tPA activation but rather is simply involved in maintaining the structure of amyloid 
aggregates. This infers that tPA activation may be facilitated by some other structural feature 
of amyloid aggregates (Galantai et al. 2006). However, as SOD aggregates were found to 
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contain no beta-sheet content (Figure 4.4), either the number of exposed lysine binding sites 
is more abundant in SOD aggregates or other non-amyloid structural elements must be 
involved. Addition of TXA in the absence of protein increased background levels of plg 
activation (subtracted from raw data, thus not shown), probably due to conformational 
changes induced in plg (Christensen and Molgaard 1992). Native proteins did not elicit any 
significant activation of plm. Even though lysine residues are displayed on the surface of 
native proteins, including extracellular proteins, native proteins do not induce plg activation 
while amorphously aggregated proteins do. The loss of native protein structure and the 
exposure of greater numbers of lysine residues to facilitate binding of tPA and plg, may 
provide a way for the plg activation system to discriminate between native and non-native 
proteins (Machovich and Owen 1997).   
 
PAI-2 expression is markedly increased in the vascular endothelium, granulosa cells and in 
microglial cells of patients with Alzheimer's disease (Akiyama et al. 1993; Dear and Medcalf 
1995) and is up-regulated (~1800-fold) and confers substantial protection in the injured brain 
following excitotoxic (kainic-acid induced) injury (Zhang et al. 2009).  Additionally, PAI-1 
expression levels have been shown to increase in both aging and protein deposition diseases 
with diminished tPA activity being correlated with poor patient outcomes in Alzheimer’s 
disease and Parkinson’s dementia (Sutton et al. 1994; Melchor et al. 2003; Yamamoto et al. 
2005; Morimoto 2006). PAI-2 inhibits uPA and also, albeit less efficiently, tPA (two-chain 
but not single-chain form). Furthermore, the rate constants of uPA and tPA inhibition are not 
as favourable as with PAl-1 (Vassalli 1991). PAI-2 inhibited approximately 75% of the tPA-
mediated plg activation induced by Ovo and SOD aggregates, confirming the role of tPA in 
aggregate-induced plm formation. Inhibition by PAI-2 still allows 25% of total plg activation 
to occur, similar to tPA bound to fibrin (Figure 4.10). Similarly, tPA has previously been 
demonstrated to be resistant to inhibition by PAI-2 when bound to fibrin (Leung et al. 1987) 
and the binding of tPA to fibrin is dependent on lysine residues (Leung et al. 1987). A 
significant increase in PAI-2 mRNA expression was observed following traumatic brain 
injury (TBI) in which a marked increase in the presence of misfolded proteins in the 
ipsilateral region of the brain 3 h after TBI was also observed (Prof Rob Medcalf, Monash 
University, personal communication). This suggests that PAI-2 may act to inhibit aggregate 
induced tPA-mediated plg activation and prevent their clearance. By extension, poor patient 
outcomes in PDDs may be due to inhibition of extracellular proteolysis of protein aggregates 
by PAI-1 and -2, as the plg activation system has been shown to alleviate A toxicity in 
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Alzheimer’s disease by degrading extracellular deposits of amyloid fibrils (Tucker et al. 
2000).  
 
There is precedent for both harmful and protective roles for tPA-mediated plg activation in 
neurological insults, depending on the primary substrate associated with each specific 
pathology. tPA is beneficial in the dissolution of fibrin-clots following stroke, helping to 
recanalise the blood vessels (Tabrizi 1999), as well as in glomurulonephritis, to help clear 
fibrin and matrix protein deposits (Kitching et al. 1997). Conversely, the plm-mediated 
breakdown of fibrin clots has been shown to release cytotoxic fibrin degradation products 
(Guo 2009). tPA has roles beyond fibrinolysis, as plm is capable of degrading extracellular 
matrix proteins such as laminin and activating metalloprotease precursors, which can 
potentiate further degradation of extracellular proteins and trigger inflammatory responses 
(Vassalli 1991).  Additionally, tPA is an essential mediator of cell death following ischemia 
or excitotoxic injury in the brain, and may play a role in neuronal and endothelial cell death 
induced by protein aggregates (Tsirka 1995; Chen 1997; Yepes 2008). Furthermore, 
following traumatic brain-injury-induced protein aggregation, excess tPA-mediated plg 
activation is detrimental, inducing inflammatory responses (Samson et al. 2009). Further 
work to examine whether the degradation of amorphous aggregates by plm inhibits or 
promotes the formation of toxic protein species will be addressed in Chapter 5. 
 
A2AP is the main physiologic plm inhibitor in mammalian plasma, and like PAI-1 and PAI-
2, is a serpin. It inhibits plm very rapidly by forming an inactive 1:1 stoichiometric complex 
with plm (Collen 1976; Collen and Wiman 1978; Lijnen 1982). In a manner similar to plm 
bound to fibrin, insoluble protein aggregates were found to shield plm from inhibition by 
A2AP, while soluble protein aggregates did not (Figure 4.15). A2AP inhibited plm bound to 
insoluble aggregates of both Ovo and SOD Agg. by approximately 13 – 15% while plm 
bound to soluble aggregates was inhibited by 60 – 67%. Inhibition by A2AP requires the 
presence of a free active site and free lysine-binding sites in plg/plm, inaccessible when 
plg/plm is bound to substrates such as fibrin (Collen 1976; Collen and Wiman 1978; Lijnen 
1982). The shielding effects are thought to localise the activity of plm to specific regions of 
the extracellular environment, to avoid inappropriate proteolysis (Longstaff and Gaffney 
1991). This would allow plm to be formed at the surface of large insoluble protein aggregates 
and to effectively degrade them into smaller protein fragments - the biological effects of these 
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plm-generated fragments are poorly understood and investigations of this are reported in 
Chapter 5.   
 
The plg activation system and thus production of active plm is tightly controlled. Free 
circulating plm bound to a substrate such as fibrin is readily inhibited by A2AP, and tPA is 
inhibited by PAI-1 and/or PAI-2 (Lijnen 1982). Previous studies have shown that partial 
proteolysis of denatured proteins and Alzheimer’s disease-associated amyloid fibrils by 
active plm, further enhanced (or was required for) subsequent plg activation, probably by 
exposing additional lysine residues to interact with tPA and plg (Table 4.1) (Machovich and 
Owen 1997; Kranenburg et al. 2002). Additionally, partial proteolysis by other circulating 
proteases such as carboxypeptidases B and N have been shown to further increase fibrin clot 
dissolution by plm, due to modification of clot super structure to improve plg activation rates 
and the steric access of plm to the substrate (Kovacs et al. 2014). Partial proteolysis by plm 
of aggregated Ovo, SOD or IgG proteins was not required for the plg activation demonstrated 
in this chapter (Figure 4.7 onwards). However in vivo, limited proteolysis by free active plm 
(or other proteases) may enhance the removal of extracellular aggregates by providing new 
binding sites for tPA and plg.  
 
Intracellularly, protective proteases are key elements of protein quality control pathways that 
are upregulated in response to various protein folding stresses, preventing the accumulation 
and aggregation of misfolded proteins which can be cytotoxic (Goldberg 2003). Interestingly, 
the plg activation system has been shown to alleviate Atoxicity in Alzheimer’s disease by 
degrading extracellular deposits of amyloid fibrils (Tucker et al. 2000). Misfolded proteins 
have also been found to activate Factor XII, leaving to kallikrein formation independent of 
coagulation (Maas et al. 2008). Other proteases belonging to the high temperature 
requirement A (e.g. HtrA1) family of serine proteases, which are involved in protein quality 
control and cell fate, are able to bind to and degrade misfolded proteins (Truebestein et al. 
2011), and are cytoprotective, by clearing tau neurofibrillary tangles and plaques associated 
with dementia (Tennstaedt et al. 2012). However, a genetic mutation in the promoter 
sequence of HtrA1 which increases expression of HtrA1, is considered a risk factor in cases 
of age-related macular degeneration (Yang et al. 2010; Yang et al. 2010), resulting in 
increased expression and abnormal cleavage of both the ECs CLU and A2M (An et al. 2010). 
Collectively, these data suggest that the plg activation system and other extracellular 
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proteases are involved in the dissolution of insoluble extracellular protein aggregates and are 
likely to form part of a larger extracellular proteostasis network.  
 
In conclusion, native proteins unfold and aggregate due to stresses, creating a mixture of 
soluble and insoluble aggregates. tPA and plg can colocalise on the surface of amorphously 
aggregated proteins via their affinity for lysine-residue binding. Plm activity is shielded from 
inhibition by A2AP when bound to insoluble aggregates. This would then allow for plm to be 
formed at the surface of and degrade amorphous aggregates (this final aspect is dealt with in 
Chapter 5). These findings are consistent with a system in which proteases and chaperones 
act together as key synergistic mechanisms in extracellular proteostasis, to degrade and clear 
extracellular pathologic protein deposits and inhibit the development of age-related protein 
misfolding diseases. A corollary is that once amorphous aggregates have undergone 
proteolytic degradation (in the absence of PAI-1or -2), smaller soluble fragments of protein 
that are released from the aggregates are cleared by binding to circulating extracellular 
chaperones and subsequent receptor-mediated endocytosis. This hypothesis is examined in 
more detail in Chapter 5.  
 
Chapter 5: Plasmin degrades protein aggregates to generate cytotoxic protein fragments 
which interact with ECs 
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CHAPTER 5 : PLASMIN DEGRADES PROTEIN AGGREGATES TO GENERATE 




5.1.1  Protein Aggregation and Cytotoxicity 
All protein deposition diseases involve the appearance of non-native proteins which 
aggregate to form insoluble protein deposits with one another and other proteostasis-
associated proteins, such as ECs (Dobson 1999; Yerbury et al. 2005; Wyatt 2009). Disease 
pathologies can appear when the complex network of protein quality control mechanisms, 
including chaperones and proteolytic systems that evolved to maintain proteostasis, are 
overcome (Soti and Csermely 2003; Morimoto 2006; Gidalevitza et al. 2010). The 
pathophysiology of protein deposition diseases can differ with respect to the identity of the 
aggregating protein, the structure of the aggregate, the location of the insoluble deposits and 
the cell type(s) affected. The way in which protein aggregates impart their cytotoxic effects is 
not entirely understood. Aggregates may accumulate and deposit within intra or extracellular 
environments and cause pathologies by either physically disrupting tissue function (e.g. 
senile plaques) or via the cellular toxicity of soluble oligomeric aggregates or proteolytic 
fragments from their degradation (Dobson 2001; Walsh et al. 2002; Caughey 2003; Chiti and 
Dobson 2006; Herczenik and Gebbink 2008; Guo 2009). Numerous pathological downstream 
effects are stimulated in cells, such as Ca
2+
 mobilisation (Demuro et al. 2005), induction of 
ER stress (Breckenridge et al. 2003; Rao et al. 2006), and generation of reactive oxygen 
species (ROS); if these effects are severe enough, cell death may result (Ankarcrona et al. 
1995; Bonfoco et al. 1995; Stefani and Dobson 2003; Emerit et al. 2004). In addition to their 
direct toxic effects, aggregated proteins can also indirectly promote damaging pathologies 
through excessive inflammatory responses, activation of tPA, and the processing of Aβ-
bound neuroendocrine factors, which can inhibit neurotransmitter release (Casserly and 






The role of proteases and chaperones in extracellular proteostasis 
109 
 
5.1.2 tPA-Mediated Plasminogen Activation System and Disease States  
Plm generated by tPA-mediated plg activation is capable of degrading ECM proteins such as 
laminin and activating metalloprotease precursors, which can potentiate proteolysis of 
basement membranes and extracellular matrix proteins, induce cytolysis and trigger 
inflammatory responses (Vassalli 1991; Chen and Strickland 1997; Cuzner 1999), as well as 
degrade essential components of the complement system and immunoglobulins, resulting in 
the release of chemotactic fragments (Lachmann et al. 1982; Schaiff and Eisenberg 1997). 
For additional information on tPA and the plg activation system see Chapter 1, section 1.4. 
 
Various neuropathological conditions such as thrombolytic stroke are thought to involve 
excitotoxic damage to the brain (Lipton and Rosenberg 1994). tPA is required for neuronal 
death in adult mice which have undergone excitotoxic insults. In contrast, infusion with PAI-
1 protects from neuronal death (Tsirka 1995). Studies have found that following ischemic 
injury (such as in stroke) tPA is upregulated resulting in increased permeability of the blood 
brain barrier and increased expression and activity of matrix metalloproteinases (MMP) 
(Aoki 2002; Kidwell 2008; Yepes 2008). Interestingly, the ECs A2M and CLU are inhibitors 
of MMPs in tissue fluids. A2M:MMP complexes are cleared via LRP-mediated endocytosis 
(Egeblad 2002), while clusterin is a negative regulator of membrane type MMP-6 produced 
by neutrophils and brain tumors (Matsuda 2003) and has been shown to bind to and inhibit 
the activity of both intra- and extracellular MMP-9 in epithelial cells (Jeong et al. 2012). By 
forming a high molecular weight complex with MT6-MMP and inhibiting the enzymatic 
activity of MMP-9, CLU appears to regulate neutrophil function, protect host tissue from 
MMP-6 and similarly protect epithelial barriers from MMP-9-mediated degradation. 
 
Amorphously aggregated proteins as well as amyloid fibrils are able to activate tPA, and in 
turn enhance plasminogen activation (Tucker et al. 2000; Kranenburg et al. 2002; Samson et 
al. 2009; Gebbink 2011). Samson et al. (2009) showed that injured cells release extracellular 
protein aggregates - staining with thiazine red R and Congo red suggested that these 
aggregates consisted in part of amyloid fibrils, but may consist of a mixture of various types 
of protein aggregates. These aggregates were able to induce the tPA-mediated formation of 
plasmin (plm); the active plm was then able to degrade the protein aggregates to facilitate 
their removal. In contrast, the continued release of aggregates may lead to deleterious effects 
by inducing an excess of plm (Samson et al. 2009; Samson et al. 2012). It has been shown 
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that plm is able to protect cells by degrading both non-aggregated Aβ and cytotoxic Aβ fibrils 
found in Alzheimer’s disease (Tucker et al. 2000). tPA is overexpressed in amyloid-rich 
areas in the brain of patients with Alzheimer’s disease and may mediate neurotoxicity via 
extracellular regulated kinase 1/2  activation (Medina et al. 2005). The ability of active plm 
to degrade amorphous aggregates has yet to be characterised.  
 
Plm has been shown to indirectly detrimentally affect cells by generating cytotoxic plm-
generated protein fragments (PGPFs) from fibrin (Guo et al. 2009). Guo et al. showed that 
cellular internalisation of fibrin fragment central E-domain (FnE) by caveolin-1 mediated 
endocytosis inhibits mitochondrial function and induces apoptosis in trophoblast-derived 
BeWo cells, endothelial cells from umbilical vein or pulmonary aorta, and placental 
trophoblast cells and was dependent on the activation of caspases 3 and 9. The mechanisms 
of toxicity are likely to apply to other cell types including vascular endothelial cells and may 
contribute to negative side effects of tPA treatment in stroke victims (Longstaff et al. 2008). 
The plasma concentration of fibrin-derived PGPFs is greatly augmented in patients with 
thrombotic disorders such as venous thromboembolism or myocardial infarction, 
disseminated intravascular coagulation, infection, certain types of leukaemia, and other 
pathologies (Francis and Marder 1987; Cesarman-Maus and Hajjar 2005; Mosesson 2005). 
PGPFs derived from either amorphous or fibrillar protein aggregates have not been analysed 
for their effects on cells. 
 
The degradation of fibrin by plm is vital for the maintenance of haemostasis, yet despite the 
apparent toxicity of the fragments produced, biological functions are not impaired under 
normal conditions. This suggests the existence of mechanisms which protect cells from 
toxicity during the plm mediated degradation of proteins. Thus, the tPA system can have both 
beneficial and detrimental actions. It can aid in the degradation of amyloid fibrils or 
potentially cause tissue damage by releasing cytotoxic fibrin-derived PGPFs. It is currently 
unknown whether ECs bind to PGPFs and mediate their disposal, thereby protecting 





The aims of the work described in this chapter were to investigate:  
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1. Whether plm can degrade amorphous aggregates to generate PGPFs  
2. If the resulting amorphous aggregate-derived PGPFs have any effects on cells 
3. How PGPFs bind to and are disposed of by cells  
4. If ECs can inhibit or alter the effects of PGPFs on cells.  
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5.2.1 Plasmin digestion of amorphous protein aggregates 
Native proteins were filter sterilised and aggregated under conditions established in section 
4.2.5 to produce amorphously aggregated Ovo, SOD and ox. IgG. Samples taken from 
protein aggregation assays were centrifuged at 15,000 x g for 15 min at 4˚C, and diluted in 
PBS to 1 mg/mL in a total volume of 100 µL. Plm (Haematologic Technologies, Inc.) was 
added to aggregates at a final concentration of 100 mU in 120 µL total volume and incubated 
overnight at 37˚C with shaking. Native protein samples were also digested with plm under 
the same conditions, to be used in later experiments as a control when assaying the biological 
effects of PGPFs derived from aggregated proteins. Insoluble, undigested material was 
removed by centrifugation at 15,000 x g for 15 min at 4˚C. The supernatant was pooled and 
the concentration of soluble PGPFs was determined by BCA assay (section 2.3). 
 
5.2.1.1    Tris-tricine SDS-PAGE 
Insoluble protein aggregates and soluble PGPFs derived therefrom were then analysed by 
12% resolving Tris-tricine SDS-PAGE under reducing conditions and stained with 
Coomassie Blue Stain. Samples containing approximately 20 µg of total protein were 
prepared by mixing an equivalent volume of sample with that of NOVEX 2X Tricine-SDS 
sample buffer (0.9 M Tris-HCl, pH 8.45, 25% (v/v) glycerol, 8% (w/v) SDS, 0.015% (w/v) 
Coomassie Blue G) and 1% (v/v) 2-mercaptoethanol. The samples were then heated for 5 min 
in a 100˚C heating block before being loaded onto the gel which was prepared as per methods 
outlined in section 2.7 (SDS-PAGE) with several exceptions. Gels were prepared by layering 
a 4% stacking gel atop a 12% resolving gel layer. The resolving gel layer was buffered using 
a final concentration of 187 mM Tris-base at pH 8.45, while the stacking gel layer was 
buffered using 94 mM Tris-base at pH 8.45. Both gel layers contained 0.1% (w/v) SDS, 
0.03% (w/v) ammonium persulfate and were polymerised by adding 20 µL of TEMED. The 
reservoir was filled with Tris-tricine running buffer (0.1 M Tris-base, 0.1 M tricine, 0.1% 
(w/v) SDS) and electrophoresis carried out at constant voltage at 125 V for 120 min or until 
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5.2.1.2     Measure of residual plasmin activity in PGPF preparations 
Soluble PGPFs derived from Ovo aggregates were dialysed using a Slide-A-LyzerTM MINI 
dialysis device (3.5 kDa MWCO; Thermo Fisher) against ice-cold HBST and analysed for 
Plm activity by measuring changes in absorbance from the breakdown of SPEC-PL, in a 96-
well polystyrene microplate at a total volume of 60 µL/well. Plm activity of PGPFs samples 
were compared to active Plm stored at -20˚C prior to assay (positive control), and Plm 
incubated alone under the same conditions and time period used to produce PGPFs (treatment 
control), which were diluted to a final concentration of 100 mU of Plm in ice-cold HBST. 
The reaction was initiated by adding 10 µL of an ice-cold 3.5 mM stock of SPEC-PL to a 
final concentration of 0.5 mM per well.  Absorbance at 405 nm (A405) was measured on a 
Spectramax Plus 382 spectrophotometer (Molecular Devices) for 240 min at 37˚C with 
measurements taken at 30 s cycles with 3 s of shaking between cycles. Plm activities were 
plotted as the change in A405 against time and analysed as described previously for plg 
activation assays in section 4.2.10. 
 
5.2.3 Chaperone interaction sandwich ELISA assays 
Plates (384 well) were coated with shaking for 1 h at 37˚C with 30 uL per well of 10 g/mL 
G7 anti-CLU monoclonal antibody or mouse anti-human A2M monoclonal antibody or 
isotype control antibody (mouse IgG1 kappa antibody). All incubation and wash steps were 
performed with shaking unless otherwise indicated. Between incubation steps, plates were 
washed 6 times for 5 min each with PBS containing 0.1% (v/v) Tx-100 (Tx-100/PBS) 
followed by an additional 6 washes with PBS. Wells were then blocked with 50 uL per well 
of 1% HDC/PBS for 1 h at 37˚C. Prior to their addition to wells, samples were prepared by 
incubating biotinylated PGPFs (50 µg/mL) in the presence or absence of 20 µg/mL of 
chaperone (CLU or A2M) or BSA (as a non-chaperone control protein) in 1% BSA/0.1% Tx-
100/PBS, pH 7.4 for 1 h at 37˚C. Biotinylated aggregated proteins, native protein and PGPFs 
derived from native protein were also incubated with chaperone as described. Following 
blocking, 30 µL per well of the various protein samples were added and incubated as before. 
Plates were then washed and incubated for 30 min at 37˚C with 30 uL per well of a mixture 
of 2.5 µg/mL each of streptavidin and biotinylated HRP in 1% HDC/PBS. Finally, the plates 
were washed and colour developed with the addition of 30 µL per well of 2.5 mg/mL OPD in 
phosphate-buffer containing citric acid (50 mM dibasic sodium phosphate, 25 mM citric acid, 
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pH 5.0) for 5 min at room temperature and the reaction halted with the addition of 30 µL of 
1M HCl per well. Absorbance was then measured at 490 nm using a Spectramax Plus 382 
plate reader (Molecular Devices). Absorbances from wells coated with isotype control 
antibody were subtracted from corresponding wells coated with G7 anti-CLU and anti-A2M 
antibodies. 
 
5.2.4 bisANS fluorescence assays 
bisANS assays were performed as described in section 3.2.5, however, samples of aggregated 
proteins, native protein and PGPFs derived therefrom were diluted in PBS to give a final 
concentration of 200 µg/mL and compared to an equal mass concentration of native-protein-
derived PGPFs. As before, BSA (5 µM) in PBS was used as a positive control for exposed 
hydrophobicity. 
 
5.2.5 Measurement of intracellular reactive oxygen species levels 
EOC 13.31 and SVEC4-10 cells were grown and maintained in 24-well tissue culture plates 
(Greiner Bio-One; section 2.1). Prior to adding to cells, samples of undigested amorphously 
aggregated and native forms of Ovo, IgG and G93A SOD, and PGPFs derived from digestion 
of both aggregates and native proteins (section 5.2.1), were incubated in the presence or 
absence of CLU or A2M or BSA (as a non-chaperone control protein) at a equivalent mass 
ratio (w/v) of 1:1 sample to chaperone, in PBS for 1 h at 37°C with gentle shaking. These 
were then incubated with cells at a final concentration of 100 µg/mL for 1 h at 37˚C. Cells 
were then incubated with 30 µM dihydrorhodamine 123 (DHR; Sigma-Aldrich) for a further 
hour before washing in PBS, harvesting with trypsin/EDTA, and resuspending in PBS 
containing 1% (w/v) BSA. DHR-associated mean fluorescence intensity was measured by 
flow cytometry (excitation at 488 nm, emission collected at 515 ± 10 nm) (section 2.8).  
  
5.2.6 Cell viability assays 
Native proteins were filter sterilised and aggregated as described in section 4.2.5 to produce 
amorphously aggregated Ovo, SOD and IgG. Sterile native or aggregated proteins were then 
digested with sterile filtered plasmin (as described in section 5.2.1) to yield PGPFs. Samples 
of aggregates, native proteins and PGPFs derived from the digestion of both, were then pre-
incubated in the presence or absence of CLU or A2M or BSA (as a non-chaperone control 
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protein) (section 5.2.5) before incubating with EOC 13.31 and SVEC4-10 cells (section 2.1) 
at a final concentration of 200 µg/mL for 24 – 90 h (depending on individual assay 
requirements) at 37°C and 5% (v/v) CO2. Cell viability was measured by real time Sytox 
Green assay and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) 
-2H-tetrazolium (MTS) assay. Real time Sytox Green assay was performed by incubating 
cells with 1 µM SYTOX Green viability dye (Life Technologies) and measuring the 
development of SYTOX Green-associated fluorescence over 90 h by time-resolved 
epifluorescence microscopy (excitation at 440 – 480 nm, emission at 504 – 544 nm), as well 
as phase contrast cell imaging (Nikon 4X objective). Images were collected at 2 h intervals 
using an Incucyte ZOOM epifluorescence live-cell imaging system (Essen Bioscience) and 
analysed using Incucyte ZOOM software v2015A. MTS assay was performed after 24 h 
incubation with samples, using a “CellTiter 96 AQueous One Solution Cell Proliferation Assay 
Kit” (Promega) by adding 20 µl/well of the MTS reagent and incubating for 2 h at 37°C to 
allow the coloured formazan product to develop. Absorbance was then measured at 490 nm 
using a Spectramax Plus 382 plate reader (Molecular Devices). 
 
5.2.7 Confocal microscopy of mitochondrial membrane polarisation 
EOC 13.31 and SVEC4-10 cells (section 2.1) were incubated for 24 h at 37°C and 5% (v/v) 
CO2 with or without 200 µg/mL of PGPFs derived from the digestion of protein aggregates; 
in some cases, before adding to the cells, the PGPFs had been pre-incubated with CLU or 
A2M or BSA (section 5.2.6). The ability of PGPFs to induce changes in mitochondrial 
membrane potential (Δmit) were measured using confocal microscopy by incubating with 
100 nM MitoTracker Deep Red chloromethyl-X-rosamine (CMXRos; Molecular Probes) for 
20 min at 37˚C in DMEM/F12 growth medium. Prior to the addition of CMXRos, in some 
cases 20 M carbonyl cyanide m-chlorophenyl hydrazone (CCCP) was incubated with cells 
for 1 h at 37˚C, as a positive control for the loss of ΔMIT. CMXRos-associated fluorescence 
was collected using 543 nm excitation and an emission window set at 580-640 nm, on a Leica 
SP5 inverted confocal microscope (Leica Microsystems). Images were analysed using Leica 
LAS AF “Lite”. 
5.2.8 Confocal microscopy of cellular PGPF uptake 
Still image and real time confocal microscopy was used to examine how PGPFs are 
internalised, measure rates of internalisation and observe whether PGPFs are directed to 
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lysosomal compartments for degradation. Cells were harvested and grown overnight in 8 
chambered µ-slides (Ibidi) using conditions described in section 2.3. CF-488-labelled protein 
aggregate-derived PGPFs (PGPFs
488
) were prepared as described in sections 2.5 and 5.2.1. 75 
nM Lysotracker Deep Red (Molecular Probes) and 20 µg/mL PGPFs
488
 were added to the 
chambered slide. In some experiments, protein-free unreacted CF-488 label (pooled from gel 
filtration purifications; section 2.3) served as a negative control for internalisation. Type F 
immersion fluid (Leica Microsystems) was then applied to the bottom of the slide and quickly 
transferred to the confocal microscope stage. Using the xyt function to acquire data, regions 
of interests were imaged, and the microscope was set to record images at 5 min intervals for 
180 min. At least 6 regions of interest per well were imaged. Within experiments, treatments 
were performed in duplicate for each type of PGPFs
488
; individual experiments were 
performed at least three times. Cells were selected based on whether the ROI would remain in 
the confocal field of view during the entire time course and to minimize fluctuations in 
fluorescence based on z-axis shift. PGPFs
488
-associated fluorescence was collected using 
excitation at 488 nm and an emission window set at 510 – 530 nm. Lysotracker-associated 
fluorescence was collected using excitation at 543 nm and an emission window set at 580-
640 nm, using a Leica SP5 inverted confocal microscope (Leica, Sydney). All data was 
acquired using Leica LAS AF software. Images of PGPF internalisation and rates of uptake 
were analysed using a combination of Leica LAS AF “Lite” and GraphPad Prism 5. 
Colocalisation data was analysed with ImageJ 1.49a (National Institute of Health, USA) 
using the plugin “Manders’ coefficients” [formerly Image Correlator Plus; developed by 
Tony Collins, Wayne Rasband and Kevin Baler, Wright Cell Imaging Facility, Toronto, 
Canada (2005)] to derive Pearson’s correlation coefficient and Mander’s overlap coefficient 
(Manders et al. 1993). 
 
5.2.9 Cell-surface binding assays 
5.2.9.1    Effects of ECs on cell-surface binding of labelled PGPFs  
EOC-13 and SVEC4-10 cells (section 2.1) were harvested by dissociation using StemPro 
Accutase (Life Technologies) (which does not cleave cell-surface markers, such as receptors) 
and resuspended in ice-cold 1% BSA/PBS/0.1% NaN3 (BSA/PBS/Az). Prior to adding to 
cells, CLU or A2M were incubated with gentle shaking for 1 h at 37°C with PGPFs
488
 
(prepared as described in sections 2.5 and 5.2.1) at a mass ratio (w/v) of 1:1 PGPFs
488
 to 
chaperone in PBS (section 5.2.5). These were then incubated with cells at a final 
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concentration of 20 µg/mL for 30 min in ice-cold BSA/PBS/Az, before washing and 
resuspending cells in the same buffer. PGPF-associated mean fluorescence intensity was 
measured by flow cytometry (excitation at 488 nm, emission collected at 515 ± 20 nm) 
(section 2.8). 
5.2.9.2    Inhibition of cell-surface PGPF binding to EOC-13 and SVEC4-10 cells 
Similar experiments to those described in 5.2.9.1 were carried out to assess the effects of 
inhibition of cell-surface receptors and endocytic mechanisms on the binding of PGPFs
488
 to 
cells. Cells were incubated for 30 min with ice-cold BSA/PBS/Az in the presence or absence 
of inhibitor (Table 5.1) prior to washing and resuspension in the same buffer and incubation 
conditions in the presence or absence of 20 µg/mL of PGPFs
488
. The cells were next washed 
and resuspended with ice-cold BSA/PBS/Az and PGPF-associated mean fluorescence 
intensity measured by flow cytometry (section 2.8). 
Table 5.1 Panel of inhibitors of cell surface receptors and endocytosis mechanisms. 
Used in experiments outlined in section 5.2.9.2. 
 
 
Inhibitor Action Conc. used 
Receptor-associated 
Protein (RAP) 
Inhibition of Low-density Lipoprotein 
Receptor-related Protein 
0.5 mg/mL 
Lipopolysaccharide Competitive Antagonist of TLR Binding 0.5 µg/mL 
Anti-TLR-2 Antibody Inhibition of TLR-2 0.1 mg/mL 
Polyinosinic Acid Inhibition of TLR-3 5 µg/mL 
Anti-TLR-4 Antibody Inhibition of TLR-4 0.1 mg/mL 
Mannan 
Competitive Antagonist of Mannose 
Receptor 
0.5 µg/mL 
CD14 Inhibition of CD14 Receptor 1 µg/mL 
Methyl-β-cyclodextrin Inhibition of Lipid Raft Formation 6.6 mg/mL 
Fucoidan 





Inhibition of Macropinocytosis 30 µg/mL 
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5.2.10 Statistical analysis 
Data presented in the results was analysed using a one-way ANOVA and a Bonferroni 
multiple comparison post-test using GraphPad Prism v5.0, unless stated otherwise. The extent 
of significance of differences between samples is denoted by asterixes shown on the graphs 
(*p<0.05, **p<0.01 and ***p<0.001). Confocal microscopy image data was analysed for 
colocalisation (section 5.2.8) with ImageJ 1.49a using the plugin “Manders’ coefficients” to 
derive Pearson’s correlation (Pr) coefficient and Mander’s overlap coefficient (Mr) from two 
8 or 16-bit monochromatic images (Manders et al. 1993). Pearson’s correlation coefficient is 
one of the standard procedures in pattern recognition for matching one image with another 
and can be used to describe the degree of overlap between two patterns. In many forms of 
correlation analysis the values for Pearson’s will range from -1 to +1. In the case of images, a 
perfect correlation gives a value of +1; perfect exclusion however does not give a value of -1. 
Low (close to zero) and negative values for Pearson’s correlation coefficient for fluorescence 
images can be difficult to interpret (Manders et al. 1993). However, a value close to 1 does 
indicate reliable colocalisation, but does not take into account differences in mean 
fluorescence intensities for the two fluorescence channels being analysed (Manders et al. 
1993). Mander’s coefficient does not suffer from this limitation as it can be determined even 
when signal intensities between two fluorescence channels differ strongly. However, unlike 
Pearson’s coefficient, for Mander’s overlap coefficient the number of objects in both 
channels of the image has to be more or less equal. Therefore, both values are usually 
reported together. Mander’s overlap coefficient is proportional to the amount of fluorescence 
of the colocalising pixels or voxels in each colour channel. Values range from 0 to 1, 
expressing the fraction of intensity in a channel that is located in pixels where there is above 









5.3.1 Plasmin digestion of amorphous aggregates 
Aggregates are known to have inflammatory and cytotoxic effects in vivo and amyloid fibrils 
are known to enhance tPA-mediated plm formation. However, it was previously unclear 
whether amorphous protein aggregates can stimulate tPA-mediated plm activation, or 
whether plm can degrade amorphous protein aggregates. Furthermore, the effects of PGPFs 
derived from amorphous protein aggregates on cells is unknown. Native proteins were 
induced to aggregate amorphously as in Chapter 4 (section 4.2.5), digested with plm to 
generate soluble PGPFs, which were then purified (section 5.2.1), and analysed by Tris-
tricine SDS-PAGE (section 5.2.1.1). The sizes of soluble PGPFs derived from aggregated 
proteins were compared using Tris-tricine SDS-PAGE to whole (undigested) protein 
aggregates (Figure 5.1). Native proteins were also digested with plm under the same 
conditions as amorphous aggregates (not shown), to test the cytotoxic effects of various 
PGPFs in later cell-based experiments (section 5.3.5). 
 
Most of the aggregated SOD, Ovo and ox. IgG was very large, too large to enter the SDS-
PAGE gel matrix completely and accumulated at the top of the resolving gel. Thus, the 
apparent molecular weight was not able to be interpolated from protein standards of known 
molecular weights using this method. Digestion with plasmin generated PGPFs of varying 
sizes. The digestion of aggregated: (i) SOD yielded PGPFs ranging from 15 – 200 kDa in 
size, which appeared as a “smear” with no visually distinct bands, (ii) Ovo yielded PGPFs of 
between 88 – 164 kDa in size, and other visually indistinct, smeared bands less than 75 kDa 
in size, (iii) ox. IgG yielded PGPFs of between 150 – 200 kDa in size and above, and three 
minor bands at 41, 44 and 48 kDa. Autolysis of plm resulting from prolonged incubation (> 2 
h at neutral pH) in aqueous solution should yield fragments of heavy chain (~ 63 kDa) and 
light chain (~ 26.5 kDa) (Wu et al. 1987), however, these bands are not easily visually 
resolved from those detected in PGPF preparations. 
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Figure 5.1 Images of Tris-tricine SDS-PAGE analyses of plm digests of amorphous protein 
aggregates. Samples of amorphously aggregated SOD, Ovo and ox. IgG taken from in vitro 
aggregation assays were diluted in PBS and incubated with or without 100 mU plm overnight at 37˚C 
to yield PGPFs and undigested aggregates (Agg.) respectively, as indicated. Samples were then 
analysed under reducing conditions on 12% Tris-tricine gels. Molecular weights of protein standards 
are indicated in kDa (M; Fermentas). 
 
Prior to testing the biological effects of PGPFs on cultured cells, PGPF preparations were 
analysed for their residual plm activity to determine whether this could contribute to any 
measured cytotoxicity. Soluble PGPFs derived from Ovo aggregates were analysed for 
residual plm activity by measuring changes in absorbance from the breakdown of SPEC-PL. 
The initial rate of reaction (or velocity) was calculated from the gradient of the change in A405 
versus t
2
 using GraphPad Prism v5 (section 5.2.1.2). The plm activity of PGPFs samples was 
compared to active plm stored at -20˚C prior to assay (positive control), and Plm incubated 
alone under the same conditions and time period used to produce PGPFs (treatment control). 
The residual plm activity of freshly prepared PGPF samples was 1 ± 0.01 µA405.min
-2
 (Figure 
5.2). This was significantly less than both the active plm positive control and plm treatment 
control, which demonstrated activities of 5810 ± 235 and 46 ± 1 µA405.min
-2
. The very low 
levels of residual plm activity in PGPF samples is insufficient to affect cells directly (Tucker 
et al. 2000), and thus any cell responses subsequently measured will be attributable to the 
PGPFs themselves. 
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Figure 5.2 Residual plasmin activity of plasmin-generated protein fragments. Ovo aggregate-
derived PGPFs (PGPF) were produced as described (section 5.2.1) and assayed for residual Plm 
activity, together with Plm incubated alone under the same conditions used to produce PGPFs (Plm 
Treatment Control), Plm stored at -20˚C prior to assay (Plm; as a positive control), and HBST 
containing SPEC-PL in the absence of Plm (Buffer Control). Data points represent the mean ± SD 
(n=3) of triplicate measurements of a single experiment, and the results shown are representative of 
three separate experiments. 
 
5.3.2  Binding of extracellular chaperones to PGPFs 
Given their general role in disposing of hydrophobic damaged proteins, the possibility that 
CLU and A2M also bind to PGPFs appeared worthy of investigation. As a first step, both 
CLU and A2M were assayed in sandwich ELISA for their ability to bind to undigested and 
plm digested forms of both aggregated and native client proteins (Figure 5.3). CLU and A2M 
were separately pre-incubated with biotinylated PGPFs, before they were incubated in plates 
containing an EC-specific capture antibody; any EC-bound biotinylated PGPFs or proteins 
were detected using a streptavidin-HRP conjugate. These assays detected significant binding 
of CLU to all three amorphous protein aggregates, which were structurally characterised 
(section 4.1) as a mixture of various sized oligomers and larger insoluble protein aggregates, 
and PGPFs derived from aggregates of SOD, Ovo and IgG. Negligible binding of CLU was 
detected to native PGPFs and background controls. The level of binding detected of CLU to 
undigested protein aggregates of SOD and ox. IgG was greater than to their corresponding 
PGPFs. Unsurprisingly, CLU bound significantly to Ovo and IgG aggregates and native IgG, 
known binding partners for CLU (Wilson and Easterbrook-Smith 1992; Humphreys et al. 
Chapter 5: Plasmin degrades protein aggregates to generate cytotoxic protein fragments 
which interact with ECs 
122 
 
1999). While there was significant binding of CLU to native Ovo but not to PGPFs derived 
from native Ovo and controls, this was substantially lower than the binding of CLU to either 
Ovo aggregates or Ovo aggregate-derived PGPFs. This suggests that the regions of native 
Ovo to which CLU binds may be destroyed by plm digestion during the formation of native 
PGPFs. In addition, while the binding of CLU to PGPFs derived from aggregates of IgG was 
significantly less than CLU binding to IgG aggregates and native IgG, it was still 
significantly higher than the binding of CLU to native IgG PGPFs and controls. 
 
A2M also bound significantly to all three amorphous protein aggregates and PGPFs derived 
from aggregates of SOD, Ovo and ox. IgG. The level of binding of A2M detected to 
undigested protein aggregates of SOD and Ovo was greater than to their corresponding 
PGPFs. There was negligible binding of A2M to native proteins or their corresponding 
PGPFs. The above data demonstrates that in addition to amorphous aggregates, ECs 






























































































Figure 5.3 CLU and A2M bind to aggregates of SOD, Ovo and ox. IgG and their corresponding 
PGPFs. Sandwich ELISA tested the binding of extracellular chaperones CLU and A2M to 
biotinylated aggregated proteins (Agg.) and to aggregate-derived PGPFs (PGPF Agg.). Biotinylated 
native protein and native protein-derived PGPFs (PGPF Native) were also incubated with chaperones 
as described. As controls, ELISA plates were incubated with biotinylated PGPF Agg. alone and BSA 
was used as a non-chaperone control protein (PGPF/BSA). Absorbances from wells coated with 
isotype control antibody were subtracted from corresponding wells coated with G7 anti-CLU and anti-
A2M antibodies. Bars represent the mean ± SD (n=9) of data from three separate experiments (in 
individual experiments, measurements were performed in triplicate). Asterixes placed immediately 
above error bars indicate that the sample is significantly different from values for PGPF native, 
PGPF/BSA and PGPF alone. Asterixes above horizontal brackets indicate a significant difference 
between the bracketed samples. * (p<0.05), ** (p<0.01), *** (p<0.001). 
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5.3.3 Aggregates and their PGPFs have greater exposed hydrophobicity than the 
corresponding native proteins 
To investigate whether the specific binding of ECs to aggregates and their PGPFs might be 
due to hydrophobic interactions, the aggregates and derived PGPFs were analysed for 
exposed hydrophobicity using a bisANS fluorescence assay (5.2.4). BSA was included as a 
positive control for bisANS fluorescence. In all cases, aggregates and their corresponding 
PGPFs had significantly higher bisANS fluorescence than wells containing only bisANS in 
buffer (i.e. no protein) (Figure 5.4). Relative to bisANS in buffer, the increases in 
fluorescence were 2.7 ± 0.1 fold for SOD aggregates, 2.1 ± 0.0 fold for SOD aggregate-
derived PGPFs; 3.5 ± 0.5 fold for Ovo aggregates, 2.7 ± 0.1 fold for Ovo aggregate-derived 
PGPFs; and 6.2 ± 0.4 fold for ox. IgG aggregates, 3.2 ± 0.0 fold for ox. IgG aggregate-
derived PGPFs. Additionally, amorphous protein aggregates gave a significantly greater 
bisANS fluorescence than the PGPFs derived from them. The fluorescence of wells 
containing native SOD or Ovo, or ox.IgG, and their respective PGPFs was not significantly 
























































































Figure 5.4 Aggregates and aggregate-derived PGPFs have increased hydrophobicity relative to 
native proteins. bisANS-associated fluorescence was used to measure exposed hydrophobicity for 
samples of aggregated protein (Agg.), aggregate-derived PGPFs (PGPF Agg.) and native protein 
diluted to 200 g/mL in PBS. This was compared to native protein-derived PGPFs (PGPF Native) and 
bisANS alone. BSA at 5 µM in PBS was used as a positive control. Bars represent the mean ± SD 
measurements of six replicates (n=6). Asterixes above error bars denote a significant difference from 
values for PGPF Native and bisANS alone; asterixes above a bracket indicate a significant difference 
between the bracketed treatments; * (p<0.05) ** (p<0.001), *** (p<0.001). 
 
5.3.4 Effect of chaperones on ROS formation in aggregate and PGPF treated cells 
Oxidative stress, including increased ROS formation, is a common feature of cells exposed to 
several acute and chronic pathologies associated with the deposition of protein aggregates 
resulting from disregulation of proteostasis machinery (Davies and Delsignore 1987; Berlett 
and Stadtman 1997; Finkel and Holbrook 2000; Grune et al. 2004). This includes 
Alzheimer’s disease (Tabner et al. 2010), amyotrophic lateral sclerosis (Okado-Matsumoto 
and Fridovich 2002), atherosclerosis (Devaraj and Jialal 1996), diabetes (Borcea et al. 1999), 
and Parkinson’s disease (Maguire-Zeiss et al. 2005). ROS formation can either be indicative 
of toxic insult or itself lead to premature cell death in various disease states (Lipton and 
Rosenberg 1994; Bonfoco et al. 1995). Furthermore, ROS can exacerbate protein misfolding 
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and may lead to worsening pathology, as implicated for mutant SOD in amyotrophic lateral 
sclerosis (Rakhit et al. 2002), α-synuclein in Parkinson’s disease (Guo and Scarlata 2013), 
and IgG in rheumatoid arthritis (Uesugi et al. 2000).  
 
Clustered populations of activated microglia surrounding extracellular deposits of protein 
aggregates and neuritic plaques are hallmarks of neurodegenerative diseases including 
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis and are likely to 
contribute to the mechanisms of neuronal damage and cognitive loss (Giulian 1999; Gao et 
al. 2003; West et al. 2004). EOC 13.31 cells were selected as a representative microglial-like 
cell line as they possess the ability to secrete many cytokines, and generate reactive 
oxygen/nitrogen species (Stansley et al. 2012) when incubated with either 1 – 40 or 1 – 42 
form of Alzheimer’s disease-associated β-amyloid (Aβ40 or Aβ42) (Ii et al. 1996; Manzano-
Leon et al. 2006) or extracellular aggregates of SOD (Roberts et al. 2013). In addition, Aβ-
induced ROS has been demonstrated to impair the function of scavenger receptor-mediated 
endocytosis in EOC 13.31 cells; this may also occur for microglia in vivo and could 
potentially contribute to the lack of Aβ clearance in Alzheimer’s disease (Manzano-Leon et 
al. 2006). 
 
As mentioned previously, fibrin-derived PGPFs have been shown to bind to and induce 
caspase-dependent apoptosis in endothelial cell types from various sources (Guo et al. 2009). 
Fibrin cytotoxicity may occur in other cell types. Endothelial cells are vital for the 
maintenance of fibrinolysis and haemostasis through the release of tPA in vivo (Levin 1983; 
Levin et al. 1997; Mosesson 2005). In addition, endothelial cells take up extracellular Aβ 
peptide and release ROS by the action of NADPH oxidases on their cell surface (Babior 
2000; Moldovan et al. 2006). They also have the ability to produce intracellular ROS and 
undergo ROS-mediated cell death in response to oxidatively-modified proteins, such as 
amyloid-like oxidized low density lipoprotein in atherosclerosis (Ciolino and Levine 1997; 
Stewart et al. 2005; Zmijewski et al. 2005). SVEC4-10 cells were selected as a representative 
endothelial-like cell line as it retains morphological and functional characteristics of normal 
endothelial cells (O'Connell and Edidin 1990), is able to generate ROS in response to toxic 
insult (ethanol) (Qian et al. 2007) and has been used to measure the uptake of Aβ peptide 
(Kandimalla et al. 2009). 
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The oxidation of dihydrorhodamine 123 (DHR) to the fluorescent product rhodamine can be 
used to measure the production of many different reactive oxygen and nitrogen species in 
cellular systems (Henderson and Chappell 1993; Hempel et al. 1999; Winterbourn 2014), 
including HOCl, ONOO
-
 and its breakdown products (Wardman 2008). Generation of 









) formed from the rapid and spontaneous decomposition of ONOO
-
 (Jourd'heuil et al. 
2001). While protein aggregates found in extracellular protein deposition diseases have been 
shown to induce ROS formation, the ability of PGPFs to do so is unknown. To ascertain 
whether PGPFs could induce the formation of intracellular ROS in a similar manner to 
aggregated proteins, cells were incubated in the presence of whole protein aggregates or 
PGPFs and intracellular ROS subsequently measured with DHR (Figure 5.5). Subsequent 
experiments involved measuring ROS with or without prior incubation with CLU and A2M, 
and additional non-chaperone (BSA) and native protein controls (Figure 5.6 – 5.8). 
 
In two separate experiments, both amorphous aggregates and aggregate-derived PGPFs were 
found to illicit the transient production of ROS in cells (Figure 5.5). ROS was rapidly 
generated within 1 h following incubation with either aggregate or PGPF, and seen to further 
rise in intensity at 2 h in both cell lines in the presence of PGPFs generated from aggregates 
of Ovo or ox. IgG, before gradually diminishing over time. In the presence of PGPFs from 
SOD aggregates, ROS further increased at 2 h in EOC 13.31 but decreased in SVEC4-10 
cells before diminishing over time as for the other PGPFs. The one hour time point was 
selected for use in further experiments to test whether the addition of chaperones could 
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Figure 5.5 Incubation of EOC 13.31 and SVEC4-10 cells with aggregates and aggregate-derived 
PGPFs results in transiently increased intracellular ROS. Whole amorphous aggregates (Agg.) or 
aggregate-derived PGPF (prepared as per section 5.2.1) at a final concentration of 100 µg/mL, or PBS 
control, were incubated with EOC 13.31 or SVEC4-10 cells. Cells were then incubated with 30 µM 
DHR 1 h prior to flow cytometric analysis. Cells were washed and ROS-associated MFI was 
measured by flow cytometry. Dead cells stained with propidium iodide were electronically excluded 
from the analyses. Results are displayed as ROS-associated MFI ± SD (n=9) and represent pooled 
data from three independent experiments. 
 
The effects of ECs on aggregate/PGPFs-associated formation of ROS were conducted in 
separate experiments performed at different times for each parent protein used to form 
aggregates and their corresponding PGPFs (Figure 5.6 SOD; Figure 5.7 Ovo; Figure 5.8 
IgG). In experiments testing the effects of SOD agg. and PGPFs on EOC 13.31 cells, relative 
to PBS control, ROS levels were increased by treatment with both SOD agg. (Figure 5.6 A 
~86%, B ~ 87%) and the corresponding PGPFs (Figure 5.6 A ~35%, B ~39%). Similar 
effects were seen on SVEC4-10 cells in which ROS levels were also increased by treatment 
with SOD agg. (Figure 5.6 C ~26%, D ~59%) and the corresponding PGPFs (Figure 5.6 C 
~9%, D ~19%). Similarly, Ovo agg. and the derived PGPFs induced increased ROS levels in 
both (i) EOC 13.31 cells (Ovo agg. induced increases, Figure 5.7 A ~48%, B ~63%; PGPF 
induced increases, Figure 5.7 A ~37 %, B ~19%) and (ii) SVEC4-10 cells (Ovo agg. induced 
increases, Figure 5.7 C ~52%, D ~52%; PGPF induced increases, Figure 5.7 C ~39%, D 
~42%). In EOC 13.31 cells, ROS levels were also increased by treatment with ox. IgG agg. 
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(Figure 5.8 A ~29%, B ~59%) and the corresponding PGPFs (Figure 5.8 A ~23 %, B ~27%). 
In contrast, in one set of experiments with SVEC4-10 cells, treatment with either ox. IgG 
agg. or the corresponding PGPFs failed to induce any significant change in ROS levels 
(Figure 5.8 C). However, in a separate set of experiments with SVEC4-10 cells, ox. IgG agg. 
and the derived PGPFs induced small increases in ROS levels (Figure 5.8 D, ~9% and ~5%, 
respectively). In all the above experiments, treatment with the native proteins did not 
significantly affect ROS levels in either cell line. Furthermore, in all cases, BSA had no 
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Figure 5.6 Effect of pre-incubation of CLU and A2M with aggregated SOD and corresponding 
PGPFs on induced ROS levels in EOC-13.31 and SVEC4-10 cells. Whole SOD aggregates (Agg.), 
SOD aggregate-derived PGPF, native SOD (Native) or PBS alone were incubated in the absence or 
presence of CLU or A2M or BSA (non-chaperone control protein) for 1 hour at 37˚C prior to addition 
to cells. Proteins were added to a final concentration of 100 µg/mL and additions are indicated by 
labelled brackets below the x-axis. Cells were then treated with 30 µM DHR for 1 h, 37˚C. Cells were 
washed and DHR-associated MFI was measured by flow cytometry. Dead cells stained with 
propidium iodide were electronically excluded from the analyses. Results are displayed as the mean 
percentage increase in DHR fluorescence relative to PBS control treated cells; data plotted are means 
± SD (n=9) and represent pooled data from three separate experiments (in each experiment 
measurements were performed in triplicate). Asterixes above error bars denote a significant difference 
between that treatment (in the presence of chaperone) and the corresponding treatment (in the absence 
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For both cell lines, pre-incubation of SOD aggregates/PGPFs with CLU significantly 
decreased ROS levels compared to SOD aggregates/PGPFs (p<0.01) in the absence of 
chaperone (aggregates/PGPFs alone) (Figure 5.6 A,C). For EOC 13.31 cells, pre-incubation 
of CLU with aggregates/PGPFs prior to their addition to cells inhibited their ability to induce 
elevated levels of ROS by ~ 67% (SOD agg.) and ~ 48% (SOD agg. PGPF) relative (Figure 
5.6 A). For SVEC4-10 cells, the corresponding level of inhibition effected by CLU was 
essentially 100% for both SOD agg. and SOD agg. PGPF (Figure 5.6 C). A2M was similarly 
able to inhibit aggregate/PGPF-induced increases in ROS. For both cell lines, pre-incubation 
of SOD aggregates/PGPFs with A2M significantly decreased ROS levels compared to SOD 
aggregates/PGPFs (p<0.01) alone (Figure 5.6 B,D).  For EOC 13.31 cells, pre-incubation of 
A2M with aggregates/PGPFs prior to their addition to cells inhibited their ability to induce 
elevated levels of ROS levels by ~ 91% (SOD agg.) and ~ 77% (SOD agg. PGPF) (Figure 5.6 
B). For SVEC4-10 cells, the corresponding level of inhibition effected by A2M was ~ 94% 
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Figure 5.7 Effect of pre-incubation of CLU and A2M with aggregated Ovo and corresponding 
PGPFs on induced ROS levels in EOC-13.31 and SVEC4-10 cells. Whole Ovo aggregates (Agg.), 
Ovo aggregate-derived PGPF, native Ovo (Native) or PBS alone were incubated in the absence or 
presence of CLU or A2M or BSA (non-chaperone control protein) for 1 hour at 37˚C prior to addition 
to cells. Proteins were added to a final concentration of 100 µg/mL and additions are indicated by 
labelled brackets below the x-axis. Cells were then treated with 30 µM DHR for 1 h, 37˚C. Cells were 
washed and DHR-associated MFI was measured by flow cytometry. Dead cells stained with 
propidium iodide were electronically excluded from the analyses. Results are displayed as the mean 
percentage increase in DHR fluorescence relative to PBS control treated cells; data plotted are means 
± SD (n=9) and represent pooled data from three separate experiments (in each experiment 
measurements were performed in triplicate). Asterixes above error bars denote a significant difference 
between that treatment (in the presence of chaperone) and the corresponding treatment (in the absence 
of chaperone); ** (p<0.01), * (p<0.05). 
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Comparing EOC 13.31 and SVEC4-10 cells, pre-incubation of Ovo aggregates/PGPFs with 
CLU elicited different and opposing effects on the level of ROS (Figure 5.7 A,C). Pre-
incubation of CLU with aggregates/PGPFs prior to their addition to EOC 13.31 cells did not 
alter their ability to induce elevated levels of ROS by Ovo agg. In contrast, in cells treated 
with Ovo agg. PGPF, pre-incubation with CLU increased levels of ROS by ~ 44% (Figure 
5.7 A; p<0.01). For SVEC4-10 cells, the corresponding significant levels of inhibition 
effected by CLU were ~ 100% (Ovo agg.) and ~ 29% (Ovo agg. PGPF) (Figure 5.7 C; 
p<0.05). As for CLU, when comparing EOC 13.31 and SVEC4-10 cells, pre-incubation of 
Ovo aggregates/PGPFs with A2M elicited different and opposing effects on the level of 
induced ROS, depending on the cell type (Figure 5.7 B,D). For EOC 13.31 cells, pre-
incubation of A2M with Ovo Agg. prior to their addition to cells significantly increased its 
ability to induce elevated levels of ROS by ~ 17% (Figure 5.7 B; p<0.05). In contrast, A2M 
had no effect on the level of ROS induced by Ovo Agg. derived PGPFs (Figure 5.7 B). For 
SVEC4-10 cells, the corresponding level of inhibition effected by CLU was ~ 100% (Ovo 
agg.; p<0.01) and ~ 48% (Ovo agg. PGPF; p<0.05) (Figure 5.7 D).  
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Figure 5.8 Effect of pre-incubation of CLU and A2M with aggregated ox. IgG and 
corresponding PGPFs on induced ROS levels in EOC-13.31 and SVEC4-10 cells. Whole ox. IgG 
aggregates (Agg.), ox. IgG aggregate-derived PGPF, native IgG (Native) or PBS alone control were 
incubated in the absence or presence of CLU or A2M or BSA (non-chaperone control protein) for 1 
hour at 37˚C prior to addition to cells. Proteins were added to a final concentration of 100 µg/mL and 
treatments are indicated by labelled brackets below the x-axis. Cells were then treated with 30 µM 
DHR for 1 h, 37˚C. Cells were washed and DHR-associated MFI was measured by flow cytometry. 
Dead cells stained with propidium iodide were electronically excluded from the analyses. Results are 
displayed as the mean percentage increase in DHR fluorescence relative to PBS control treated cells; 
data plotted are means ± SD (n=9) and represent pooled data from three separate experiments (in each 
experiment measurements were performed in triplicate). Asterixes above error bars denote a 
significant difference between that treatment (in the presence of chaperone) and the corresponding 
treatment (in the absence of chaperone); ** (p<0.01), * (p<0.05). 
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For EOC 13.31 cells, pre-incubation of ox. IgG aggregates/PGPFs with CLU significantly 
increased induced ROS levels compared to ox. IgG agg. and ox. IgG PGPF alone (Figure 5.8 
A). Pre-incubation with CLU increased the ability of ox. IgG agg. and the derived PGPFs to 
induce elevated levels of ROS by ~ 68% and ~ 117%, respectively (Figure 5.8 A). Pre-
incubation with A2M had the opposite effect to CLU on the induction of ROS in EOC 13.31 
cells by ox. IgG aggregates/PGPFs. Pre-incubation of A2M with aggregates/PGPFs 
significantly inhibited their subsequent ability to induce ROS by ~ 52% (ox. IgG agg.) and ~ 
90% (ox. IgG agg. PGPF) (Figure 5.8 A). As mentioned before, ox. IgG agg. and the 
corresponding PGPFs generally induced very limited ROS production in SVEC4-10 cells. 
Pre-incubation of CLU with these protein species before adding to SVEC4-10 cells had no 
significant effect on induced ROS levels (Figure 5.8 C). In contrast, pre-incubation of A2M 
with ox. IgG aggregates/PGPFs did significantly affect induced ROS levels (Figure 5.8 D). 
A2M effectively abolished the small amount of ROS induced by ox. IgG agg. but 
substantively increased (by many-fold) ROS induced by ox. IgG PGPF (Figure 5.8 D).  
 
5.3.4 Effect of chaperones on the cytotoxicity of protein aggregates and PGPFs 
Cell death by either apoptosis or necrosis, which are distinct from one another, can involve 
the formation of ROS (Fink and Cookson 2005; Kroemer et al. 2009) which if severe enough 
may end in cell death (Fleury et al. 2002; Emerit et al. 2004). The extent and type of cell 
death depends on the intensity of the insult (Bonfoco et al. 1995) and cell death signalling via 
mitochondrial mediated caspase-dependent and independent pathways (Ankarcrona et al. 
1995; McManus et al. 2014). It is not known whether PGPFs derived from amorphously 
aggregated proteins can harm cells, or whether chaperones can ameliorate any cytotoxic 
effects. Nucleic acid stain (Sytox Green) and cell proliferation (MTS) assays were used to 
analyse the potential of amorphously aggregated proteins and their PGPFs to induce cell-
death in EOC 13.31 and SVEC4-10 cells, and whether the presence of ECs ameliorated their 
cytotoxic effects. In both EOC 13.31 and SVEC4-10 cells, protein aggregates and their 
corresponding PGPFs were found to exert significant cytoxicity as indicated by an increase in 
Sytox green fluorescence (compared to PBS control; p<0.05); similar to the positive control 
etoposide (Figure 5.9). Native Ovo and IgG lacked any significant cytotoxicity towards either 
cell line. Relative to the PBS control, native SOD significantly decreased Sytox green-
fluorescence after 48 h (p<0.05), suggesting that prolonged incubation of SOD with EOC 
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13.31 and SVEC4-10 has a positive effect on cell viability. This may be due to an antioxidant 
action of SOD (Dhanasekaran et al. 2004).  






























































































Figure 5.9 Amorphous protein aggregates and derived PGPFs induced cell death in EOC-13.31 
and SVEC4-10 cells. Proteins were incubated with EOC 13.31 and SVEC4-10 cells at a final 
concentration of 200 µg/mL at 37°C for 90 h. Real time Sytox green assay was performed by 
incubation with 1 µM SYTOX Green viability dye (Life Technologies) and measuring the 
development of SYTOX Green-associated fluorescence in live cultured cells for 90 h by time-
resolved epifluorescence microscopy. Results displayed as SYTOX green-associated mean 
fluorescence intensity ± SD (n=6), and the data shown is pooled from three independent experiments. 
Vertical brackets marked with an asterix denote a significant difference between the bracketed 
treatments and the PBS control; * (p<0.05). 
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MTS assays are used to measure the amount of metabolically active and hence viable cells. 
For both cell types, as in Sytox-green assays, aggregate-derived PGPFs exerted significant 
toxicity (Figure 5.10; p < 0.001). For both cell types, pre-incubation of PGPFs derived from 
SOD/Ovo/ox. IgG aggregates with CLU or A2M (but not BSA) prior to their addition to cells 
significantly reduced PGPF-induced cytotoxicity (Figure 5.10; p < 0.001). Native proteins 
and their corresponding PGPFs, and the non-chaperone control protein BSA, had no 
significant effect on the viability of either cell type. 
 
Relative to PBS control, SOD agg. PGPFs reduced the viability of EOC 13.31 cells by ~ 72% 
and the viability of SVEC4-10 cells by ~ 45%. Pre-incubation of CLU or A2M with SOD 
agg. PGPF prior to their addition to cells, completely inhibited their cytotoxicity against both 
cell types (Figure 5.10). In the case of SVEC4-10 cells, this treatment actually increased the 
number of viable cells above that of the PBS control (Figure 5.10). Ovo agg. PGPFs reduced 
the viability of EOC 13.31 cells by ~ 44% and in SVEC4-10 cells by ~ 55%. Pre-incubation 
of CLU or A2M with SOD agg. PGPF prior to their addition to EOC13.31 cells, reduced the 
cytotoxicity of the PGPFs by ~ 82% % and ~ 79%, respectively (Figure 5.10). The 
corresponding levels of inhibition of PGPF-induced cytotoxicity for SVEC4-10 cells were ~ 
90% and ~ 84% for CLU and A2M, respectively (Figure 5.10). Lastly, ox. IgG agg. PGPFs 
reduced the viability of EOC 13.31 cells by ~ 44% and in SVEC4-10 cells by ~ 30%. Pre-
incubation of CLU or A2M with ox. IgG agg. PGPF prior to their addition to EOC 13.31 cells 
inhibited PGPF-induced cytotoxicity by ~ 82% % and ~ 100%, respectively (Figure 5.10). In 
SVEC4-10 cells, pre-incubation of ox. IgG aggregate derived PGPFs with CLU completely 
protected against cytotoxicity and actually increased viable cell numbers to ~ 124% of the 
PBS control; corresponding treatment with A2M reduced PGPF-associated toxicity by ~ 88% 
(Figure 5.10). 
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Figure 5.10 Effect of CLU and A2M on the cytotoxicity of amorphous protein aggregates and 
PGPFs derived from them. Sterile samples of aggregates, native proteins and PGPFs derived from 
the digestion of both were prepared as described in section 5.2.1. Samples were then pre-incubated in 
the presence or absence of CLU or A2M or BSA (non-chaperone control protein) for 1 h at 37˚C 
before incubating with EOC 13.31 and SVEC4-10 cells at a final concentration of 200 µg/mL at 37°C 
for 24 h. The identity of treatments is indicated by labelled brackets below the x-axis. The MTS assay 
was performed as described in section 5.2.6. Results are plotted as a percentage of the A490 for PBS 
control wells. Individual data points are means ± SD (n=9), and the data shown is pooled from three 
independent experiments done in triplicate. Asterixes placed immediately above error bars indicate 
that the sample is significantly different to the corresponding PBS control; asterixes above horizontal 
brackets indicate a significant difference between the indicated treatment in the presence versus 
absence of chaperone; *** (p<0.001). 
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5.3.5 Protein aggregates and PGPFs induce loss of mitochondrial membrane potential  
While ROS formation can be indicative of either apoptosis or necrosis, the rapid dissipation 
of mitochondrial membrane potential (ΔMIT) following cytotoxic insult can be indicative of 
apoptosis (Zamzami et al. 1995; Fleury et al. 2002; Kroemer et al. 2009). To examine the 
mode of cell death induced by protein aggregates and PGPFs, ox. IgG aggregates, their 
corresponding PGPFs or native IgG-derived PGPFs were incubated with EOC 13.31 and 
SVEC4-10 cells while measuring ΔMIT over time. As controls, cells were also separately 
incubated with CCCP (to induce loss of ΔMIT) and etoposide (to induce apoptosis). 
 
In two separate experiments, both CCCP and etoposide significantly and rapidly dissipated 
ΔMIT over time, relative to the PBS control (Figure 5.11; p<0.001). Both ox. IgG aggregates 
and aggregate-derived PGPFs induced significant loss of ΔMIT in both EOC 13.31 and 
SVEC4-10 within 3 h (p<0.001). Native IgG PGPFs had no significant effect on ΔMIT 
during the duration of the experiment. Confocal transmission images showed cells exhibiting 
a gradual change in morphology known as “rounding up” suggestive of apoptosis (not 
shown). Taken together, the rapid loss of ΔMIT and morphological changes suggest that the 
cytotoxicity of ox. IgG PGPF may induce apoptosis, although more evidence is needed to 
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Figure 5.11 Ox. IgG aggregates and derived PGPFs induced loss of mitochondrial 
mitochondrial potential in EOC-13.31 and SVEC4-10 cells. Samples of 200 µg/mL ox. IgG 
aggregates or PGPFs derived from ox. IgG aggregates, or native IgG, were incubated for 9 h with 
EOC 13.31 and SVEC4-10 cells which were continuously imaged by time resolved confocal 
microscopy. Changes in mitochondrial membrane potential (ΔMIT) were measured as described in 
section 5.2.7. As positive controls, cells were incubated with CCCP to induce loss of ΔMIT, and 
etoposide to induce apoptosis. Images were analysed using Leica LAS AF “Lite” and results are 
displayed as the percent of ΔMIT of PBS control ± SD (n=6), and the data shown are pooled from 
three independent experiments. Vertical brackets marked with an asterix denote a significant 
difference between the bracketed treatments versus the PBS control; *** (p<0.001). 
 
5.3.6 Cell surface-binding and internalisation of labelled PGPFs
488
 
5.3.6.1   PGPFs
488
 are internalised rapidly and co-localise with lysosomes 
Live-cell imaging is a powerful technique - it allows the monitoring of cell-based events that 
are normally difficult to measure using fixed time points, such as the internalisation of 
proteins and their trafficking to cellular compartments. PGPFs were labelled with CF-488 
(PGPFs
488
) and purified by SEC. PGPFs
488
 were then incubated with cells which were 
subsequently imaged using confocal microscopy. PGPFs were internalised into the cytoplasm 
and dendritic-like projections but not the nucleus of: astrocyte-like (AST-1), microglial-like 
(EOC 13.31), motor neuron-like (NSC-34) and endothelial-like (SVEC4-10) cells, and 
purified human polymorphonuclear neutrophils (PMN) (Figure 5.12). Having identified that 
Ovo agg. PGPFs
488
 are internalised into several cell types, in subsequent experiments the 
internalisation of labelled PGPFs derived from SOD, Ovo and ox. IgG aggregates was 
studied in greater detail using two cell lines, EOC 13.31 and SVEC4-10.  




Figure 5.12 Representative confocal microscopy images of the internalisation of fluorescently 
labelled Ovo aggregate-derived PGPFs488 into cells. A range of cell-types grown on cover slips 
were incubated with Ovo aggregate-derived PGPFs
488 
for 1 h and imaged using confocal microscopy. 
PGPFs
488
 were internalised into all cell-types assayed, including astrocyte-like (AST-1; A), 
microglial-like (EOC 13.31; B – C), motor neuron-like (NSC-34; D – E), purified human 
polymorphonuclear neutrophils (PMN; F), and endothelial-like (SVEC4-10; G – H) cells. Free CF-
488 label served as a negative control for internalisation (5.2.8). No visible internalisation of the 
negative control was observed.  
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Using image analysis including Pearson’s correlation coefficient and Mander’s overlap 
coefficient (for a description of statistical analysis method used to derive correlation 
coefficients, see section 5.2.10), PGPFs were found to significantly co-localise with 
lysosomes (Figure 5.13). Overlayed confocal images show intracellular PGPF
488
-associated 
fluorescence overlapping with that of Lysotracker staining in EOC 13.31 and SVEC4-10 
cells. This suggests that PGPFs are being shuttled to lysosomes after being internalised. In 
both EOC-13 and SVEC4-10 cells, PGPFs
488
 were rapidly internalised within 15 min into the 
intracellular space and subsequently shuttled to lysosomes (Figure 5.14). The rates of 
internalisation of aggregate-derived PGPFs differed between both the parent protein 
aggregate used to generate the PGPFs as well as the cell type. In EOC-13 cells, the rates of 
internalisation of ox. IgG PGPFs
488
 were significantly higher than that of PGPFs derived 
from aggregates of either SOD or Ovo. In contrast, in SVEC4-10 cells, the rate of 
internalisation of Ovo aggregate derived PGPF
488
 was significantly higher than the rates of 
uptake of PGPFs
488 
derived from aggregates of either SOD or oxidized IgG. Generally, the 
rate of PGPFs
488
 internalisation was significantly higher in EOC-13.31 cells than in SVEC4-
10 cells.  



















Figure 5.13 Representative confocal microscopy images of the internalisation of fluorescently labelled aggregate-derived PGPFs into the lysosomes 
of EOC 13.31 and SVEC4-10 cells. 75 nM Lysotracker Deep Red (Molecular Probes) and 20 µ/mL PGPFs
488
 were added to EOC 13.31 (A – C) and 
SVEC4-10 (D – F) cells (section 5.2.8). Images are representative of regions of interest taken at 30 min of a 3 h time course imaged by time-resolved 
confocal microscopy. PGPFs
488
 (red fluorescence) derived from aggregates of SOD (A, D), Ovo (B, E), and ox. IgG (C, F) were overlayed with lysosomes 
(green fluorescence). The extent of colocalisation was analysed with ImageJ using the plugin “colocalization finder” to derive Pearson’s correlation 
coefficient (Pr) ranging from -1 to +1 and Mander’s overlap coefficient (Mr) ranging from 0 to 1 (correlation statistical analysis; section 5.2.10). 
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Figure 5.14 Internalisation rates of aggregate-derived PGPFs into EOC-13.31 and SVEC4-10 
cells. Initial rate of uptake was calculated using a linear regression of arbitrary fluorescence units 
versus time in minutes (AFU/min). This was calculated over 180 min of recorded internalisation, 
which was based on the increase in PGPF
488
 fluorescence into an intracellular, circular region of 
interest (ROI) over the recorded period (section 5.2.8). Results represent the mean initial rate of 
fluorescence uptake of at least 6 regions of interest imaged per well and is expressed as AFU/min ± 
SD (n=6). For each type of PGPFs
488
, measurements were performed in duplicate and each 
experiment was performed at least three times. Asterixes above horizontal brackets indicate a 
significant difference in the rates of internalisation for different PGPF
488
 between the bracketed 
samples; * p<0.05, ** p<0.01, *** p<0.001.  
 
5.3.6.2    Binding of PGPFs
488
 to the surface of cells is via multiple mechanisms and is 
affected by the presence of chaperones 
As a first step to examine if pre-incubation of PGPFs affects their binding to the cell-surface, 
and which receptors or endocytic mechanism(s) might be involved, EOC 13.31 and SVEC4-
10 cells were incubated with labelled PGPFs that had been pre-incubated (or not) with ECs. 
The incubations were performed for 30 min on ice in the presence of 0.1% (w/v) sodium 
azide (to stop internalisation of the PGPFs) and the level of cell bound PGPFs
488 
was then 
quantified by flow cytometry. 
In the absence of ECs, PGPFs bound to both EOC-13.31 and SVEC4-10 cells (Figure 5.15). 
Generally more PGPF
488
 bound to EOC-13.31 than to SVEC4-10 cells. Neither A2M or CLU 
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had any significant effect on the binding of SOD aggregate derived PGPF
488
 to either EOC-
13.31 or SVEC4-10 cells (Figure 5.15). In contrast, A2M significantly inhibited the binding 
of Ovo aggregate derived PGPF
488
 to EOC-13.31 and SVEC4-10 cells by ~ 24% and ~ 35%, 
respectively. Corresponding values for the inhibition of binding produced by CLU were ~ 
30% and ~ 34%, respectively. A2M and CLU also significantly decreased cell-surface 
binding of ox. IgG derived PGPFs to SVEC4-10 cells relative to the corresponding controls 
by ~ 43% and ~ 59%, respectively. In contrast, relative to the corresponding control, A2M 
significantly increased the binding of these same PGPFs to EOC-13.31 cells by ~ 37%. Pre-
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Figure 5.15 Effect of CLU and A2M on the binding of aggregate-derived PGPF to the surface of 
EOC-13.31 and SVEC4-10 cells. Prior to adding to cells, PGPFs
488 
were incubated with or without 
CLU or A2M (section 5.2.9.1). Cells were then incubated in the presence (PGPF) or absence (PBS 
Control) of PGPFs
488
 at a final concentration of 20 µg/mL for 30 min in ice-cold BSA/PBS/Az. Cells 
were washed in the same buffer and MFI measured by flow cytometry. Dead cells stained with 
propidium iodide were electronically excluded from the analyses. Results are displayed as the MFI ± 
SD (n=9) of three independent experiments performed in triplicate. Asterixes above horizontal bars 
indicate a significant difference between the indicated treatments compared to cells in the absence of 
chaperones (PGPF Alone); ** (p<0.001), *** (p<0.001). 
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Next, a panel of inhibitors was selected based on broad-specificity for multiple receptors and 
endocytic mechanisms as well as more specific antagonists for receptors of an immune-cell 
origin (section 5.2.8.1; Table 5.1). The results indicate that the receptors and mechanism(s) 
by which aggregate-derived PGPFs bind to the surface of cells varies with both the PGPFs 
source as well as cell type used (Table 5.2). EIPA, LPS and MethBCD significantly inhibited 
the binding of SOD aggregate derived PGPF
488
 to EOC 13.31 cells. Thus, this binding 
appears to be mediated in part by toll-like receptors and lipid rafts, and internalisation by 
macropinocytosis. Macropinocytosis was not expected to occur under experimental 
conditions, as they were conducted at 4˚C, regardless a significant reduction in PGPF
488
-
associated fluorescence was observed. In the case of Ovo aggregate derived PGPF
488
, 
significant inhibition of binding to EOC-13.31 cells was obtained by GST-RAP, LPS, 
MethBCD and mannan, implicating the involvement of LDL family of receptors, toll-like 
receptors, mannose receptor, and lipid rafts. Lastly, the binding of ox. IgG derived PGPF
488
 
to EOC-13.31 cells was significantly inhibited by anti-TLR2 and anti-CD14 antibodies, 
fucoidan and PolyI, implicating toll-like receptors (TLR) 2 and 3, CD14, and scavenger 
receptors in the binding. CD14 is a pattern recognition receptor with a hydrophobic binding 
pocket (Kelley et al. 2013), found either in a secreted soluble form or anchored on the surface 
of immune cells (Jersmann 2005). CD14 acts as to deliver lipoproteins to TLR1 and TLR2 
(soluble form) and as a co-receptor for the detection of bacterial LPS by forming a ternary 
complex with the Toll-like receptor TLR 4 and MD-2 (anchored form) (Jersmann 2005; 
Ranoa et al. 2013). In the case of SVEC4-10 cells, the only significant instances of inhibition 





on the binding of ox. IgG derived PGPF
488
, implicating lipid rafts and scavenger receptors 
respectively. 
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Table 5.2 Summary of the effects of specific inhibitors on the binding of labelled PGPFs488 derived from aggregated SOD, Ovo and ox. IgG to the 
surface of EOC-13.31 and SVEC4-10 cells. 
Cell Line PGPF 





anti-    
TLR-4 
Ab 
LPS    
(pan-
TLR) 
anti-           
CD14 
Ab 
EIPA Fucoidan Mannan M-β-CD RAP 
EOC-13.31 SOD - - - 57.5±7.8 - 20.2±9.2 - - 37.3±5.8 - 
 
Ovo - - - 21.5±7.4 - - - 19.2±5.2 25.7±0.1 46.9±7.9 
 
ox. IgG 16.6±6.3 21.1±6.9 - - 41.6±8.7 - 89.2±0.3 - - - 
SVEC4-10 SOD - - - - - - - - 23.3±7.2 - 
 
Ovo - - - - - - - - - - 
 
ox. IgG - - - - - - 28.7±9.0 - - - 
 
Cells were incubated in the absence or presence of inhibitor (section 5.2.9.2) for 30 min in ice-cold BSA/PBS/Az, followed by incubation in the same buffer 
and temperature for a further 30 min in the presence or absence of 20 µg/mL PGPFs
488
. Cells were washed and MFI measured by flow cytometry. Results are 
displayed as the MFI ± SD (n=9) of three independent experiments performed in triplicate for each separate inhibitor. Horizontal dashes denote that no 
significant inhibition was measured. 
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5.4  DISCUSSION 
 
5.4.1 Proteolytic degradation of amorphous aggregates by the plg activation system 
In the CNS, both neurons and microglial cells express tPA (Salles and Strickland 2002), plg 
(Tsirka et al. 1997), PAI-1 (Masos and Miskin 1997), PAI-2 (Akiyama et al. 1993; 
Dietzmann et al. 2000), and neuroserpin (Teesalu et al. 2004; Yepes and Lawrence 2004; 
Melchor and Strickland 2005). tPA is secreted from neurons and microglia following 
aggregate-induced excitotoxic injury, such as in Alzheimer’s disease and spongiform 
encephalopathies (Fischer et al. 2000; Siao and Tsirka 2002; Siao 2003) and has been shown 
to bind to and become activated by structural components of amyloid fibrils, which acted as 
both a co-factor and substrate (Kranenburg et al. 2002; Gebbink et al. 2009). The ability of 
amorphously structured aggregates (but not native proteins) to significantly enhance tPA-
mediated plg activation was demonstrated in Chapter 4. This activated form of tPA then 
cleaves plg into the active serine protease plm which can degrade protein aggregates into 
PGPFs (Figure 5.1).  
 
Plm was found to degrade amorphous aggregates efficiently; for example, after 8 h of 
reaction time, 100 mU plm would generate 3.13 mg/mL of soluble PGPFs of varying sizes 
from 4 mg/ml of SOD aggregate (determined using BCA assay (section 2.3); not shown) 
(Figure 5.1 and 5.2). This activity is similar to that reported for in vitro plm degradation of 
aggregated Aβ (Tucker et al. 2000). Concentrations of plm used to generate PGPFs from 
amorphous aggregates were half that reported for plg in plasma (1.6 – 2 µM) (Cederholm-
Williams 1981; Kwaan 1992). The resting cerebrospinal fluid concentrations for plg are 
reported to be much lower than plasma concentrations (3 – 15 nM) (Mezzapesa et al. 2014), 
this however appears sufficient to allow the degradation of Aβ peptide in mice (Melchor et al. 
2003). Additionally, the concentration of plg in CSF is further increased during breakdown of 
the BBB (Mezzapesa et al. 2014). Disruption of the BBB can be mediated by (i) plasmin, (ii) 
endothelial cell activation (Gonzalez-Villalobos et al. 2006; Gonzalez-Velasquez et al. 2011), 
or (iii) endothelial cell death induced by fibrin-derived PGPFs (Guo et al. 2009).  
 
Interestingly, impaired BBB integrity is observed in Alzheimer’s disease (Yamada 2000; 
Jellinger 2002). Sub-toxic concentrations of less than 10 µM (43 µg/mL) of soluble 
oligomeric Aβ aggregates can activate endothelial cells (HBMVEC cells) by inducing nuclear 
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factor-κB activation, and lead to the breakdown of tight junctions and the BBB and allow 
infiltration/transmigration of monocytes (Gonzalez-Velasquez and Moss 2008; Gonzalez-
Velasquez et al. 2011). It is possible that endothelial activation may result from other protein 
aggregates and PGPFs which could allow for infiltration of plg and the recruitment of 
monocytes through the permeabilised BBB. This series of events would intensify both tPA-
mediated plg activation and inflammatory pathology. 
 
5.4.2 Binding of extracellular chaperones to aggregates and PGPFs 
CLU and A2M are expressed by a wide variety of cells; CLU expression is up-regulated in 
response to a variety of stresses, while A2M is present at high levels in extracellular fluids 
(Wyatt et al. 2013). Both are found co-localised with aggregates at sites of extracellular 
deposition in numerous diseases (Dabbs et al. 2013). CLU and A2M were shown to bind to 
both amorphous aggregates and their corresponding PGPFs (Figure 5.3). These interactions 
are consistent with a model hypothesised by Wyatt et al. in which extracellular proteases and 
ECs cooperate to maintain extracellular proteostasis by synergistically facilitating the 
degradation of aggregates and their subsequent disposal (Wyatt et al. 2013). In addition, since 
CLU and A2M bind to aggregates/PGPFs of both SOD (amyotrophic lateral sclerosis) and 
IgG (corneal dystrophy, multiple myeloma and rheumatoid arthritis), the involvement of ECs 
in these diseases should be further investigated. 
 
Native A2M and A2M:protease complexes have been shown to inhibit the aggregation of 
proteins (Chapter 3) (French et al. 2008; Wyatt et al. 2013). However, A2M:(Trp or Plm) 
complexes would be cleared quickly in vivo, thus A2M:protease complexes were not tested 
for their ability to bind to PGPFs. Around sites of existing extracellular amorphous 
aggregates, plm is likely to be in an active state, assisting with proteolysis; at the same 
locations A2M is likely to inhibit plm by forming complexes with it, thereby restricting 
"bystander" damage to extracellular proteins by excessive levels of plm. There may, 
however, be instances where A2M already bound to PGPFs could become activated by 
protease, thereby increasing the rate of PGPF removal by LRP via receptor-mediated 
endocytosis. 
 
Amorphous protein aggregates and the PGPFs derived from them have greater exposed 
hydrophobicity than the corresponding native proteins (Figure 5.4). This increase in exposed 
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hydrophobicity correlates with increased binding of ECs to aggregates/PGPFs (Figure 5.3 and 
5.4). However, one notable exception to this is the greater binding of CLU to native IgG than 
to PGPFs from IgG aggregates. This is not entirely unexpected, as in addition to binding to 
exposed hydrophobicity, CLU is known to bind to the Fab and Fc fragments of both native 
and heat-aggregated human IgG (Wilson and Easterbrook-Smith 1992). These native binding 
sites may be destroyed by plm digestion during the formation of the PGPFs. ECs are known 
to bind to misfolded proteins by interacting with regions of exposed hydrophobicity 
(Humphreys et al. 1999; Poon et al. 2000; Yerbury et al. 2005; Yerbury et al. 2007; French et 
al. 2008); this represents the most likely mechanism to account for why ECs preferentially 
bind to aggregate-derived PGPFs but not to native protein-derived PGPFs. The interaction 
between ECs and PGPFs may facilitate removal of the latter from the extracellular space and, 
in conjunction with plg activation and the subsequent proteolytic degradation of protein 
aggregates, may constitute an important part of the overall proteostasis quality control 
machinery. 
 
5.4.3 The effects of PGPFs on microglial and endothelial cells 
5.4.3.1   In the absence of ECs 
Proteolytic fragments liberated by plasmin degradation of amorphous aggregates (PGPFs) 
were shown to bind to the surface of cells by various mechanisms and receptors and become 
internalised into lysosomal compartments. Furthermore, in EOC 13.31 and SVEC4-10 cells, 
PGPFs increased the levels of ROS (Figure 5.5 – 5.8), were cytotoxic (Figure 5.9 and 5.10), 
and induced loss of ΔMIT (Figure 5.11). For three different proteins, aggregates and PGPFs 
prepared from these, but not the corresponding native proteins or PGPFs prepared directly 
from those, exerted cytotoxicity towards both microglial and endothelial cell lines which was 
preceded by a large increase in ROS formation (Figure 5.4 – 5.8). Moreover, PGPFs from 
both SOD and Ovo aggregates induced significantly less ROS formation than undigested 
aggregates, while there was no significant difference in the level of induced ROS formation 
between ox. IgG aggregates and their PGPFs (Figure 5.5 – 5.7). As mentioned previously, 
ROS has deleterious effects on cells and can elicit cell death signalling pathways. The 
induction of intracellular ROS production had a rapid onset but was transient, decreasing over 
time (Figure 5.4), and was followed by cell death (Figure 5.8) indicating triggering of either 
apoptosis or necrosis cell-death pathways (Lipton and Rosenberg 1994; Bonfoco et al. 1995; 
Fleury et al. 2002; Fink and Cookson 2005).  
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Similar to the effects of fibrin-derived PGPFs on endothelial cells (Guo et al. 2009), ox. IgG-
derived PGPFs most likely induced cell death via apoptosis, including activation of intrinsic 
mitochondrial pathways, indicated by the loss of mitochondrial membrane potential and the 
formation of ROS (Figure 5.10) (Zamzami et al. 1995; Fleury et al. 2002; Fink and Cookson 
2005; Kroemer et al. 2009). The fact that PGPFs derived from amorphous aggregates, but not 
those derived from the corresponding native proteins, induce cell death suggests that the 
cytotoxic effects are mediated by a conformational or structural feature inherent to the 
aggregates rather than any specific amino acid sequence. Amorphous aggregates are often 
regarded as generally non-toxic to cells, despite their occurrence in many PDDs (Chapter 1, 
Table 1.1). Results presented in this thesis, however, demonstrate that amorphous aggregates 
of SOD, Ovo and ox. IgG can induce the formation of ROS and are cytotoxic (Figure 5.4 – 
5.9). 
 
It should be noted that several PDDs such as Parkinson’s disease, dementia (Parkinson’s 
disease-related), Huntington’s disease, and ALS, are associated with non-classical modes of 
cell death including excitotoxicity (Lipton and Rosenberg 1994; Ankarcrona et al. 1995; 
Bonfoco et al. 1995; Lau and Tymianski 2010) and lysosomal membrane permeabilisation 
(Zhang et al. 2009; Freeman et al. 2013). Excitotoxicity and lysosomal permeabilisation are 
both associated with ROS formation and mitochondrial dysfunction and cells may adopt 
either an apoptotic or necrotic appearance, with or without caspase activation, depending on 
the situation (i.e. influenced by the intensity of insult).  
 
Confocal imaging suggests that PGPFs were internalised mainly into lysosomal 
compartments as well as into the cytoplasm (Figure 5.12). Disposal of PGPFs by lysosomal 
degradation is insufficient to prevent the cytotoxicity measured by SYTOX (Figure 5.8) and 
MTS assays (Figure 5.9). The appearance of PGPFs in both lysosomes and within the 
cytoplasm suggests that either sufficient amounts are being internalised into the cytoplasm 
via non-classical endocytotic mechanisms to induce cytotoxicity, or PGPFs may be able to 
disrupt lysosomal vesicles and thereby impart cytotoxicity.  
 
 
5.4.3.2   In the presence of ECs 
The role of proteases and chaperones in extracellular proteostasis 
153 
 
For both microglial and endothelial cells, pre-incubation of protein species with CLU and 
A2M significantly and dramatically reduced ROS formation induced by SOD aggregates and 
PGPFs derived from them (Figure 5.6). Similarly, in endothelial cells, CLU and A2M 
inhibited ROS formation induced by Ovo aggregates and the corresponding PGPFs (Figure 
5.7), and A2M inhibited ROS formation induced by ox. IgG aggregates and the 
corresponding PGPFs (Figure 5.8). In microglial cells, however, opposing effects were seen - 
pre-incubation of protein species with CLU and A2M both increased ROS formation when 
cells were exposed to Ovo aggregates and their corresponding PGPFs (Figure 5.7), and CLU 
increased ROS formation when cells were exposed to ox. IgG aggregates and PGPFs derived 
from these (Figure 5.8). It remains controversial whether microglial cells have beneficial or 
detrimental functions in various neuropathological conditions. Low level activation of 
microglia has been shown to initiate neuroprotective mechanisms such as phagocytosis of 
tissue debris and damaged cells (Streit et al. 2005). It has also been observed that in 
Alzheimer’s disease microglia play an important role in the clearance of cytotoxic Aβ 
aggregates via phagocytosis (Neumann et al. 2009). In addition, activation of microglia may 
assist in the clearance of protein aggregates and PGPFs, by increasing the expression of LRP 
(Marzolo et al. 2000) and scavenger receptors (Weiner and Frenkel 2006). Increased 
expression of LRP has been shown to facilitate clearance of A2M:Aβ (Narita et al. 1997) and 
other A2M:client complexes (French et al. 2008), while scavenger receptors have been 
shown to bind to ox. IgG PGPFs (Table 5.2), and facilitate the clearance of soluble HMW 
complexes of CLU:client protein complexes by CD14+ monocytes (Wyatt et al. 2011). 
Therefore, ECs may assist in the disposal of PGPFs by activating microglia (evidenced as a 
ROS burst) to stimulate them to clear protein aggregates, PGPFs, and cellular debris much in 
the same way as monocytes. 
 
There is no simple relationship between the effect of ECs on the binding of PGPFs and the 
subsequent induced ROS formation (Figure 5.15). For example, ECs decrease cell-surface 
binding of Ovo aggregate PGPFs to both cell types, and decrease ROS formation in EOC 
13.31 cells, but increase ROS formation in SVEC4-10 cells (Figure 5.8). Furthermore, how 
ECs affected ROS formation in relation to cell-surface binding in the same cell line depended 
on the chaperone being used. For example, both CLU and A2M increased cell-surface 
binding of ox. IgG aggregate PGPFs to EOC 13.31 cells, however, ROS formation was 
increased when incubated with CLU but decreased when incubated with A2M (Figure 5.9). 
However, these differences may relate to differences in the types of receptors expressed by 
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microglia versus endothelial cells, and thus differences in subsequent signalling pathways 
elicited. Interestingly, the binding of SOD PGPFs to the cell-surface is not affected by pre-
incubation with ECs (Figure 5.15), despite the fact that the ECs dramatically decreased ROS 
formation (Figure 5.6) and cytotoxicity (Figure 5.10). In MTS assays, a straightforward 
pattern was observed. Pre-incubation of ECs with amorphous protein aggregates and 
aggregate-derived PGPFs suppressed their cytotoxicity towards both microglial and 
endothelial cells completely, and in some cases appeared to promote cell proliferation 
significantly above that of the PBS control (Figure 5.8), indicating that ECs provide general 
protection against these cytotoxic protein species.  
 
It appears that the ability of extracellular protein aggregates to mediate activation of plm and 
the subsequent release of toxic PGPFs passes unnoticed in routine proteostasis. This suggests 
the existence of mechanisms to protect cells from PGPF toxicity during plm-mediated 
degradation of protein aggregates. This may include the involvement of ECs which, as shown 
earlier, are able to bind to aggregate-derived PGPFs (Figure 5.3). The results also suggest that 
in the treatment of ALS and rheumatoid arthritis, and potentially other degenerative PDDs, 
increased levels of ECs in vivo could provide a therapeutic benefit. 
 
5.4.4 The dichotomy of the action of plm-mediated release of PGPFs in a biological 
context 
The activity of plm resulting from activation by protein aggregates can be either beneficial or 
detrimental, depending on circumstances. Similarly, PGPF-induced ROS formation or cell 
death may be beneficial or detrimental in different contexts.  
 
5.4.4.1   The bad 
Amorphous aggregates can serve as a cofactor for tPA-mediated plm formation (Chapter 4), 
contributing to neurotoxicity by attacking ECM and cell surface proteins, in a manner 
analogous to how tPA-induced plm formation has been suggested to contribute to neuronal 
loss in ischemia or excitotoxicity (Chen and Strickland 1997; Tsirka et al. 1997; Medina et 
al. 2005). Cellular internalisation of fibrin fragment central E-domain by caveolin-1 mediated 
endocytosis inhibits mitochondrial function and elicits caspase-mediated apoptosis in 
placental trophoblast cells (Guo et al. 2009). Plasma concentrations of fibrin-derived PGPFs 
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is greatly augmented in patients with thrombotic disorders such as venous thromboembolism 
or myocardial infarction, disseminated intravascular coagulation, infection, certain types of 
leukemia, and other pathologies such as diabetic retinopathy (Cederholm-Williams et al. 
1981; Francis and Marder 1987; Cesarman-Maus and Hajjar 2005; Mosesson 2005). 
Similarly, localised plm-mediated degradation and release of PGPFs may accompany the 
deposition of extracellular amorphous protein aggregates. 
 
The cytotoxicity imparted by protein aggregates in degenerative PDDs has previously been 
largely attributed to cytotoxic protein oligomers or large insoluble aggregates causing direct 
damage to cells/tissues (Stefani and Dobson 2003; Chiti and Dobson 2006). The release of 
cytotoxic PGPFs from extracellular deposits of amorphously aggregated protein may 
represent a novel physiologically relevant mechanism which, in conjunction with decreased 
availability or absence of chaperones (such as when they are sequestered by aggregates 
(Okado-Matsumoto and Fridovich 2002; Narayan et al. 2012)), could contribute to 
inflammation and other pathologies associated with disease.  
 
5.4.4.1    The good  
As mentioned previously, amorphous aggregates and their corresponding PGPFs induced 
ROS formation in cells (Figure 5.4 – 5.8). ROS formation may be beneficial in the 
phagocytic removal of unhealthy cells. Phagocytes can also internalise protein aggregates 
directly and degrade them, aided by ROS. Additionally, it is thought that apoptosis induced 
by fibrin-derived PGPFs may be beneficial by aiding in clearing damaged cells from injury 
sites, but have deleterious cytotoxic effects when produced excessively, such as in acute lung 
injury and chronic lung disease (Sio et al., 2003; Gando et al., 2004; Guo et al., 2009). More 
generally, the interaction of the plm activation system with ECs may allow the body to clear 
insoluble extracellular protein deposits resulting from disease by firstly digesting them into 
smaller soluble fragments (PGPFs) and then with the aid of the ECs neutralise their toxicity 
and dispose of them via cell uptake and lysosomal degradation (Wyatt et al. 2013). Without 
this co-ordinated system, the body would be left with a static protein mass, potentially 
disrupting tissues and sequestering chaperones.   
 
5.4.5 PGPFs-mediated inflammatory responses triggered by cell-surface binding 
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The ability of soluble and insoluble protein aggregates to promote excessive and 
damaging/cytotoxic inflammatory responses was briefly mentioned above. This is potentiated 
via the activation of microglia or neutrophils; this is evident for SOD, αSyn and IgG 
aggregates in ALS, Parkinson’s disease and rheumatoid arthritis respectively (Robinson et al. 
1993; Zhang et al. 2005; Roberts et al. 2013). PGPFs were found to bind to cells by a variety 
of different mechanisms including via lipid rafts, and toll-like and scavenger receptors (Table 
5.2). Similar binding interactions have been reported previously for undigested aggregates of 
Aβ (Verdier et al. 2004) and SOD (Roberts et al. 2013). 
 
Toll-like, CD14 and scavenger receptors are known as pattern recognition receptors, and have 
been shown to bind to and facilitate the clearance of a broad variety of protein aggregates in 
Alzheimer’s disease, age-related macular degeneration and ALS. Binding induces signalling 
pathways which subsequently invoke inflammatory responses in these diseases by the 
activation of cells such as microglia (Coller and Paulnock 2001; Herczenik et al. 2007; Jana 
et al. 2008; Liu et al. 2008; Kaarniranta and Salminen 2009; Liu et al. 2009; Roberts et al. 
2013). Activated microglia can damage neurons by secreting pro-inflammatory cytokines 
such as TNF-α, IL-1β, and reactive oxygen/nitrogen species. Production of these same 
species by monocytes, macrophages and neutrophils (Colton and Gilbert 1987; Stansley et al. 
2012) can in neurons mediate cell death (Boje and Arora 1992; Blasko et al. 2004; Kitazawa 
et al. 2004; Walker and Lue 2005; Sastre et al. 2006), stimulate Aβ production (Blasko et al. 
2004), and induce tau hyperphosphorylation (Kitazawa et al. 2004).  
 
The binding to microglial cells of PGPFs derived from aggregates of three different proteins, 
is mediated in part by pattern recognition receptors (Table 5.2) which are known to activate 
microglial cells, and specifically signalling pathways to stimulate ROS generation and 
inflammatory cytokine production (Coller and Paulnock 2001; Lue et al. 2001; Roberts et al. 
2013). Thus, PGPFs may contribute to the neuroinflammatory pathology witnessed in 
numerous PDDs. There are many reports describing the anti-inflammatory properties of CLU 
and A2M and their effects on the immune system (van Gool et al. 1990; Kurdowska et al. 
2000; McLaughlin et al. 2000; Navab et al. 2005). Some of their immunomodulatory 
properties have been attributed to their ability to bind exposed hydrophobic residues 
(LaMarre et al. 1991; Tschopp et al. 1993; Mathew et al. 2003). Again, this may be another 
context in which ECs could be beneficial to modulate the effects of PGPFs in vivo. 
 




Current therapies for PDDs are largely limited to treatments to ameliorate the symptoms of 
disease rather than directly address the underlying causes. Pre-emptive treatments to avoid 
the onset of disease are so far yet to be realised. Progress will be reliant upon advances in 
understanding of the cellular and molecular processes that underpin disease onset and 
progression. Results presented in this Chapter suggest a novel mechanism by which both 
extracellular proteases and chaperones may work cooperatively in vivo. In this model tPA-
mediated plm activity efficiently degrades large insoluble amorphous aggregates into soluble, 
yet toxic PGPFs which are then bound by ECs to facilitate their removal and subsequent 
degradation by cells to maintain proteostasis. Clearly, the advances reported in this Chapter 
are a promising first step which may lead to confirmation of the operation of these processes 
in vivo and, ultimately, to the development of effective therapeutic strategies to combat 
serious degenerative PDDs. 
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CHAPTER 6 : CONCLUSIONS 
 
Aging is characterised by a progressive loss of physiological integrity, impaired function and 
increased vulnerability to death. This deterioration is the primary risk factor for major human 
pathologies, including cancer, diabetes, and cardiovascular and neurodegenerative disorders 
(Lopez-Otin et al. 2013). Age-related pathologies such as Alzheimer’s disease, Parkinson’s 
disease, cataracts and many other protein deposition diseases (> 40) involve the common 
features of abnormal and chronic expression of misfolded or aggregated proteins, and their 
inappropriate deposition, either intra- or extracellularly, in the brain or other tissues specific 
to the disease (Dobson 2003; Wyatt et al. 2013). Proteins have evolved their structure to 
maximise function and have an inherent tendency to aggregate (Dobson 2003; Stefani and 
Dobson 2003; Bucciantini et al. 2004). Furthermore, endogenous and exogenous stresses 
(e.g. mutations, extremes of pH or temperature) can cause the unfolding of proteins or impair 
proper post-translational folding, leading to the surface exposure of hydrophobic residues on 
protein molecules. Failure to refold or degrade unfolded proteins can result in their 
aggregation to form either structured fibrils or unstructured amorphous aggregates. The 
aggregation process can generate toxic protein oligomers and/or insoluble deposits which can 
disrupt tissue and organ function (Dobson 2003; Wyatt et al. 2013).  
 
In addition to their direct toxic effects, aggregated proteins can also indirectly promote 
inflammatory responses and the processing of neuroendocrine factors (Casserly and Topol 
2004; Kranenburg et al. 2005). This has made it necessary for organisms to evolve a variety 
of defences against misfolded or abnormal proteins.  All organisms utilise an array of quality 
control mechanisms that act to preserve the conformation, concentration and correct sub-
compartmentalisation of their proteomes, collectively termed the proteostasis network (Balch 
et al. 2008; Hutt et al. 2009). This network is critical for organismal viability, and when 
operating correctly maintains the solubility and function of the entire proteome in both intra- 
and extracellular environments, responding to stresses as they arise (Balch et al. 2008; 
Powers et al. 2009). As a consequence of aging, however, protein quality control systems 
malfunction and the ability of the body to defend itself against a variety of serious protein 
deposition diseases is decreased. In particular, intracellular chaperone and proteasome 
systems show reduced expression and activity and, unsurprisingly, higher levels of misfolded 
and aggregated proteins result (Esser et al. 2004; Morimoto 2008; Powers et al. 2009; Koga 
et al. 2011; Cook et al. 2012).  




Intracellular proteases and chaperones work together to maintain protein fold and solubility, 
inhibit aggregation and clear intracellular protein aggregates (Ross and Poirier 2005). In 
contrast, the corresponding extracellular mechanisms are much less well understood (Dobson 
2003; Wyatt et al. 2013). An earlier proposed model of how extracellular proteostasis may 
function (Figure 6.1) put forward the hypothesis that levels of extracellular misfolded 
proteins are controlled by (i) binding of still soluble misfolded proteins to cell-surface pattern 
recognition receptors and subsequent internalisation and degradation, and (ii) interactions 
with ECs (for example, CLU and A2M) which by binding to the misfolded client protein 
molecules maintain their solubility and facilitate their clearance by receptor-mediated 
endocytosis (Wyatt et al. 2011). Building upon this model, this thesis has attempted to further 




A2M is a broad-spectrum inhibitor of extracellular proteases with a unique mode of action 
that functions in haemostatic and inflammatory reactions (Harpel 1973; Imber 1981; LaMarre 
et al. 1991). Native tetrameric A2M has also been shown to bind to misfolded proteins and 
inhibit the amorphous and fibrillar aggregation of client proteins, as well as become 
Figure 6.1 Hypothetical model of extracellular 
proteostasis. When present at low levels, soluble 
misfolded proteins or oligomers can be cleared 
by direct binding to cell surface receptors and 
subsequent uptake and lysosomal degradation. 
When present at higher levels (favouring more 
extensive protein aggregation and deposition), 
the same species may form stable soluble 
complexes with extracellular chaperones. This 
acts to neutralise the toxicity of protein 
oligomers, and keep the species soluble so that 
they can be efficiently cleared by cell surface 
receptors and subsequently degraded. Adapted 
from Dabbs, R. A. et al. (2010) 
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subsequently proteolytically activated forming A2M:protease complexes which expose LRP-
binding sites (French et al. 2008). A2M is found in the plasma and CSF of healthy humans 
mainly as a tetramer in a range of 2.8 – 5.6 µM (Gourine et al. 2002). However, in different 
animal species A2M can exist as tetrameric, dimeric and monomeric forms, all of which can 
function as protease inhibitors (Sottrup-Jensen 1989). In humans, under physiological 
conditions 4-5% of the extracellular A2M pool is in the form of circulating disufide-linked 
dimers (Ozawa et al. 2011). A2M dimers have been found to be dissociated by oxidative 
compounds secreted by leukocytes (hypohalous acids) (Reddy et al. 1989; Reddy et al. 1994) 
and by neutrophils and microglia (OCl
-
) (Wyatt et al. 2014). Increased oxidative modification 
(carbonylation) of A2M has been shown in the plasma of patients with rheumatoid arthritis 
(accompanied by a two-fold higher expression of A2M) (Wu and Pizzo 2001) and 
Alzheimer’s disease (Cocciolo et al. 2012). SDS- and OCl
-
-dissociated dimers of A2M 
inhibit fibrillar protein aggregation (Ozawa et al. 2011; Wyatt et al. 2014). In humans, A2M 
monomers in plasma have been identified as a clinical biomarker in patients with diabetes at 
a range of 1 – 1.7 µM (Takada et al. 2013) and increased ~2-fold relative to healthy controls 
in cardiac hypertrophy (Rajamanickam et al. 1998), myocardial infarction in diabetes, 
(Annapoorani et al. 2006), and cardiac diseases (Rathinavel et al. 2005; Ramasamy et al. 
2006). In addition, A2M monomers can be generated extracellularly in vivo by thioredoxin 
(Larsson et al. 1988), which is secreted by lymphocytes in response to oxidative stress and 
inflammation (Kondo et al. 2004; Nakamura et al. 2006).  
 
In the current study, native tetrameric A2M was dissociated by mild reductive or 
physiologically-relevant oxidative (redox) stress to form A2M monomers and dimers, 
respectively. A2M species can inhibit aggregation by binding to misfolded and fibrillar and 
amorphously aggregating proteins via hydrophobic interactions, thereby facilitating their 
removal via LRP receptor-mediated endocytosis. The ability of A2M dimers and monomers 
to inhibit protein aggregation was more potent than that of the native A2M tetramer. The 
level of chaperone activity of A2M dimers/monomers also correlates with the level of 
surface-exposed hydrophobicity. Altogether, the ability of dimers and monomers to be 
generated in vivo, their presence in diseased patients, together with the observation that 
misfolded proteins are a hallmark of these same diseases, suggests that dimers/monomers 
may function as physiologically relevant ECs. A2M activated with either Trp or Plm prior to 
incubation with misfolding client proteins, was shown to potently inhibit the stress-induced 
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aggregation of a variety of proteins; this activity was more potent than that of native A2M. In 
addition, A2M:Trp and A2M:Plm complexes were able to partially degrade some aggregating 
client proteins, however, due to the exposure of LRP-binding sites these are likely to be 
cleared by cell-surface receptors within minutes (Gliemann et al. 1985; Roche and Pizzo 
1987; Roche and Pizzo 1988), and thus the residual protease activity of the complexes is 
unlikely to be physiologically relevant. Protease-activation of A2M after the formation of 
soluble A2M:client complexes has been shown to expedite disposal by LRP, and may 
facilitate clearance of misfolded client proteins via LRP in diseases which involve 
extracellular protein aggregation and increased extracellular protease secretion such as in 
arthritis (Abbink et al. 1991) and diabetic retinopathy (Sanchez et al. 2007). Furthermore, the 
binding of A2M:protease complexes induces increased expression and secretion of (i) tPA 
(Fischer et al. 2000; Siao and Tsirka 2002; Siao 2003) and A2M (Hughes et al. 1998; Lauer 
et al. 2001) from microglia, and (ii) plg and A2M from mononuclear cells (Zhabin et al. 
1995). These interactions provide a feed-forward mechanism to co-localise chaperones and 
proteases at sites of protein aggregation, which act together to facilitate return of the system 
to normal healthy proteostasis. Collectively, the results presented here show that the 
chaperone activity of A2M can be changed in response to a variety of conditions related to 
diseases, such as reductive/oxidative stress, inflammation, and increased protease secretion. 
 
tPA is an essential mediator of cell death following ischemia or excitotoxic injury in the 
brain, and may play a role in neuronal and endothelial cell death induced by aggregates 
(Tsirka 1995; Chen 1997; Yepes 2008). Additionally, the fact that excitotoxicity is found in 
PDDs and other neurological disorders concurrent with ROS formation and mitochondrial 
dysfunction, and that tPA is required for excitotoxic neuronal death, suggests a link between 
aggregate-induced tPA activation and extracellular protein aggregates. tPA was previously 
shown to bind to structural components of fibrillar protein aggregates (Kranenburg et al. 
2002; Samson et al. 2009). Fibrillar protein aggregates formed after cellular injury can serve 
as a cofactor for tPA and plg to enhance the generation of plm, which in turn facilitates the 
removal of unhealthy and nonviable cells (Samson et al. 2009; Samson et al. 2012). In 
addition, plm can degrade fibrillar protein aggregates, akin to the dissolution of fibrin-clots 
(Tucker et al. 2000; Melchor et al. 2003; Gebbink et al. 2009). These studies however, did 
not measure whether amorphous aggregates could induce tPA-mediated plg activation nor the 
effects on cells of plasmin-generated protein fragments (PGPFs) derived from protein 
aggregates. The degradation of fibrin by plasmin is vital for the maintenance of haemostasis, 
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yet despite the apparent toxicity of the PGPFs produced (Guo et al. 2009), biological 
functions are not impaired under normal conditions. This suggests the existence of 
mechanisms which protect cells from toxicity during the plasmin mediated degradation of 
proteins. Aβ42 promotes upregulation of the tPA/plg proteolytic system, which can degrade 
both native and amyloid fibrils of Aβ, reducing the load of amyloid plaques in vivo with no 
associated toxicity to cells (Tucker 2000; Tucker et al. 2000; Melchor et al. 2003; Lee et al. 
2007). Thus the plg activation system may also play an important role in extracellular 
proteostasis, and this was examined further in this thesis.  
 
In the current study, native SOD, Ovo and IgG were exposed to stresses to induce their 
amorphous aggregation. This created a mixture of soluble and insoluble protein aggregates. 
tPA and plg were shown to co-localise on the surface of amorphously aggregated proteins via 
their binding to lysine residues. It was also shown that when bound to insoluble protein 
aggregates, active plm was shielded from inhibition by A2AP. These findings are consistent 
with a model in which active plm formed at the surface of amorphous protein aggregates 
could remain persistently active and progressively degrade the aggregate. The action of plm 
on amorphous protein aggregates was shown to release smaller soluble fragments of protein 
(PGPFs). PGPFs were bound and internalised (via different mechanisms) to both endothelial 
and microglial cells, and were subsequently trafficked to lysosomes in both cell types. When 
incubated with cells, PGPFs generated from different types of protein aggregates all elicited 
ROS formation and cytotoxicity. ECs were able to bind to PGPFs, significantly ameliorating 
their negative effects on cells. In addition, ECs had differential effects on the binding of 
PGPFs to cells, depending on the combination of individual protein and cell type, probably 
reflecting differences in the repertoire of surface receptors expressed by the different cell 
types. CLU and A2M each have known specific cell surface receptors that recognise and 
internalise them in complex with ligands for subsequent lysosomal degradation (Hammad et 
al. 1997; Shibata et al. 2000). More detailed analysis of the interactions between ECs and the 
tPA system, and the toxicity and fate of the resulting chaperone:PGPFs complexes, will 
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In summary, findings presented in this thesis suggest a novel system in which proteases and 
circulating ECs act together as key synergistic agents in extracellular proteostasis; together 
they mediate the progressive degradation and safe clearance of large insoluble protein 
deposits. We hypothesise that extracellular amorphous protein aggregates, amyloid fibrils, 
and fibrin can all act as substrates and activators for tPA, and that ECs such as CLU and 
A2M bind to cytotoxic PGPFs generated by proteolytic breakdown of the aggregates to 
facilitate their clearance and ultimate degradation. These actions will collectively inhibit the 
development of age-related protein misfolding diseases (Figure 6.2). This model is consistent 
with the idea that in healthy individuals extracellular proteostasis operates to provide efficient 
clearance of toxic protein species (Yerbury et al. 2005; Wilson et al. 2008). As mentioned 
previously, the likelihood of onset of PDDs increases with age and is thought to coincide with 
a reduction in the ability of protein quality control systems to maintain proteostasis, allowing 
pathophysiological deposits of extracellular protein aggregates to form. This may have 
implications in Alzheimer’s disease where plm has been shown to degrade and clear 










Figure 6.2 Hypothetical model of an extracellular proteostasis mechanism involving the 
cooperation of extracellular proteases and chaperones. Stress conditions induce native proteins to 
misfold and expose hydrophobic residues. ECs can bind to misfolded proteins and dispose of them by 
internalisation via receptor-mediated endocytosis and lysosomal degradation. However, amorphous or 
amyloid fibril structured aggregates can form, as a mixed population of soluble and larger insoluble 
aggregates. Both soluble and insoluble aggregates then serve as a cofactor for tPA and Plg. tPA-
mediated activation is partially inhibited by PAI-1 and PAI-2. tPA induces activation of Plg into the 
serine protease Plm which can then degrade aggregated proteins into PGPFs. Free Plm is readily 
inhibited by A2AP, however Plm bound to insoluble amorphously aggregated proteins is protected 
from inhibition. PGPFs are released into the extracellular space and can either bind to (i) cell-surface 
receptors, followed by receptor-mediated endocytosis (RME) and trafficking to lysosomes for 
degradation; they can also induce the formation of reactive oxygen species (ROS) and cytotoxicity 
(skull), (ii) ECs and subsequently be internalised by RME and degraded in lysosomes. The binding of 
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The levels of expression of plasminogen activator inhibitor-1 and -2 (PAI-1 / PAI-2) have 
been shown to increase in tissues and plasma with age and cellular senescence (Kumar et al. 
1993; West et al. 1996; Eren et al. 2014). PAI-2 expression is also markedly increased in the 
vascular endothelium, granulosa cells and in microglial cells of patients with Alzheimer's 
disease (Akiyama et al. 1993; Dear and Medcalf 1995). The inhibition of tPA-mediated plg 
activation by PAI-1 / PAI-2 may result in an age-dependent decrease in the efficiency of 
clearance of extracellular protein deposits. The expression of PAI-1 also increases following 
inflammatory responses (Festa et al. 2002; Levi et al. 2003). PDDs are associated with 
inflammation and activation of the complement system; protein aggregates themselves have 
been shown to promote excessive and damaging/cytotoxic inflammatory responses (Papp et 
al. 2003; Tabner et al. 2005), which results in the release of oxidants, proteinases, and 
cytokines (Casserly and Topol 2004). This is potentiated via the activation of microglia or 
neutrophils, and is evident for aggregates of SOD, αSyn and IgG in ALS, Parkinson’s disease 
and rheumatoid arthritis, respectively (Robinson et al. 1993; Zhang et al. 2005; Roberts et al. 
2013). In these disease states, A2M may become chaperone-activated, triggered by, for 
example, oxidation-induced dissociation into dimers, or by interaction with proteases. In the 
disease state, however, this activation is insufficient to prevent pathology.  
 
PGPFs may also activate endothelial and microglial cells to compromise BBB integrity and 
exacerbate inflammatory responses, respectively. This was demonstrated by their ability to 
significantly increase ROS formation, which can trigger cytokine release via endothelial and 
microglial activation. It is possible that endothelial and microglial activation may occur for 
other aggregates and PGPFs derived thereof, such as those from amyloid fibrils in 
Alzheimer’s disease where the recruitment of monocytes through permeabilised BBB 
accompanies an intensified inflammatory pathology (Yamada 2000; Kaur et al. 2001; Nagele 
et al. 2004; Gonzalez-Velasquez et al. 2008). 
 
The extracellular proteostasis field is in its infancy, but in time will provide important 
insights into the mechanisms underlying extracellular PDDs. However, much work is 
required before that point is reached. In particular, research demonstrating that the processes 
described here occur in vivo are necessary. In addition, further research into other possible 
components of the quality control system is required. Further work would also involve 
identifying the mechanisms and signalling pathways by which PGPFs are cytotoxic and more 
importantly, how the binding of ECs to PGPFs ameliorates their cytotoxicity when incubated 
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with cells. It would also be worthwhile establishing whether PGPFs do induce the activation 
and release of cytokines and PAI-1 / PAI-2 from endothelial and microglial cells and the 
receptors that recognise ECs bound to PGPFs. This will need to be followed by important 
work determining the role of the proposed extracellular proteostasis mechanisms in specific 
diseases which are associated with either amyloid fibrils or amorphous protein aggregates.  
 
Increased knowledge of these mechanisms could lead to the development of new therapies to 
treat serious PDDs and other age-related diseases such as Alzheimer’s disease, amyotrophic 
lateral sclerosis, and rheumatoid arthritis. Current therapeutic strategies involve (i) native 
protein replacement (Balch et al. 2008), (ii) abrogating the aggregation of proteins using 
small molecules of either naturally occurring or synthetic origin termed “chemical and 
peptidic chaperones” (Wyatt et al. 2009), which can act by either steric hindrance of protein-
protein interaction (Fulop et al. 2004; Gibson and Murphy 2006), shielding regions of 
exposed hydophobicity (Baskakov and Bolen 1998) or, in the case of amyloid fibrillogenesis, 
minimising structural changes leading to β-sheet formation (Soto et al. 1998), and (iii) 
mesenchymal stem cell therapy, which decreases apoptosis and promotes endogenous cell 
growth (Joyce et al. 2010). However, these approaches suffer from inadequate delivery 
methods and inefficient targeting of cells/tissues of interest (Balch et al. 2008). For example, 
most chemical and peptidic chaperones cannot cross the BBB to correctly treat 
neurodegenerative diseases (Wyatt et al. 2009). Small molecules termed “proteostasis 
regulators” which manipulate signalling pathways and/or the transcription and translation of 
elements of the protein quality control machinery show promise in developing future 
therapies for the treatment of PDDs (Balch et al. 2008). For example, one strategy using 
RNA interference directed against the proteostasis regulator age-1 induced an increase in 
chaperone expression levels and conferred protection from polyQ cytotoxicity (Morley et al. 
2002). In a similar manner, potential future strategies could include bolstering existing 
proteostasis systems by manipulating the expression levels or activity of the plg activation 
system, or ECs and/or their receptors. Conceivably, these changes could enhance the body's 
own existing systems to safely degrade and clear disease-associated insoluble protein 
aggregates.  
 
The findings of the National Institute of Neurological Disorders and Stroke (No authors 
listed, 1995) and the European Cooperative Acute Stroke Study (Hacke 1995) showed that 
intravenously administered recombinant tPA for the treatment of acute ischemic stroke after 3 
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hours of stroke onset resulted in poor recovery outcomes and enhanced tissue damage. It has 
been noted that fibrin deposition on the surface of placental cells was associated with 
apoptosis which could be prevented by inhibiting fibrinolysis, suggesting that cell death was 
caused by the degradation of products of fibrin (Isermann 2003). The toxicity of PGPFs 
derived from the degradation of fibrin may contribute to the negative side effects associated 
with tPA treatment in stroke victims (Guo et al. 2009). The potential of ECs to interact with 
PGPFs and aid in their clearance could lead to new stroke therapy that combines the use of 
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